............................ New Concepts in Diabetes and Its Treatment
..
This Page Intentionally Left Blank
............................
New Concepts in Diabetes and Its Treatment
Editors
Francesco Belfiore, Catania Carl Erik Mogensen, Aarhus
22 figures and 60 tables, 2000
............................ Francesco Belfiore, MD Institute of Internal Medicine University of Catania, Ospedale Garibaldi
Carl Erik Mogensen, MD Medical Department M (Diabetes and Endocrinology), Kommunehospitalet University Hospital in Aarhus
Library of Congress Cataloging-in-Publication Data New concepts in diabetes and its treatment / editors, F. Belfiore, Carl Erik Mogensen. p. cm. Includes bibliographical references and indexes. ISBN 3–8055–6907–6 (hardcover : alk. paper) 1. Diabetes. I. Belfiore, Francesco. II. Mogensen, Carl Erik. [DNLM: 1. Diabetes Mellitus – therapy. 2. Diabetes Mellitus – complications. WK 815 N5315 2000] RC660.N396 2000 616.462–dc21 99–057726 CIP
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Ó Copyright 2000 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland) www.karger.com Printed in Switzerland on acid-free paper by Reinhardt Druck, Basel ISBN 3–8055–6907–6
............................
Contents
1
Introduction Belfiore, F. (Catania); Mogensen, C.E. (Aarhus)
Chapter I 3
Etiological Classification, Pathophysiology and Diagnosis Belfiore, F.; Iannello, S. (Catania)
Chapter II 20 Insulin Secretion and Its Pharmacological Stimulation Belfiore, F.; Iannello, S. (Catania)
Chapter III 38 Insulin Resistance and Its Relevance to Treatment Belfiore, F.; Iannello, S. (Catania)
Chapter IV 56 Diet and Modification of Nutrient Absorption Iannello, S. (Catania)
Chapter V 72 Insulin Treatment in Type 1 and Type 2 Diabetes: Practical Goals and
Algorithms Belfiore, F.; Iannello, S. (Catania)
Chapter VI 90 Overview of Diabetes Management: ‘Combined’ Treatment and
Therapeutic Additions Belfiore, F.; Iannello, S. (Catania)
Chapter VII 103 Clinical Emergencies in Diabetes. 1: Diabetic Ketoacidosis and
Hyperosmolar Nonketotic Syndrome Belfiore, F.; Iannello, S. (Catania)
Chapter VIII 111 Clinical Emergencies in Diabetes. 2: Hypoglycemia Belfiore, F.; Iannello, S. (Catania)
Chapter IX 125 Mechanisms of Diabetic Complications (Nephropathy) as Related to
Perspectives of Treatment Cooper, M.E. (West Heidelberg, Vic.)
Chapter X 135 Diabetic Retinopathy Bek, T. (Aarhus)
Chapter XI 152 Nephropathy and Hypertension in Diabetic Patients Mogensen, C.E. (Aarhus)
Chapter XII 174 Lipid Abnormalities and Lipid Lowering in Diabetes Belfiore, F.; Iannello, S. (Catania)
Chapter XIII 186 Cardiovascular Disease and Diabetes Zuanetti, G. (Milan)
Chapter XIV 199 Diabetic Neuropathy Boulton, A.J.M.; Malik, R.A. (Manchester)
Contents
VI
Chapter XV 208 Foot Problems in Diabetes Shaw, J.E.; Boulton, A.J.M. (Manchester)
Chapter XVI 218 Erectile Dysfunction in Diabetes and Its Treatment Tagliabue, M.; Molinatti, G.M. (Turin)
Chapter XVII 229 Multifactorial Intervention in Type 2 Diabetes mellitus Gæde, P.; Pedersen, O. (Copenhagen)
Chapter XVIII 241 Managing Diabetes and Pregnancy Kitzmiller, J.L. (San Jose, Calif.)
253 Author Index 254 Subject Index
Contents
VII
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 1–2
............................
Introduction
Diabetes mellitus and its complications are clinical conditions of growing importance both from the clinical as well as epidemiological standpoint. The relevance of diabetes at clinical and individual level is given by its lifethreatening acute complications and, especially, by its chronic complications affecting several organs and systems, with increased risk for ocular, renal, cardiac, cerebral, nervous and peripheral vascular diseases. The high prevalence of diabetes in many developed countries or in special ethnic groups, entailing premature disability and mortality, points to its relevance at population level. It is, therefore, mandatory for both the specialist and the practitioner to be acquainted with the pathophysiological mechanisms, clinical manifestations and, above all, therapy of diabetes mellitus. Recent data showing that control of hyperglycemia may prevent the onset or slow down the progression of complications point to the importance of an appropriate and efficacious treatment. Indeed, the aim of this book is to serve as a tool to provide physicians with the latest views on diagnostic aspects and pathophysiological mechanisms as a premise to go deep into the various facets of the modern management of diabetes. This book begins with introductory chapters on classification and clinical aspects, after which an account is given of insulin secretion as modulated by sulfonylureas and of insulin resistance (in its genetic and acquired components) as modified by diet and the new lipase-inhibitory drug or by metformin (and perhaps troglitazone agents). Insulin therapy of both type 1 and, when required, type 2 diabetes is adequately covered. This is followed by an integrated view of metabolic control, including combined therapy and self-monitoring, in the light of the lesson from DCCT (Diabetes Control and Complications Trial) and UK-PDS (United Kingdom Prospective Diabetes Study).
1
The mechanisms of complications are treated as an introduction to the understanding of possible therapeutic strategies. Then retinopathy, nephropathy, hypertension and cardiovascular disease are considered in their clinical aspects and therapeutic interventions. Extensive space is devoted to the various neuropathic manifestations, including erectile dysfunction, as well as to the foot problems. Final chapters highlight the need for multifactorial treatment and the clinical and therapeutic problems of diabetic pregnancy. The international panel of authors has made any effort to condense this rich content into a relatively short text and to present it in a clear and smoothto-read form. While more extensive information may be found in larger treatises (see Suggested Reading, below), we hope that this medium-size book will be useful to all physicians interested in the management of diabetic patients by providing them with a simple yet updated source of information concerning the New Concepts in Diabetes and Its Treatment. Francesco Belfiore Carl Erik Mogensen
Suggested Reading Alberti KGMM, Zimmet P, DeFronzo RA: International Textbook of Diabetes mellitus, ed 2. Chichester, Wiley, 1999. Belfiore F (ed): Frontiers in Diabetes. Basel, Karger, vol 8/1987, vol 9/1990, vol 10/1990, vol 11/1992, vol 12/1993, vol 14/1998. Bray G, Bouchard C, James WPT (eds): Handbook of Obesity. New York, Dekker, 1997. Kakn CR, Weir GC (eds): Joslin’s Diabetes mellitus, ed 13. Malvern, Lea & Febiger, 1994. Mogensen CE (ed): The Kidney and Hypertension in Diabetes mellitus, ed 5. Boston, Kluwer Academic, 2000. Pickup JC, Williams G (eds): Textbook of Diabetes, ed 2. Oxford, Blackwell, 1997. Porte D Jr, Sherwin RS (eds): Ellenberg and Rifkin’s Diabetes mellitus, ed 4, Amsterdam, Elsevier, 1990, and ed 5, Old Tappan/NJ, Appleton & Lange, 1996.
Introduction
2
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 3–19
Chapter I
............................
Etiological Classification, Pathophysiology and Diagnosis F. Belfiore, S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Introduction According to the classical definition, diabetes mellitus is a disorder resulting from both genetic predisposition and favoring environmental factors, and is characterized by alterations in the metabolism of carbohydrate, fat and protein, which are caused by a relative or absolute deficiency of insulin secretion and different levels of insulin resistance. In the patients with long-standing diabetes, late complications develop consisting of alterations and failure of various organs (especially the noninsulin-sensitive ones) including the eyes (retinopathy with vision loss), kidneys (nephropathy leading to renal failure), nerves (peripheral and autonomic neuropathy), heart and blood vessels (precocious and severe cardiovascular, cerebrovascular and peripheral vascular atherosclerosis). Diabetes mellitus includes etiologically and clinically different diseases that have hyperglycemia in common, representing a syndrome rather than a single disease. Until 1997, the classification and diagnosis of diabetes were based on the criteria developed by an international work group, sponsored by the National Diabetes Data Group (NDDG) of the American National Institute of Health, and published in 1979. The World Health Organization (WHO) Expert Committee on Diabetes in 1980 and the WHO Study Group on Diabetes mellitus in 1985 adopted the recommendations of the NDDG with slight alterations. In 1995, an International Expert Committee was established (sponsored by the American Diabetes Association) with the aim to review the scientific literature since 1979 and to decide the adequate changes in the classification and diagnostic criteria of diabetes. The committee work culminated in a document
3
published in 1997, divided into four sections (definition and description of diabetes, classification of diabetes, diagnostic criteria and testing for diabetes), which we summarize in this chapter.
Definition and Description of Diabetes mellitus The basis of the metabolic alterations in diabetes is the reduction (to a various degree) of insulin action on insulin-sensitive tissues, due to deficiency of insulin secretion or to insulin resistance or both. The majority of cases of diabetes mellitus falls into two major forms: type 1 and type 2 diabetes.
Type 1 Diabetes Immune-Mediated Type 1 Diabetes Type 1 diabetes (previously also named insulin-dependent diabetes mellitus – IDDM – or juvenile-onset diabetes) is an immune-mediated form of diabetes, which accounts for approximately 5–10% of all diabetics in the Western world. It occurs mainly in healthy nonobese children or young adults but may also affect subjects at any age, and results from an absolute deficiency of insulin secretion (evidenced by low or undetectable levels of plasma Cpeptide), caused by a cellular-mediated autoimmune destruction of pancreatic b-cells. Although the affected subjects are usually nonobese, the presence of obesity is not incompatible with the diagnosis of type 1 diabetes. The course may be rapid in children and young adults, slower in older patients. Adult patients can retain for some time a residual b-cell function while children and adolescents often show early the effects of severe insulin lack, with a diabetes appearing abruptly over days or weeks and rapidly progressing to acute lifethreatening complication (ketoacidotic coma), which may be the first manifestation of the disease, particularly in presence of precipitating factors such as infections or other stress. Genetic Predisposition. Type 1 diabetes is favored by a not yet fully understood genetic predisposition, linked to the HLA system. Pedigree studies of type 1 diabetes families have shown a low prevalence of direct vertical transmission. However, the risk to develop the disease for children who are first-degree relatives of type 1 diabetic patients is between 5 and 10%, the risk being increased when there is haploidentity with the affected sibling and even more when there is HLA identity. It has also been observed that the risk is 5-fold higher for children of a diabetic father compared to children of a diabetic mother (sexual imprinting). Candidate genes for type 1 diabetes have been
Belfiore/Iannello
4
suggested to occur in chromosomes 2, 6, 11 and 15. However, the major gene seems to be located at the HLA locus in the chromosome 6. Indeed, it is now largely accepted that type 1 diabetes is strongly associated to HLA system, especially with the class II molecules which encode for the D allele. Patients who express the DR3 or DR4 alleles or those who are heterozygous (DR3/ DR4) are especially susceptible to type 1 diabetes. Class I alleles (B8, B15) also seem to be associated to type 1 diabetes as they show linkage disequilibrium, i.e. show nonrandom association with the D alleles. Recently, great importance has been attributed to the DQ locus. It has been shown that DQb1*0301 and DQb1*0302 segregate with DR4 and that DQb1*0201 segregates with DR3. Presence of DQb1*0201 and DQb1*0302 or, especially, the heterozygous state DQb1*0201/0302 entails high risk. On the other hand, DQb1*0502 and DQb1*0602 are associated with the DR2 haplotypes and would be protective. Immunologic Mechanisms. Class II molecules are expressed by macrophages, endothelial cells and lymphocytes, and are required for the presentation of an antigen to the regulatory T cells, which become activated, thus triggering the immune response. In other words, the favoring HLA haplotypes indicated above permit the interaction of environmental factors (such as certain viral infections or chemical agents) with specific cell membrane components (the HLA molecules), which results in the presentation of the antigen to the regulatory T lymphocytes, thus triggering an autoimmune mechanism. Several viral infections have been suggested as favoring type 1 diabetes, including Coxsackievirus infections, infectious mononucleosis, mumps, congenital rubella, hepatitis and encephalomyocarditis. Some toxins have also been implicated. Consumption of cow’s milk during the early life may be an important environmental factor associated with type 1 diabetes development and, because the role of bovine albumin in the induction of b-cell autoimmunity have not been confirmed, b-casein has been suggested as the responsible protein. Virus, toxins, or other factors may directly damage b-cells or favor apoptosis (programmed cell death), or may expose cryptic antigen to the immune system, or may act through molecular mimicry (exogenous molecules similar in amino acid sequence to some endogenous molecules), or they may induce expression of class II molecules in the b-cells (which therefore would become antigenpresenting cells, able to trigger the autoimmune response). An alternative hypothesis which does not rely on exogenous antigen postulates a defective removal of autoreactive T cells, which normally are destroyed in the thymus in the early life. In contrast to the most common form of type 1 diabetes, linked to environmental factors (formerly called type IA), in approximately 10% of all cases of type 1 diabetes (more frequently in females, with HLADR3, from 30 to50 years of age), the disease is a primary autoimmune disorder (previously called type IB) and is associated to other endocrine and nonendo-
Etiological Classification, Pathophysiology and Diagnosis
5
crine autoimmune diseases (Grave’s disease, Hashimoto’s thyroiditis, Addison’s disease, primary gonadal failure, vitiligo, pernicious anemia, connective tissue disease, celiac disease, myasthenia gravis, etc.). This primary autoimmune pathogenesis seems to be confirmed by a persistence of islet cell autoantibodies (ICAs) forever. In 85–90% of patients, diabetes is early associated with one or more serological genetic markers such as ICAs, IAAs (insulin autoantibodies), GAD65 (autoantibodies to glutamic acid decarboxylase) and IA-2 or IA-2b (autoantibodies to tyrosine phosphatase). These autoantibodies disappear over the course of a few years in the majority of patients, and may be the result rather than the cause of the autoimmune process. Clinical Picture. Manifest type 1 diabetes is characterized by symptoms linked to the marked hyperglycemia, such as polyuria (due to the osmotic effect of glucose), polydipsia (to compensate for the water lost with polyuria), polyphagia (to compensate for the energetic substrate glucose lost in the urine), weight loss and fatigue (due to loss of glucose in urine and to dehydration), and blurred vision (due to lens osmotic disturbances). These patients are insulindependent for their survival and prone to ketosis; impairment of growth, susceptibility to certain infections, hypertension, lipoprotein metabolism alterations, periodontal disease and psychosocial dysfunctions are frequent. Idiopathic Type 1 Diabetes The idiopathic diabetes includes some forms of type 1 diabetes (common in individuals of African and Asian origin) due to unknown etiology, with strong genetic inheritance (not HLA-associated), without markers of autoimmunity. There is severe deficit of insulin secretion and tendency to ketoacidosis, with absolute requirement of insulin therapy. Pathophysiology of Type 1 Diabetes The pathophysiological changes occurring in type 1 diabetes as a consequence of the severe insulin deficiency may be better understood by comparing the normal picture of the main metabolic pathways, as summarized in figure 1, with the abnormal situation present in type 1 diabetes, outlined in figure 2 (see also chapter III on Insulin Resistance). In type 1 diabetes, the deficit of insulin and the prevalence of counterregulatory hormones, primarily glucagon, leads to the activation of glycogenolysis and gluconeogenesis in liver, with ensuing enhanced hepatic glucose output (HGO). In addition, the deficiency in insulin action results in reduced glucose utilization in peripheral insulin sensitive tissues (primarily muscle) as well as in activation of lipolysis in the adipose tissue (insulin normally exerts an antilipolytic effect), with enhanced release of FFA. The latter, although they cannot be directly converted into glucose in man, favor gluconeogenesis in the liver. Combination of enhanced HGO and reduced glucose utiliza-
Belfiore/Iannello
6
Fig. 1. Scheme showing the main metabolic pathways of intermediate metabolism in the three insulin-sensitive tissues (liver, muscle and adipose tissue) participating in the metabolic homeostasis. Note that most metabolic pathways are opposed to each other to form couples composed of a ‘forward pathway’ and a ‘backward pathway’, thus allowing substrate cycling. Examples are: glycogen synthesis and glycogenolysis (steps 1 and 2 in liver, 11 and 12 in muscle), glycolysis and gluconeogenesis (steps 5 and 6), triglyceride synthesis and hydrolysis (lipolysis) (steps 17 and 18 in adipose tissue; 26 and 27 in liver), protein synthesis and proteolysis (steps 13 and 14), etc. Some cycles are ‘inter-tissular’, linking liver and muscle, such as the Cori cycle (expanded to include alanine in addition to lactate and pyruvate), composed of steps 10, 6, 3, 8 and 9, pertaining to carbohydrate metabolism, as well as the cycle linking liver and adipose tissue (steps 19, 22, 26, 28 and 29), pertaining to lipid metabolism. In the normal state, blood glucose is kept at the normal level through a balance between hepatic glucose production (step 3) and glucose utilization by peripheral tissues, mainly the muscle (step 8). VLDL and triglycerides are kept normal through a balance between hepatic production (step 28) and peripheral degradation by LPL, primarily at adipose tissue level (step 29). Ketones are not present because Ac-CoA is entirely oxidized to CO2 (or utilized for the synthesis of FFA – step 24).
tion results in hyperglycemia. In addition, FFA exert anti-insulin effects at the muscle level, through the mechanism of the glucose-FFA cycle (Randle’s cycle), which may cause resistance to the therapeutically administered insulin (see the chapter on Insulin Resistance). It should also be considered that hyperglycemia itself favors glucose utilization (glucose effectiveness), perhaps by acting on noninsulin-dependent glucose transporters (GLUT1 in gut, GLUT2 in liver and GLUT3 in brain), and that in type 1 diabetes this glucose effect may be reduced, i.e. there may be ‘glucose resistance’.
Etiological Classification, Pathophysiology and Diagnosis
7
Fig. 2. Scheme of the main metabolic pathways (similar to that outlined in figure 1) and of their changes in activity rate occurring in states of severe insulin deficiency, such as decompensated type 1 diabetes (thick or thin arrows indicate increased or decreased activity, respectively). Note the prevalence of the catabolic pathways over the anabolic ones: glycogenolysis over glycogen synthesis (steps 2 and 1 in liver, steps 12 and 11 in muscle), gluconeogenesis over glycolysis (steps 6 and 5), triglyceride hydrolysis or lipolysis over triglyceride synthesis (steps 17 and 18), proteolysis over proteosynthesis (steps 14 and 13), etc. Concerning the ‘inter-tissural’ cycles, note the prevalence of hepatic glucose production (step 3) over glucose utilization (step 8), leading to glucose accumulation in blood (unnumbered arrow starting from glucose). The enhanced hepatic glucose production (step 3), effected by the enzyme glucose-6-Pase, utilizes glucose-6-P in part derived from glycogen (step 2) but mainly formed through the gluconeogenic process (step 6) which in turn utilizes the gluconeogenic precursors (pyruvate, lactate and alanine) coming from the muscle (step 10), where they are mainly produced from amino acids (step 15) derived from the enhanced proteolysis (step 14). Note the overall process of conversion of protein to glucose (steps 14, 15, 10, 6 and 3), and consider that some amount of the glucose-6-P formed through the gluconeogenic process may be converted into glycogen (this latter conversion being favored by cortisol). With regard to the FFA-VLDL cycle, linking liver and adipose tissue, note the enhanced FFA release from adipose tissue (step 19), the enhanced afflux of FFA to muscle (step 20), where they are oxidized (step 21) and oppose the oxidation of glucose-derived pyruvate (glucose-FFA cycle, see the text), thus inducing insulin resistance. Note also the hyperafflux of FFA to the liver, where they may be reesterified to triglycerides (step 26) or b-oxidized to Ac-CoA (step 23). The triglycerides so formed may be deposited in the hepatocytes (steatosis) or may be incorporated into VLDL which are secreted into the circulation (step 28), leading to the marked hypertriglyceridemia of the decompensated diabetes. The large amount of Ac-CoA produced by b-oxidation of FFA cannot be entirely oxidized in the Krebs cycle (also for the relative deficiency of oxalacetate, which is diverted towards gluconeogenesis) and is converted into ketone bodies (step 25) leading the ketoacidosis. Thus, in the diabetic state, blood glucose is elevated because hepatic glucose production (step 3) prevails over glucose utilization
Belfiore/Iannello
8
Type 2 Diabetes Type 2 diabetes (previously also named non-insulin-dependent diabetes mellitus – NIDDM – or adult-onset diabetes) occurs in approximately 90–95% of diabetic people in the Western world, resulting from insulin resistance and insufficient compensatory insulin secretion. The disease has an insidious onset and remains asymptomatic and undiagnosed for a long period, even if the moderate hyperglycemia is able to induce severe diabetic late complications. Type 2 diabetes is strongly favored by genetic predisposition. However, although it shows familial aggregation as well as a high concordance (80%) in monozygotic twins, its mode of inheritance is not fully understood. It may well be a polygenic disease. In any case, the risk of offspring and siblings of type 2 diabetic patients to develop the disease is relatively elevated. In addition to the genetic predisposition, favoring environmental factors are involved, such as excessive caloric intake, obesity with increased body fat in the abdominal (visceral) site, sedentary habit, etc. The insulin levels may be normal or even increased (especially in presence of obesity) for a long time, but may decrease in the late stage of the disease. The abnormal carbohydrate metabolism can be early identified measuring fasting glycemia (FPG) or performing an oral glucose tolerance test (OGTT). This type of diabetes is noninsulin-dependent for survival and is nonketosis prone. Hyperglycemia is usually improved or corrected by diet, weight loss and oral hypoglycemic drugs. In type 2 diabetics an acute life-threatening complication, the nonketotic hyperosmolar coma, can develop whereas ketoacidosis seldom occurs spontaneously, although it may arise during stress, infections or other illnesses. Pathophysiology of Type 2 Diabetes This disease is due to a varying combination of insulin resistance and reduction (especially in the late stage of the disease) in insulin secretion (see chapter II on Insulin Secretion and chapter III on Insulin Resistance). The metabolic alterations are less pronounced than those in type 1 diabetes, outlined in figure 2 (see also chapter III on Insulin Resistance). Due to insulin resistance (and to enhanced counterregulatory hormones), there is increased HGO (which contributes primarily to fasting hyperglycemia) and reduced peripheral glucose utilization. There is also elevation of plasma FFA (resulting from activation of lipolysis and/or the often enhanced fat mass due to coexisting by peripheral tissues, mainly the muscle (step 8). VLDL and triglycerides are increased because hepatic production (step 28) prevails over peripheral degradation by LPL, primarily at the adipose tissue level (step 29). Ketones are formed at high rate (step 25) because the large amount of Ac-CoA cannot be entirely oxidized to CO2.
Etiological Classification, Pathophysiology and Diagnosis
9
obesity), which in turn contributes to insulin resistance through the mechanism of the glucose-FFA cycle. As mentioned above (under Type 1 Diabetes), hyperglycemia itself favors glucose utilization (glucose effectiveness). This mechanism may be impaired in type 2 diabetes, i.e. ‘glucose resistance’ may be present. It has been observed that in obesity and type 2 diabetes (as well as in acromegaly and Cushing’s disease), in the postabsorptive period, noninsulinmediated glucose uptake is a major determinant of glucose disposal and is similar in the different pathologies studied. On the other hand, although absolute rates of basal insulin-mediated glucose uptake are reduced in insulinresistant states, they do not achieve statistical value compared with control subjects because of compensatory hyperinsulinemia.
Other Specific Types of Diabetes Various, less common, types of diabetes are known to occur, in which the secretory defect is based upon different mechanisms. Genetic Defects of b-Cell Function The maturity-onset diabetes of the young (MODY) is a genetically heterogeneous monogenic form of noninsulin-dependent diabetes, characterized by early onset, usually before 25 years of age and often in adolescence or childhood, and by autosomal dominant inheritance. There is no HLA association nor evidence of cell-mediated autoimmunity. It has been estimated that 2–5% of patients with type 2 diabetes may have this form of diabetes mellitus. However, the frequency of MODY is probably underestimated. Clinical studies have shown that prediabetic MODY subjects have normal insulin sensitivity but suffer from a defect in glucose-stimulated insulin secretion, suggesting that pancreatic b-cell dysfunction, rather than insulin resistance, is the primary defect in this disorder. To date, three MODY genes have been identified. MODY-1. Studies in an affected family showed that the gene responsible for MODY-1 is tightly linked to the adenosine deaminase gene on chromosome 20q. Further research has shown that responsible for MODY-1 is a mutation in the gene-encoding hepatocyte nuclear factor (HNF)-4a, a member of the steroid/thyroid hormone receptor superfamily and an upstream regulator of HNF-1a expression. MODY-2. This form is due to mutations in glucokinase (GK – see chapter II for the functional meaning of GK in b-cells) and is associated with defects in insulin secretion, reduction in hepatic glycogen synthesis and in the net accumulation of hepatic glycogen as well as increased hepatic gluconeogenesis following meals, resulting in impaired glucose tolerance or diabetes mellitus
Belfiore/Iannello
10
characterized by mild chronic hyperglycemia. The hyperglycemia due to GK deficiency is often mild (fewer than 50% of subjects have overt diabetes) and is evident during the early years of life. Despite the long duration of hyperglycemia, GK-deficient subjects have a low prevalence of micro- and macrovascular complications of diabetes. Obesity, arterial hypertension and dyslipidemia are also uncommon in this form of diabetes. MODY-3. In several families, this form of MODY was found to be linked with microsatellite markers on chromosome 12q. The disease was estimated to be linked to this chromosome region in approximately 50% of families in a heterogeneity analysis. It is the most common form of MODY. Affected patients exhibit major hyperglycemia with a severe insulin secretory defect, suggesting that the causal gene is implicated in pancreatic b-cell function. MODY-3 was further shown to be due to mutations in the gene-encoding HNF-1a (which is encoded by the gene TCF1). HNF-1a is a transcription factor that helps in the tissuespecific regulation of the expression of several liver genes and also functions as a weak transactivator of the rat insulin-I gene. Familial Hyperinsulinemia. The high-affinity sulfonylurea receptor, a novel member of the ATP-binding cassette superfamily, is one component of the ATP-sensitive K+ channel. The protein is critical for regulation of insulin secretion from pancreatic b-cells, and mutations in the receptor (or in the KATP channels) have been linked to familial hyperinsulinemia, a disorder characterized by unregulated insulin release despite severe hypoglycemia. Other forms may be due to mutation in the GK gene, leading to a hyperresponsive enzyme. Other. In addition, a diabetes type associated with deafness may be linked to point mutations in mitochondrial DNA, and still other forms with less clearly defined defects are known to occur. In about 50% of cases of MODY, the genetic background is uncertain. It should be stressed that the role of the above genes (responsible for b-cell dysfunction) in the susceptibility to the more common late-onset form of type 2 diabetes remains uncertain. Genetic studies seem to exclude any function as major susceptibility genes, although they might play a minor role in a polygenic context or a major role in particular populations. Rare Genetic Defects of Insulin Action These are a heterogeneous group of rare conditions which includes: (a) syndromes associated with acanthosis nigricans, which is a brown to almost black hyperpigmentation of the skin, most often located in the neck, axilla, groin or other areas, less rare in Blacks or in subjects of Hispanic origin. The affected patients show high insulin levels. Some cases are due to mutation in the insulin receptor resulting in diminished tyrosine-kinase activity (type A syndrome). Others are due to antibodies to the insulin receptors which prevent insulin
Etiological Classification, Pathophysiology and Diagnosis
11
binding (type B syndrome). Interestingly, some cases have been reported in which antibodies to the receptor exert an agonistic effect, producing hypoglycemia. (b) Generalized or partial (face and trunk) lipodystrophies, which may be congenital or acquired, are characterized by fat depletion, and result from decrease in the number or affinity of the receptor for insulin or from postreceptor defects. Patients show high insulin levels, hyperglycemia (without ketoacidosis for the scarcity of fat), hypertriglyceridemia (with eruptive xanthomas), enlargement of liver, spleen, heart, and hypertrophy of external genitalia. Lymphadenopathy and hirsutism may also occur as well as varicose veins, mental retardation and kidney involvement. In the congenital form, there is also muscle hypertrophy. (c) Leprechaunism syndrome, due to mutation in insulin receptors (which may be altered in both the a and b subunits and whose expression in the cell membrane is markedly reduced), and consisting of insulin resistance associated with severe growth retardation, elfin appearance of the face, hirsutism, absence of subcutaneous fat and thickened skin. (d) Other rare conditions such as the Werner’s syndrome, the Alstro¨m syndrome, the Rabson-Mendenhall syndrome (which may be associated with acanthosis nigricans), the pineal hypertrophy syndrome, and the ataxia telangiectasia syndrome. Diseases of the Exocrine Pancreas Any disease process affecting the pancreas may involve the islets and produce diabetes (table 1). May we recall the fibrocalculous pancreatopathy, that occurs in India, Africa and West Indies with a frequency similar to that of type 2 diabetes. This form involves young people with malnutrition and pancreatic calculi, and is characterized by severe hyperglycemia and insulin dependence but not by proneness to ketosis, as a moderate insulin secretion is retained.
Gestational Diabetes mellitus (GDM) GDM is defined as any degree of glucose intolerance with onset during pregnancy. It should be distinguished by the mild deterioration of glucose tolerance which may occur also during normal pregnancy (particularly in the 3rd trimester). The prevalence of GDM can range from 2 to 3% of pregnancies, depending on the different racial/ethnic subpopulations studied. A known diabetic woman who becomes pregnant is not classified as GDM. The GDM is a serious problem and its recognition is important to prevent the associated perinatal morbidity or mortality and the maternal complications (cesarean delivery and chronic hypertension). GDM usually returns to a normal glucose tolerance state after delivery, but 60% of affected women can develop diabetes within 15
Belfiore/Iannello
12
Table 1. Etiologic classification of diabetes mellitus 1. Type 1 diabetes A. Immune-mediated B. Idiopathic 2. Type 2 diabetes 3. Other specific types A. Genetic defects of b-cell function (MODY-1, MODY-2, MODY-3, mitochondrial DNA, and others) B. Genetic defects in insulin action (type A insulin resistance, leprechaunism, Rabson-Mendenhall syndrome, lipoatrophic diabetes, and others) C. Diseases of the exocrine pancreas (pancreatitis, pancreatectomy, trauma, neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy, and others) D. Endocrinopathies (acromegaly, Cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma, and others) E. Drug- or chemical-induced diabetes (vacor, pentamidine, nicotinic acid, glucocorticoids, thyroid hormone, diazoxide, b-adrenergic agonists, thiazides, dilantin, a-interferon, and others) F. Infections (congenital rubella, cytomegalovirus, and others) G. Uncommon forms of immune-mediated diabetes (‘stiff-man’ syndrome, anti-insulin receptor antibodies, and others) H. Other genetic syndromes sometimes associated with diabetes (Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, Wolfram’s syndrome, Friedreich’s ataxia, Huntington’s chorea, Lawrence-Moon-Biedl syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome, and others) 4. Gestational diabetes mellitus (GDM)
years after parturition. About 6 weeks after the delivery, the GDM woman should be reclassified as diabetic or glucose intolerant or normoglycemic.
Comment In the previous NDDG/WHO classification, diabetes mellitus was divided into 5 distinct types: IDDM, NIDDM, GDM (gestational diabetes), malnutrition-related diabetes and other types, and the category of IGT (impaired glucose tolerance) was included, in which plasma glycemia during an OGTT was above normal but not diabetic. The 1997 Expert Committee changed the NDDG/ WHO classification, including only 4 clinical classes: (1) type 1 diabetes, (2) type 2 diabetes, (3) other specific types and (4) GDM (table 1). The most important changes introduced include the following: (a) Elimination of the terms ‘insulindependent’ or ‘noninsulin-dependent’ diabetes mellitus and ‘IDDM’ or
Etiological Classification, Pathophysiology and Diagnosis
13
‘NIDDM’ (which are confusing as they classified the patient according to treatment rather than etiology). (b) Preservation of the terms ‘type 1’ or ‘type 2’ diabetes (with Arabic numerals) and elimination of the confusing terms ‘type I’ or ‘type II’ diabetes (with Roman numerals); patients with no evidence of autoimmunity are classified as being affected by type 1 idiopathic diabetes. (c) Type 1 diabetes does not include those forms of b-cell destruction due to nonautoimmune-specific causes. (d) Type 2 diabetes includes the most common form characterized by insulin resistance and insulin secretory defect. (e) The class previously named malnutrition-related diabetes mellitus has been eliminated. (f ) The IGT stage has been retained, and the stage of IFG was added. (g) GDM, as defined by WHO and NDDG, was retained.
Diagnostic Criteria for Diabetes mellitus A precocious diagnosis of diabetes is important to prevent or attenuate late diabetic complication, and depends upon the adequate use and interpretation of laboratory tests (especially in absence of specific symptoms). Many different diagnostic schemes have been in use. Recently, on the basis of the available data, the diagnostic criteria previously recommended by NDDG or WHO were modified. According to the revised criteria by the Expert Committee [1997], the ‘normal values’ and the ‘diagnostic values’ for diabetes (which do not coincide with the goals of therapy) are as follows (values given in the text refer to venous plasma glucose which is the preferred measurement; equivalents for whole blood and capillary glucose estimations, according to the IDF guidelines [1999] to type 2 diabetes, are indicated in footnotes). Normal Values. The upper limit of normal venous plasma values has been set at 110 mg/dl (6.1 mmol/l) for FPG and at 140 mg/dl (7.8 mmol/l) for the 2-hour value after glucose load (OGTT). Diagnostic Values. (a) FPG q126 mg/dl (or 7.0 mmol/l)1 after a fasting of at least 8 h, confirmed on a subsequent day, to rule out a labeling or technical error; (b) 2-hour value during OGTT q200 mg/dl (or q11.1 mmol/l)2, confirmed in a repeated test to make the final diagnosis; (c) symptoms of diabetes and a casual value q200 mg/dl (or 11.1 mmol/l) at any time of day. For epidemiological studies, diabetes prevalence and incidence should be estimated by a FPG q126 mg/dl. The value of FPG was changed from the Same value for capillary plasma glucose; q110 mg/dl (?6.0 mmol/l) for venous or capillary whole blood glucose. 2 q220 mg/dl (q12.2 mmol/l) for capillary plasma glucose; q180 mg/dl (q10.0 mmol/l) for venous whole blood glucose; q200 mg/dl (q11.0 mmol/l) for capillary whole blood glucose. 1
Belfiore/Iannello
14
previous value (q140 mg/dl) to current value (q126 mg/dl), because (1) the cutpoint of FPG q140 mg/dl defines a greater degree of hyperglycemia than did the cutpoint of the 2-hour value q200 mg/dl, and (2) this degree of hyperglycemia usually reflects a serious abnormality associated with serious chronic diabetic complications. The 2-hour value q200 mg/dl has been retained for the diagnosis of diabetes because it was well accepted, and enormous clinical and epidemiological data are based on this cutpoint value. The criteria for diagnosis of diabetes in an asymptomatic child should be stricter than those for the adults to avoid overdiagnosis of diabetes, and it should be considered that normal children commonly present OGTT values lower than adults. The diagnostic values for GDM as proposed by O’Sullivan and Mahan [1993], revised by NDDG and adopted by ADA and the American College of Obstetricians and Gynecologists (ACOG), are set lower than those for nonpregnant adults. A screening test is indicated between 24 and 28 weeks of gestation in asymptomatic female patients at risk, and a value 1 h after a 50 g of glucose load q140 mg/dl (or 7.8 mmol/l) can identify the individuals at risk for GDM in whom a full diagnostic 3-hour OGTT with 100 g of glucose should be performed. GDM occurs with an FPG q105 mg/dl (or 5.8 mmol/l) and a 2-hour value during OGTT q165 mg/dl (or 9.2 mmol/l). An intermediate metabolic state was introduced, which is characterized by glucose levels above those considered as normal but below those accepted for the diagnosis of diabetes mellitus. Referring to the fasting state, this condition was named impaired fasting glycemia or IFG (FPG q110 but p126 mg/dl or q6.0 but p7.0 mmol/l )3. Referring to the postload state, it was named impaired glucose tolerance or IGT (2-hour postload value in OGTT q140 mg/dl but p200 mg/dl or q7.8 but p11.1 mmol/l)4, without spontaneous hyperglycemia). IFG or IGT are not clinical entities but rather risk factors for future type 2 diabetes and cardiovascular disease, being associated with the metabolic syndrome or insulin resistance syndrome, characterized by abdominal or visceral obesity, hypertension, dyslipidemia (hypertriglyceridemia and low HDL value) and hyperuricemia. Conversion of IGT to type 2 diabetes takes years or decades and occurs in about 10–50% of IGT patients. Thus, IGT may not progress to overt diabetes and may revert to normoglycemia, especially in obese patients after dietary treatment and weight reduction. Same value for capillary plasma glucose; q100 but p110 mg/dl (q5.5 but p6.0 mmol/l) for venous or capillary whole blood glucose. 4 q160 but p220 mg/dl (q8.9 but p12.2 mmol/l) for capillary plasma glucose; q120 but p180 mg/dl (q6.7 but p10.0 mmol/l) for venous whole blood glucose; q140 but p200 mg/dl (q7.8 but p11.1 mmol/l) for capillary whole blood glucose. 3
Etiological Classification, Pathophysiology and Diagnosis
15
Table 2. Subjects in whom OGTT should be performed First-degree relative of type 2 diabetic patients (especially if monozygotic twin of a diabetic patient or offspring of two diabetic parents) Subjects with abnormal or borderline glycemic values (FPG q110 mg/dl but p126 mg/dl) during screening test for diabetes Pregnant women with suspected GDM Obese subjects (especially when a family history of diabetes is present) Individuals with a family history of MODY Members of racial or ethnic groups with high prevalence of diabetes (American Indians or Pacific Islanders, African-Americans, Hispanics, etc.) Patients with unexplained neuropathy or coronary disease or peripheral vascular disease or retinopathy or nephropathy (especially under 50 years of age) Patients with hyperglycemia or glycosuria found during acute illness, stress situations, surgical procedures, steroid administration, etc.
Oral Glucose Tolerance Test The OGTT is not recommended for routine clinical use (being a nonspecific test) and should be standardized for both procedure and interpretation, while the use of FPG is encouraged as a simple, convenient, accurate, acceptable to patients and low cost test for diagnosing diabetes. FPG and 2-hour OGTT values are equivalent for the diagnosis of diabetes (even if not perfectly correlated with each other), and actually the FPG alone is preferable for its better reproducibility (6% variation) whereas OGTT, repeated in adults during a 2to 6-week interval, presents an intraindividual coefficient of variation of 17% for the 2-hour value. OGTT remains, however, the most sensitive and practical test for the early recognition of asymptomatic diabetes without high FPG value, and it is an invaluable tool in research studies. If the OGTT is used, the test procedures recommended are that of WHO. The indications of OGTT are outlined in table 2. The following variables may affect the OGTT results: Technical Variables. Venous versus capillary blood: In adults venous blood from an antecubital vein is usually employed, obtained with minimum stasis. In the capillary blood, glucose approximates that of arterial blood, and is higher than in venous blood by 2–3 mg/dl in the fasting state and by 20–70 mg/dl during OGTT. Plasma or serum versus whole blood : Plasma or serum is generally employed, providing more stable values. In these materials glucose concentration is 15% higher than in whole blood. The blood sample should be immediately refrigerated to prevent glycolysis of glucose by blood cells (fluoride cannot be
Belfiore/Iannello
16
used when glucose is measured by enzymatic methods), which would result in artifactual low glucose values. Methods for determining glycemia: The most commonly used methods are the glucose-specific enzymatic methods. The use of strips, read with glucose reflectance meter, is not recommended for diagnostic purpose (for its great variability) whereas it is useful for blood glucose self-monitoring during diabetes treatment. Glucose dose and concentration: In the past, glucose doses for OGTT varied from 50 to 100 g. To avoid nausea and to achieve a better standardization the use of an oral flavored solution of 75 g glucose dissolved in 300 ml of water for adults is now recommended. In children, 1.75 g/kg ideal body weight (up to a maximum of 75 g) should be used. During pregnancy, the OGTT is performed utilizing 100 g of glucose. The glucose solution should be consumed over 5 min. Timing of samples for OGTT: Blood samples are obtained in the fasting state and after 30, 60, 90, 120 min according to NDDG for testing individual patients. According to WHO, only 0- and 120-min samples should be used, which makes the test more suitable for testing large population groups or for epidemiological studies. During pregnancy, a 180-min sample should also be obtained. For the diagnosis of reactive hypoglycemia, the OGTT should be prolonged to 5 h. Time of day: There is a diurnal variation in glucose tolerance (which deteriorates in the afternoon); thus, a standard OGTT should be obtained in the morning, after a fasting of 10–14 h. Host Variables. Preceding diet: A diet containing 250 g of carbohydrate is recommended for at least 3 days before the test. In subjects on reduced diets, a diet containing at least 200 g of carbohydrates should be taken for 1 week before the OGTT. Coffee or smoking are avoided before and during the test. Physical activity: OGTT should not be performed in patients at bed rest, hospitalized or immobilized (conditions which may reduce glucose tolerance). A moderate walking during the test is permitted, but physical exercise should be avoided. Acute or chronic illness: OGTT should not be performed in patients affected by acute infections, acute cardiovascular and cerebrovascular diseases, active endocrinopathies, hepatic or renal diseases, or in subjects under stress or treated with some drugs such as glucocorticoids, estrogens, salicylates, thiazides, nicotinic acid, dilantin, etc. Age: Glucose tolerance deteriorates with advancing age (because of decreased or delayed insulin secretion, reduced insulin sensitivity, increase of insulin antagonists, physical inactivity, obesity and other associated diseases, etc.). In the elderly, the 2-hour glycemic level would increase by 10 mg/dl for each decade over 50 years.
Etiological Classification, Pathophysiology and Diagnosis
17
Other Tests Oral cortisone-glucose tolerance test is not a diagnostic test but is used for research purpose. The intravenous glucose tolerance test (or IVGTT) should be used as a diagnostic test only for patients with gastrointestinal disorders interfering with absorption of glucose. It is less physiological than OGTT, bypassing the effects of several relevant gastrointestinal hormones active with oral glucose load. Glucose (25 g as 50% solution) is infused over 3 min and samples are obtained every 10 min for 1 h. Through a formula, the K coefficient can be calculated, whose normal value is between 1.2 and 2.2; values =1 indicate diabetes, values between 1 and 1.2 are regarded as borderline. Determination of insulin during OGTT is not recommended for routine diagnostic purpose (because of extreme variability in fasting state and after glucose load), although it can be of prognostic value. Values are elevated in subjects with insulin resistance. HbA1c measurement is not currently used for diagnosis of diabetes whereas it is useful in monitoring the metabolic control. Normal values of HbA1c range from 4.0–4.5 to 6.0–6.4% of total hemoglobin, although differences exist among values depending on laboratories and/or methods. According to the IDF guidelines [1999] to type 2 diabetes, HbA1c can be useful for the diagnosis provided that confirmatory venous plasma glucose estimations are obtained, the assay is DCCT standardized, an HPLC chromatogram is reviewed for presence of abnormal hemoglobins, and erythrocyte turnover is not abnormal. Approximately: HbA1c ?7.5% B fasting plasma glucose q7.0 mmol/l (?125 mg/dl), and HbA1c ?6.5% B fasting plasma glucose ?6.0 mmol/l (q110 mg/dl). Glycosuria is not useful for the diagnosis, being present only when glycemia is higher than the renal threshold for glucose. It may be useful for a coarse monitoring of diabetic control. The aged people may have a higher than normal renal threshold for glucose (having glycosuria only at elevated glucose levels), whereas pregnant women often have a lowered glucose threshold (showing glycosuria even with normal glycemia).
Testing for Diabetes mellitus Type 1 Diabetes. In type 1 diabetes, routine testing for immune markers (outside of clinical trials or research studies) is not recommend for many reasons, including: (a) cut-off values have not been completely established for clinical settings; (b) there is no consensus on proven measures that can prevent
Belfiore/Iannello
18
or delay the clinical onset of disease (when a positive autoantibody test is obtained); (c) the cost-effectiveness of the screening is questionable. The autoantibody tests, however, may be useful to detect which newly diagnosed patients have immune-mediated type 1 diabetes. Type 2 Diabetes. Type 2 diabetes is commonly undiagnosed in about 50% of affected subjects. On the other hand, retinopathy may develop early, even 7 years before the diagnosis of overt diabetes. Thus, the unapparent hyperglycemia can cause microvascular complications and favor macrovascular disease. Therefore, the undiagnosed diabetes is a serious problem. Early detection and treatment are indispensable to reduce the late complications of type 2 diabetes. Thus, testing for diabetes (especially with FPG) should be recommended in the clinical setting and in high-risk subjects. In asymptomatic and undiagnosed individuals, testing for type 2 diabetes by FPG should be performed in: (a) all individuals at age 45 and above, repeated at 3-year intervals if results are normal; (b) individuals at younger age if at risk (obese subjects, first-degree relatives of diabetic patients, components of high-risk ethnic populations, women with GDM, mothers of obese baby ?9 lb or 4 kg, etc.); (c) hypertensive subjects with low HDL cholesterol (p35 mg/dl) or high triglycerides (q250 mg/dl); (d) individuals with IGT or IFG on previous testing.
Suggested Reading Expert Committee on the Diagnosis and Classification of Diabetes mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Diabetes Care 1997;20:1183–1197. Fajans SS: Classification and diagnosis of diabetes; in Rifkin H, Porte D (eds): Diabetes mellitus. Theory and Practice, ed 4. New York, Elsevier, 1990, pp 346–356. International Diabetes Federation (IDF), 1998–1999 European Diabetes Police Group: A Desktop Guide to Type 2 (Non-Insulin-Dependent) Diabetes mellitus. Brussels, IDF, 1999. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–1057. O’Sullivan JB: Diabetes mellitus after GDM. Diabetes 1993;40(suppl):131–135. Velho G, Blanche H, Vaxillaire M, et al: Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997;40:217–224. World Health Organization: Diabetes mellitus: Report of a WHO Study Group. Tech Rep Ser No 727. Geneva, WHO, 1985. Yamagata K, Furuta H, Oda N, et al: Mutations in the hepatocyte nuclear factor-4a gene in maturity-onset diabetes of the young (MODY-1). Nature 1996;384:458–460. Yamagata K, Oda N, Kaisaki PJ, et al: Mutations in the hepatocyte nuclear factor-1a gene in maturity-onset diabetes of the young (MODY-3). Nature 1996;384:455–458.
F. Belfiore, Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, I–95123 Catania (Italy) Tel. +39 095 330981, Fax +39 095 310899, E-Mail
[email protected]
Etiological Classification, Pathophysiology and Diagnosis
19
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 20–37
Chapter II
............................
Insulin Secretion and Its Pharmacological Stimulation F. Belfiore, S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Insulin Secretion Introduction Pancreatic b-cells synthesize a large polypeptide chain, the proinsulin, which is then cleaved into the so-called connecting peptide (C-peptide) and the insulin molecule, composed of two peptide chains containing 51 amino acid residues. Both insulin and C-peptide are packaged in the secretory granules. During the secretory process, the granule content is discharged outside the b-cell through a process of exocytosis, leading to the release of insulin and C-peptide in equimolar amounts, together with small quantities of uncleaved proinsulin. In contrast to insulin, C-peptide is not taken up by the liver (and the other insulin-sensitive tissues), and therefore its plasma level is a good index of insulin secretion.
Regulation of Insulin Secretion by Substrates Glucose Glucose is the main physiological regulator of insulin secretion. In vitro, prolonged stimulation with glucose (or sulfonylureas) induces a biphasic insulin secretory response by pancreatic islets characterized by an initial rapid first phase lasting about 5 min, during which about 2–3% of the insulin content of pancreas is released, followed by a slower second phase in insulin secretion, which results in the liberation of up to 20% of total pancreatic content during
20
a period of 60 min of glucose perfusion. A similar biphasic pattern of secretory response to glucose has also been reported in vivo in man with the hyperglycemic clamp technique. The two secretory phases, however, are not apparent after a carbohydrate-rich meal because the elevation in blood glucose is not rapid enough. Nevertheless, an efficient initial insulin secretory response (dependent upon the b-cell sensitivity to glucose elevation) is required for an optimal glucose control and for avoiding an excessive secretion during the second phase, which entails the risk of late hypoglycemia (reactive hypoglycemia). Glucose, besides its direct stimulation of insulin release, also potentiates the secretory response to nonglucose stimuli, which may play a role during the absorption of mixed meals. In addition, glucose exerts a priming effect of bcells, as a previous exposure of b-cells to glucose causes an enhanced secretory response to a subsequent stimulation with glucose (or even with nonglucose stimuli), as if the b-cell has memory of the previous glucose exposure. Chronic exposure to glucose, however, induces desensitization of b-cells, which does not seem to be due to a reduced content or synthesis of insulin. This is relevant to the condition of persistent hyperglycemia occurring in the diabetic state. With regard to insulin secretion, three concepts should be distinguished: the set point for blood glucose, the b-cell threshold for glucose, and the bcell glucose sensor. The set point entails the concept that there is a control system that ‘sets’ the level of glucose at a given value, which in man is fixed to about 5 mmol/l glucose. The set point is the result of the activity of b-cells as well as of a-cells and d-cells. The glucose threshold for both b-cells and a-cells is between 5 and 6 mmol/l: when glucose rises above this level, the insulin-secreting b-cells are turned on whereas the glucagon-secreting a-cells are turned off, and vice versa. Glucose threshold increases during starvation, when b-cells are blind to even relatively high glucose levels, and returns to normal upon refeeding. In order to be able to respond to increase in glucose concentration above the threshold value, b-cells must be equipped with a glucose sensor, which has been identified in the glucose-phosphorylating enzyme glucokinase (GK). This enzyme, long known to be present in the liver, has been shown to occur also in the b-cells (the liver and the b-cell enzymes differ at genetic level). GK differs from the ubiquitous enzyme hexokinase (which catalyzes the same reaction as GK, i.e. glucose phosphorylation), in that hexokinase has a high affinity (or a low Km) for glucose and therefore works at the maximum activity at very low, underphysiological glucose concentration, whereas GK has a low affinity (or a high Km) for glucose, which entails that its activity increases with increasing glucose concentration. Its presence in the liver allows this organ to take up glucose when glycemia in the portal vein increases (such as during the absorption
Insulin Secretion and Its Pharmacological Stimulation
21
period), whereas its presence in the b-cells allows these cells to perceive the increase in blood glucose and to respond with adequate insulin release. In order to stimulate insulin release, glucose must first be transported into the b-cell by the glucose transporter (GLUT-2 isoform), and then phosphorylated by GK to produce glucose-6-P. However, glucose transport in bcells possesses a very high capacity and therefore plays a little regulatory role. Glucose-6-P produced by GK is further metabolized along several pathways, through which ATP is generated. Shortly, glucose metabolism results in elevation of the ATP/MgADP ratio which inhibits ATP-sensitive K+-channels, thus lowering membrane potential and triggering Ca influx through the voltagedependent Ca2+-channels, which stimulates insulin secretion (fig. 1). Genetic alterations of key components of the insulin secretory machinery have been described. Mutations of KATP-channels or the associated sulfonylurea receptors may cause hyperinsulinemia and hypoglycemia due to persistent depolarization of the b-cell membrane. Mutations in the GK gene (most of which affect the glucose-binding site) may result in hyporesponsiveness to glucose, as it occurs in MODY-2 patients, or in hyperresponsiveness, as noted in the familial GKlinked hyperinsulinemia and hypoglycemia (FHI-GK). Oscillations in the glycolytic pathway and b-cell metabolism contribute to the oscillatory nature of b-cell ionic events and insulin secretion. Insulin release is a complex oscillatory process with rapid pulses (10 min) superimposed on slower circhoral oscillations (50–100 min). Moreover, ultradian oscillations of insulin secretion appear to be an integral part of the feedback loop between glucose and insulin secretion, and are abnormal in states of glucose intolerance. Other Substrates Fats also influence insulin release. In man, FFA were shown to enhance the secretory response to glucose, which is in agreement with the demonstration that pancreatic islets are equipped with the enzymes necessary for the utilization of FFA and ketone bodies. Amino acids such as isoleucine, arginine and lysine, potentiate the secretory effect of glucose, whereas leucine may be regarded as a primary stimulus, active even in the absence of glucose. Amino acids do not seem to act by serving as fuels for b-cells. They might act by contributing to activate Ca channels. An important signal for insulin secretion may reside in the inextricable interplay between glucose and lipid metabolism. Specifically, glucose metabolism leads to the generation of malonyl-CoA, which inhibits carnitine palmitoyltransferase-1, with the attendant accumulation of long-chain acyl-CoA esters in the cytosol (see also chapter III and figure 3). Malonyl-CoA and long chain acyl-CoA esters may act as metabolic coupling factors in b-cell signalling.
Belfiore/Iannello
22
Fig. 1. Regulation of insulin secretion by the b-cell. (Continuous lines ending with black arrows indicate transformation or translocation of substrates or ions; dotted lines ending with white arrows indicate stimulation; dotted lines ending with filled circles indicate inhibition). Glucose metabolism (regulated by GK which acts as ‘glucose sensor’) results in production of ATP which inhibits ATP-sensitive K+-channels, thus lowering membrane potential and triggering Ca influx through the voltage-dependent Ca2+-channels. High cytosolic Ca stimulates (through complex processes, not shown) insulin secretion. Sulfonylureas stimulate insulin secretion by acting through their receptor, closely associated with the ATP-sensitive K+channels. Parasympathetic stimulation (acetylcholine) promotes insulin secretion through activation of PLC, which produces IP3 and DAG (from PIP2); IP3 causes release of Ca from the intracellular stores (endoplasmic reticulum) into cytosol; DAG activates PKC which in turn stimulates secretion. Glucagon enhances secretion by activating AC (with the participation of Gs), thus producing cAMP and activation of PKA. Epinephrine (through the a2receptor) inhibits secretion by inhibiting AC (with the participation of Gi), thus exerting effects opposed to those of glucagon. Abbreviations (alphabetic order): a2>a2-Adrenergic receptor; AC>adenylate cyclase; cAMP>cyclic AMP; DAG>1,2-diacylglycerol; GK>glucokinase; Glg>glucagon receptor; GLP1>glucagon-like peptide 1; Gq>a further type of G protein; Gs and Gi>stimulatory and inhibitory G proteins; IP3>inositol-1,4,5-trisphosphate; M3>a type of muscarinic receptor; PIP2>phosphatidylinositol-4,5-P; PKA>protein kinase A; PKC>protein kinase C; PLC>phospholipase C.
Insulin Secretion and Its Pharmacological Stimulation
23
Regulation of Insulin Secretion by Hormones and Neurotransmitters Acetylcholine, produced by parasympathetic activity, stimulates insulin secretion through muscarinic receptors (which can be blocked by atropine), probably by enhancing DAG (diacylglycerol) and IP3 (inositol-3-P) formation (fig. 1). Parasympathetic stimulation may occur during the early (cephalic and intestinal) phase of insulin secretion following a meal as well as during hypoglycemic episodes. In the latter instance, however, hypoglycemia limits the parasympathetic effect on insulin secretion, because this effect is glucosedependent. The parasympathetic innervation of the pancreas may also trigger the release of vasoactive intestinal polypeptide (VIP), which stimulates the secretion of insulin (and glucagon) while increasing the blood flow to the pancreas and the external pancreatic secretion. Norepinephrine (released upon sympathetic stimulation) and epinephrine (produced by adrenal medulla) exert both an inhibitory effect, through the aadrenergic receptors (fig. 1), and a stimulatory effect, through the b-adrenergic receptors, the overall effect being an inhibition of glucose-stimulated insulin release and a little effect in the basal state. Sympathetic nerve activity may also release other neurotransmitters, such as galanin, which would inhibit both basal and stimulated insulin secretion. Gastrointestinal hormones (or gut hormones) contribute to the overall insulin secretion, as shown by the higher insulin secretion after glucose given per os compared to intravenous glucose. For this action, they are also called incretins. They include: the gastric inhibitory polypeptide (GIP), secreted by the endocrine cells of duodenum and jejunum; cholecystokinin (CCK), both the long (CCK-33) and the short (CCK-8) peptide chain, released by duodenum and proximal part of jejunum after ingestion of fats and proteins; the glucagon-like peptide-1 (7–36) amide, or GLP-1 (7–36), formed from GLP-1 (the precursor proglucagon, produced by the L-cells in the distal part of small intestine, is processed by tissue-specific proteolysis to produce glucagon in pancreatic a-cells and GLP-1 in the intestine), is released after carbohydraterich meals (fig. 1); the neuropeptide Y (NPY), a neurotransmitter present in both the central nervous system and the enteric nervous system which produces stimulation of food intake (and of resting metabolic rate), while probably acting as an incretin to enhance insulin release. The counterregulatory hormones (or stress hormones) also affect insulin secretion. Glucagon is a potent stimulus for the islet b-cell (fig. 1), and intravenous bolus injection of 1 mg glucagon has been widely used to assess endogenous insulin secretion for clinical or research purposes. Glucagon stimulates insulin release mainly through glucagon receptors but not GLP-1 receptors on islet b-cells. On the other hand, insulin may affect glucagon secretion
Belfiore/Iannello
24
because capillaries go from the central part of the islets, where insulin is mainly produced, to the periphery of the islets where glucagon-producing a-cells are mainly located. The other stress hormones affect insulin secretion through a generally inhibitory action. The effect of epinephrine has been mentioned above. Cortisol and growth hormone (GH) are thought to play a role during prolonged stress periods. Leptin may potentiate glucose-induced insulin secretion by a mechanism involving cAMP or phospholipase C/protein kinase C activation. It also inhibits NPY release. In contrast to early studies, recent data indicate that amylin is a third active pancreatic islet hormone that works with insulin and glucagon to maintain glucose homeostasis. It would regulate glucose inflow to the circulation by influencing the rate of gastric emptying and would also inhibit hepatic glucose production in the postprandial period.
Assessment of Insulin Secretion Fasting Insulin Level. The fasting insulin level (normally between 5 and 15 lU/ml) may reflect the insulin secretory capacity. It may be very low (=5 lU/ml) in subjects with high insulin sensitivity (lean and/or trained subjects) and elevated (?15 lU/ml) in insulin-resistant subjects. It should be pointed out that an apparent normal insulin level in insulin-resistant diabetic subjects indicates decreased secretory capacity, since an equal level of glucose in a ‘normal’ subject would be associated with a higher insulin level which would promptly normalize glucose. It should be pointed out that the insulin values usually referred to are those obtained with the commonly used radioimmunoassay method, which yields the total insulin levels, whereas more sophisticated methods are available that allow to distinguish the true insulin from the proinsulin. True insulin may be lower than total insulin by 15–20%. Acute Insulin Response to Glucose (AIRG). AIRG following glucose given as intravenous bolus consists of a rapid increase in insulin level which returns towards normal within 10 min. The magnitude of AIRG is not affected by the preexisting glucose level, which makes this test feasible even in diabetic patients. AIRG is often absent in patients with type 2 diabetes whereas it is enhanced in insulin-resistant obese subjects. Acute Insulin Response to Non-Glucose Stimuli (AIRNG). AIRNG includes response to amino acids, neurotransmitters and hormones. AIRNG obtained with arginine increases with the increase in the preexisting glucose level. By plotting the AIRNG values against those of glycemia, a ‘curve’ is obtained which reflects the correlation between these two variables. From the analysis
Insulin Secretion and Its Pharmacological Stimulation
25
of this curve, it is possible to deduce the insulin secretory capacity of the pancreas, the maximal acute insulin response to nonglucose stimuli or AIRMAX , and the b-cell sensitivity to the potentiation effect of glucose. The AIRMAX (which indicates the maximal secretory response) is reduced in type 2 diabetes and may increase in insulin-resistant hyperinsulinemic subjects. The b-cell sensitivity to the potentiation effect of glucose is little changed in type 2 patients, suggesting preserved b-cell sensitivity in these patients.
Insulin Secretion in Type 2 Diabetes Both impaired insulin action (insulin resistance) and reduced insulin secretion (insulin deficiency) may contribute to the development of type 2 diabetes. It is now accepted that in type 2 diabetes the situation may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance. It is noteworthy that recent data would suggest that the hyperinsulinemia of insulin resistance may result from an increase in insulin secretion secondary to increased b-cell sensitivity to glucose, as well as a decrease in insulin clearance. In type 2 diabetes the b-cell mass is reduced by about 50%, which is known from experimental pancreatectomy to be not enough to cause fasting hyperglycemia. Therefore, in most type 2 patients a functional defect in b-cells may occur, leading to insulin secretory defect. This is confirmed by the almost absent acute insulin response to glucose (AIRG), diminished maximal acute insulin response to nonglucose stimuli (AIRMAX), decreased insulin secretory capacity, with normal b-cell sensitivity to the potentiation effect of glucose. Type 2 diabetes subjects have their own ‘set’ of fasting plasma glucose which is more or less increased compared to normal. This is due to reduced insulin secretion into portal vein which is unable to completely suppress hepatic glucose production, resulting in hyperglycemia. The latter, on the other hand, is somewhat ‘useful’ in that it forces the hypofunctioning b-cell to secrete more insulin. The apparently ‘normal’ fasting insulin in type 2 diabetes in the presence of fasting hyperglycemia should indeed be considered as reduced. In fact, restoring normal glucose levels in mild diabetes by an insulin infusion reduces the endogenous insulin concentration to subnormal values. The same reasoning apply for the insulin response to oral glucose, i.e. to the insulin curve during OGTT. The insulin response (area under the curve or AUC) may be normal or most often elevated in absolute terms, but should be regarded as reduced considering the elevated glycemic values. Moreover, the insulin response during OGTT may show a sluggish initial response and elevated values in the later stages, the latter perhaps resulting
Belfiore/Iannello
26
from the elevated glucose values. In type 2 diabetes there is also an increased release of proinsulin, which may account for 30% of total insulin compared to 15% in normal subjects. Concerning the insulin response to intravenous glucose, as occurs during IVGTT, in type 2 diabetes there is a marked reduction in the first phase of insulin release. The second phase may also be reduced in diabetic patients with fasting glycemia ?250 mg/dl, but may be normal or increased in ‘compensated’ patients with fasting glycemia =200 mg/dl (even if also in these instances the insulin response should be regarded as diminished, considering the existing hyperglycemia). Reduced insulin response is also recorded during prolonged glucose infusion. The insulin response to nonglucose stimuli, such as intravenous arginine, secretin, isoproterenol, isoprenaline, tolbutamide, or even a mixed meal, may be normal in type 2 diabetic patients with fasting glycemia =200 mg/dl. This is due to the potentiation of the insulin response to nonglucose stimuli exerted by the hyperglycemia present in the diabetic patients. Finally, in type 2 diabetic patients the oscillations in insulin secretion, which are significant for glycemic control, cannot be detected, even in the patients with mild form of the disease.
Causes of the Insulin Secretory Defect A major role is certainly played by genetic predisposition, but several biochemical mechanisms and neurohormonal factors may contribute. Little is known about susceptibility genes to the common polygenic forms of type 2 diabetes. Studies of genes involved in insulin secretion or insulin action have been successful to a certain extent by showing the implication of the insulinreceptor substrate-1 (IRS-1) gene, the ras associated with diabetes (rad) gene, the glucagon receptor gene, or the sulfonylurea receptor (SUR) gene (among others) in a low percentage of cases of type 2 diabetes in particular populations. However, the majority of susceptibility genes are still to be described. Recently, an inherited or acquired defect of FAD-linked mitochondrial glycerophosphate dehydrogenase in b-cells has been proposed to contribute to the impairment of insulin release in type 2 diabetes. Intravenous administration of b-endorphins or naloxone to type 2 diabetic patients enhances both basal and OGTT stimulated insulinemia, which suggests a possible pathogenetic role of these compounds in the dysfunction of b-cells. Prostaglandins may also be implicated, as suggested by the improvement of insulin response to intravenous glucose and the increase of the slope of
Insulin Secretion and Its Pharmacological Stimulation
27
glucose potentiation after infusion of sodium salicylate (inhibitor of prostaglandin synthesis). A similar effect has been observed with the a-adrenergic blocking agent phentolamine, which suggests a role of the a-adrenergic system. It has also been suggested that galanin and pancreostatin, peptides which inhibit insulin secretion, may be increased in the pancreatic islets of type 2 diabetic patients. Finally, hyperglycemia, once established, may contribute to aggravate the b-cell dysfunction, through several mechanisms most of which are included in the concept of ‘glucotoxicity’. The glucotoxicity concept may help to explain the beneficial effect on insulin secretion obtained in type 2 diabetic patients after adequate treatment achieving glycemic control as well as the transient improvement in the b-cell function which may occur in type 1 diabetic patients after therapeutical control of hyperglycemia (‘honeymoon’ phenomenon). It has been proposed that at least one factor contributing to the pathogenesis of type 2 diabetes is desensitization of the GLP-1 receptor on b-cells. At pharmacological doses, infusion of GLP-1, but not of GLP, can improve and enhance postprandial insulin response in type 2 patients. Agonists of GLP-1 receptor have been proposed as new potential therapeutic agents in type 2 diabetic patients. It should also be emphasized that complex alterations of glucidic and lipidic metabolism in the b-cells may play a role. In particular, in obese/diabetic hyperinsulinemic subjects, LC-CoA derived from the enhanced availability of FFA may affect the b-cells’ secretory response according to the following mechanism: as the glycemic level increases, the b-cells utilize more glucose; this leads to enhanced production of malonyl-CoA, which blocks the intramitochondrial transport of LC-CoA, which therefore accumulates in the cytosol and (through its complex biological effects) stimulates insulin secretion (see also chapter III and figure 3 for details). Altered expression of genes encoding enzymes in the pathway of malonylCoA formation and FFA oxidation contributes to the b-cell insensitivity to glucose in some patients with type 2 diabetes. Clearly, the detrimental impact of diabetic hyperlipidemia on b-cell function has been a relatively neglected area, but future pharmacological approaches directed at preventing ‘lipotoxicity’ may prove beneficial in the treatment of diabetes.
Insulin Secretion in Other Types of Diabetes Various, less common types of diabetes are known to occur, in which the secretory defect is based upon different mechanisms, as outlined in chapter I on Etiological Classification.
Belfiore/Iannello
28
Pharmacological Stimulation of Insulin Secretion Insulin Secretion as Modified by Sulfonylureas The main drugs able to stimulate insulin secretion are the sulfonylureas. These compounds have been used in the management of type 2 diabetes since 1955 and, when properly utilized, are easy to use and appear to be effective and safe. It is estimated that 30–40% of diabetic patients are taking oral sulfonylureas. Indications and contraindications for sulfonylureas are shown in tables 1 and 2, respectively.
Table 1. Patients candidate for sulfonylurea treatment Most patients with type 2 diabetes, not well controlled with dietary restriction and exercise Children and adults with the MODY (maturity-onset diabetes of youth) type of diabetes Obese-diabetic patients with marked insulin resistance Lean type 2 diabetic patients with preserved insulin secretory capacity
Table 2. Contraindications to sulfonylurea treatment Patients with type 1 diabetes Patients with pancreatic diabetes Patients with an acute illness or stress or undergoing surgery Patients with hepatic or liver diseases Patients predisposed to hypoglycemia: Underweight or malnourished Elderly Diabetic pregnancy: Potential teratogenicity Perinatal mortality Severe neonatal hypoglycemia Diabetic female patients during lactation Patients with a history of severe adverse reactions to sulfonylureas
Different Sulfonylureas The first oral hypoglycemic drug was synthesized in 1926 by altering the guanidine molecule. The sulfonylureas used today are derived from this native molecule. The ‘first-generation’ sulfonylureas, which were developed initially, are effective in large doses, while the ‘second-generation’ drugs, developed more recently, are effective in smaller doses. Some sulfonylureas, such as tolbutamide,
Insulin Secretion and Its Pharmacological Stimulation
29
Table 3. Main characteristics of sulfonylureas Compound
Dose, mg/day Doses q.d. Duration of hypoglycemic effect, h
Metabolism/ excretion
First generation Acetohexamide Tolbutamide Chlorpropamide Tolazamide
250–1,500 500–3,000 100–150 100–1,000
1–2 2–3 1 1–2
12–18 6–12 60 12–14
Liver/kidney Liver Kidney Liver
Second generation Glibenclamide (or glyburide) Glyburide, micronized Glipizide Gliclazide Gliquidone Glimepiride Repaglinide1
1.25–20 0.75–12 2.5–40 80–320 30–120 1–8 0.5–16
1–2 1–2 1–2 1–3 1–3 1 1–4
16–24 12–24 12–24 10–20 6–12 D24 4–6
Liver/kidney Liver/kidney Liver/kidney Liver/kidney Liver Kidney Liver
1
Repaglinide is a nonsulfonylurea hypoglycemic agent of the meglitinide family.
have a short duration of action (6 h), others, such as chlorpropamide, have a long duration of action (up to 60 h), several others show an action of intermediate duration. Some characteristics of the sulfonylureas which are or have been in clinical use are summarized in table 3. ‘First-Generation’ Sulfonylureas. Tolbutamide has a ‘short’ duration of action (see table 3) and is carboxylated by the liver to a totally inactive derivative. Being metabolized only in the liver, this compound may be useful in nephropathic diabetic patients. Tolazamide has a more potent hypoglycemic activity than tolbutamide and an ‘intermediate’ duration of action (see table 3). It is metabolized only by the liver with the production of some very little active metabolites excreted in the urine (85%). It is safer in the elderly and in nephropathic diabetic patients. Tolazamide also has a diuretic action. Chlorpropamide has a more potent hypoglycemic activity than tolbutamide and a ‘very long’ duration of action (see table 3), and therefore it can induce more hypoglycemic episodes than tolbutamide. It is hydroxylated by the liver with production of some active metabolites excreted in the urine (by 80–90%) and, thus, is contraindicated in the elderly and in nephropathic diabetic patients. Several side or toxic effects may occur with chlorpropamide,
Belfiore/Iannello
30
such as alcohol-induced flushing, occasional hypersensitivity reactions as well as water retention and hyponatremia (due to sensitization of renal tubules to antidiuretic hormone). Acetohexamide has a more potent hypoglycemic activity than tolbutamide and an intermediate duration of action. It is reduced by the liver to 1-hydroxyhexamide which is a potent hypoglycemic drug, excreted by 60% in the urine. Thus, it is contraindicated in the elderly and in nephropathic diabetic patients. Acetohexamide also has diuretic and uricosuric actions. ‘Second-Generation’ Sulfonylureas. Glyburide or glibenclamide has been used since 1969. It has a 50–100 times more potent hypoglycemic activity than the ‘first-generation’ drugs and has a relatively long duration of action. It is metabolized by the liver to several both inactive and mildly active metabolites, excreted partially in the urine (50%) and partially in the bile (50%). It may induce severe hypoglycemic episodes and is contraindicated in the elderly and in nephropathic diabetic patients. Glyburide absorption is not affected by food but it takes 30–60 min to achieve adequate plasma levels, so that this drug should be taken before the morning meal. Glipizide has been used since 1973, has a 50–100 times more potent hypoglycemic activity than the ‘first-generation’ drugs (comparable to that of glyburide) and has an ‘intermediate’ duration of action (see table 3). It is metabolized by the liver to several inactive metabolites, excreted in the urine (by 68%) and in the feces (by 10%). It may induce severe hypoglycemic episodes (similarly to glyburide) and is contraindicated in the elderly and in nephropathic diabetic patients. The absorption of glipizide is delayed by about 30 min when it is ingested with a meal, so that it is recommended to take the drug 30 min before meals. Glipizide has a greater effect than glyburide in raising postprandial plasma insulin level and lowering postprandial plasma glucose level while glyburide has a better effect than glipizide in raising fasting insulinemia and reducing fasting glycemia (probably, reducing fasting hepatic glucose production). For this metabolic difference, a ‘combined’ administration of the two sulfonylureas was suggested. Gliclazide has a potent hypoglycemic activity (comparable to that of glyburide and glipizide) and has an ‘intermediate’ duration of action. It is metabolized by the liver to several probably inactive metabolites, excreted in the urine (by 60–70%). It has been suggested that gliclazide exerts antiplatelet aggregating activity, with a potential preventing effect on diabetic microangiopathy, although this effect has not been confirmed. Gliquidone has a short duration of action (the mean half-life was approximately 1.2 h and the mean terminal half-life was 8 h), is metabolized in the liver to totally inactive or minimally active derivatives, and is excreted in the intestine (by about 100%). For these reasons, gliquidone is safer in the elderly
Insulin Secretion and Its Pharmacological Stimulation
31
and in nephropathic diabetic patients. A newly developed sulfonylurea, glimepiride, has been reported to have a more potent hypoglycemic action than glibenclamide while its ability to stimulate insulin secretion is much weaker, possibly due to less stimulation of insulin secretion and more pronounced extrapancreatic effects. It is effective at lower dosage, has a more rapid onset of action than glibenclamide and a long duration of action. There is increased plasma elimination of glimepiride with decreasing kidney function, which is explainable on the basis of altered protein binding with an increase in unbound drug. Efficacy and Interactions. Good response with sulfonylureas will occur in 70–75% of patients during the first years of treatment, provided that the patient selection is appropriate. Primary failure occurs in 15–25% of cases and may depend on a poor selection of the patients (unrecognized type 1 diabetic patients treated with sulfonylureas). Chronic therapy may be associated with progressively less beneficial effects (secondary failure), sometimes as result of intercurrent factors which impair insulin action and secretion (such as stress, infections, dietary disregard, etc.) (see also chapter III on Insulin Resistance and Its Relevance to Treatment). The response to the hypoglycemic drugs may be restored with the disappearance of the intercurrent event. All sulfonylureas are bound to serum albumin and, since a large number of drugs may compete for ionic binding sites on albumin, sulfonylureas can influence the effect of many drugs (and these drugs, conversely, can influence the effect of sulfonylureas). The physician must understand potential interactions with a number of commonly used drugs, that may significantly alter the activity of the sulfonylureas both diminishing (diuretics, b-blockers, corticosteroids, estrogens, indomethacin, alcohol, rifampicin, etc.) or increasing (sulfonamides, salicylates, clofibrate, chloramphenicol, MAO inhibitors, probenecid, allopurinol, b-blockers, alcohol, etc.) their hypoglycemic effect. It is noteworthy that some drugs (such as b-blockers and alcohol) can alter sulfonylureas activity in opposite directions. Sulfonylureas of ‘second generation’ may have less interactions than those of the ‘first generation’. Some data of literature demonstrate that serum levels of sulfonylureas (tolbutamide, chlorpropamide, glyburide and gliquidone) in treated diabetic patients show extremely interindividual variations, with no correlation between the dose and the plasma level. Mechanism of Sulfonylurea Action Acute Effects on Insulin Secretion. Sulfonylureas act primarily by acutely stimulating release of insulin from pancreatic b-cells (obviously, in presence of functioning pancreatic islets), and this stimulation of insulin secretion is a
Belfiore/Iannello
32
direct effect, as unquestionably proven by studies with perfused pancreases, isolated perifused islets and cultures of b-cells. Available data suggest that sulfonylureas bind to a specific receptor (closely associated with the ATP-sensitive K+-channels) on the outside of plasma membrane of the b-cells. Recent studies with human pancreatic islets showed that 3H-glibenclamide binds to saturable sites in islet membrane preparations in a linear fashion. This binding was both temperature- and time-dependent. Scatchard analysis of the equilibrium binding data indicated the presence of a single class of saturable, high-affinity binding sites. The displacement experiments showed the following rank order of potency of the oral hypoglycemic agents tested: glibenclamide > glimepiride ? tolbutamide ? chlorpropamide A metformin. This binding potency order was parallel with the insulinotropic potency of the evaluated compounds. Glimepiride has been reported to bind to a 65-kDa subunit of the sulfonylurea receptor. This characteristic may entail a minor effect of the K-channel in other tissues, such as myocardium (where the closure of K-channels may interfere with the repolarization process). Upon binding to their receptors, sulfonylureas inhibit the K+-channels, diminish K+ efflux and cause depolarization of the plasma membrane. This depolarization induces voltage-dependent Ca2+-channels to open and extracellular Ca2+ to enter the cell. Increased cytoplasmic Ca2+ stimulates the fusion of the secretory granule membrane with cell membrane, followed by extrusion of insulin outside the cell (exocytosis) (see also fig. 1). Metabolic studies demonstrate that sulfonylureas stimulate the first phase of insulin release and have little effect on the second phase. They can act in the absence of glucose but also may potentiate glucose-mediated insulin release. As consequence of the stimulation of secretion, sulfonylureas can induce morphological alterations of the b-cells such as degranulation, loss of zinc and aspects of emiocytosis. Chronic Effects on Insulin Secretion. Whether chronic sulfonylurea treatment results in increased insulin secretion is a controversial problem. The finding that after chronic treatment of type 2 diabetic patients insulinemia returns to pretreatment level, without deterioration of glucose control, suggests long-term extrapancreatic effects of sulfonylureas. The lower plasma glucose achieved with sulfonylurea drugs in type 2 diabetic patients might be expected to stimulate less insulin secretion (blood glucose is the major stimulus to insulin release), and this can explain the inability of some studies to demonstrate the chronic effect of sulfonylurea in stimulating insulin secretion. Available literature data, however, do not support the concept that the improvement of glycemia during chronic sulfonylurea treatment can be attributed solely to an increased insulin secretion.
Insulin Secretion and Its Pharmacological Stimulation
33
Table 4. Extrapancreatic effects of sulfonylureas Hormonal effects Potentiation of insulin action on skeletal muscle and adipose tissue glucose transport Potentiation of insulin action on hepatic glucose production (activation of glycogen synthase and glycogen synthesis) Decrease of hepatic insulin extraction Decrease of insulin degradation (inhibition of insulinase activity) Stimulating effect on gastrointestinal hormone release Direct metabolic effects Insulin receptors (partial restoration of their number in plasma membrane in type 2 obesediabetic patients) Liver (increase in fructose 2,6-bisphosphate; increase in glycolysis; decrease in gluconeogenesis; decrease in long-chain fatty acid oxidation) Skeletal muscle (increase of glucose and amino acid transport; increase of fructose 2,6bisphosphate) Myocardial tissue (increase of contractility; increase of oxygen consumption; increase of glycogenolysis; decrease of Ca2+-ATPase; increase of glucose transport and glycolysis; increase of phosphofructokinase activity and pyruvate oxidation) Adipose tissue (increase in glycogen synthase; inhibition of lipolysis, increase in glucose transport) Platelet arachidonic acid metabolism (inhibition of cycloxygenase and 12-lipoxygenase pathways)
Other Effects. Sulfonylurea treatment does not appear to stimulate proinsulin biosynthesis. On the other hand, studies performed with in vivo and in vitro animal perfused pancreases, or with isolated perifused islets and isletcell cultures, reported an acute and chronic sulfonylurea-induced inhibition of the biosynthesis of proinsulin (through unknown mechanisms). Sulfonylureas, acutely or chronically, do not alter glucagon secretion both in normal subjects and diabetic patients. Sulfonylureas appear to stimulate pancreatic d-cell somatostatin release (with unclear physiological effect). Extrapancreatic Effects of Sulfonylureas. Diverse in vitro and in vivo extrapancreatic effects of sulfonylureas have been reported over the last 30 years (most of which, however, were obtained with drug concentrations larger than those achieved in therapeutic use) (table 4). These effects of sulfonylureas are due to direct actions on liver and/or muscle and, occurring in the absence of changes in insulin binding, are probably mediated by postreceptor events. As a whole, the extrapancreatic effects of sulfonylureas are of minor clinical significance. A possible exception is glimepiride, which may exert more significant extrapancreatic actions, including activation (through dephosphorylation) of GLUT-4.
Belfiore/Iannello
34
Table 5. Sulfonylurea side or toxic effects Hematologic reactions (agranulocytosis, bone marrow or red cell aplasia, hemolytic anemia) Skin reactions (rash, pruritus, erythema, purpura, photosensitivity) Hypersensitivity reaction (rush, fever, arthralgia, angiitis, jaundice, etc.) Alcohol-induced flushing (most frequently associated with chlorpropamide treatment) Gastrointestinal complaints (nausea, vomiting, jaundice or hepatitis or cholestasis) Antithyroid activity Diuretic effect or antidiuresis with hyponatremia Cataract formation (reported in some dogs treated with high doses of glimepiride) Teratogenicity
Side or Adverse Effects of Sulfonylureas. The most important adverse effect of sulfonylureas is hypoglycemia which, although occurring less often than with insulin, when it occurs it tends to be more severe, prolonged and sometimes fatal. The incidence of sulfonylurea-induced hypoglycemia is 0.19–4.2/1,000 treatment years (compared to 100/1,000 patients/year for insulin-induced hypoglycemia) and is most frequent in patients taking long-acting drugs (such as glyburide and chlorpropramide) which, for this reason, should be avoided in patients with predisposing conditions (the best treatment of hypoglycemia is prevention). The case fatality rate of hypoglycemia induced by sulfonylureas is 4.3% (see also chapter VIII on Clinical Emergencies in Diabetes. 2: Hypoglycemia). It is noteworthy that sulfonylureas predispose to hypoglycemia during and after exercise. In this regard, it has been claimed that glimepiride maintains a more physiological regulation of insulin secretion during physical exercise, with less risk of hypoglycemia. Other sulfonylurea side effects or toxic reactions occur at low rate (1.5% for glyburide) (table 5) and appear within the first 2 months of treatment. The chlorpropamide alcohol flushing (CPAF), occurring in 30–40% of type 2 and 10% of type 1 diabetic patients, is linked to a genetic predisposition to diabetes development (autosomic trait) and can be considered a good genetic marker of type 2 diabetes mellitus.
Other Drugs Modifying Insulin Secretion Repaglinide is a nonsulfonylurea hypoglycemic agent of the meglitinide family, a new class of drugs with insulin secretory capacity which exert a rapid- and also short-acting effect, thus entailing reduced risk of long-lasting, and hence dangerous, hypoglycemia. Repaglinide appears to bind to receptor
Insulin Secretion and Its Pharmacological Stimulation
35
sites different from those of sulfonylureas (two binding sites have been identified). Repaglinide lowered fasting and postprandial blood glucose levels in animals, healthy volunteers and patients with type 2 diabetes mellitus. Repaglinide is rapidly absorbed and eliminated, which may allow a relatively fast onset and offset of action. Excretion occurs almost entirely by nonrenal mechanisms. In comparative clinical trials in patients with type 2 diabetes mellitus, repaglinide 0.5–4 mg twice or 3 times daily before meals provided similar glycemic control to glibenclamide (glyburide) 2.5–15 mg/day. Addition of repaglinide to existing metformin therapy resulted in improved glycemic control. In contrast with glibenclamide, use of repaglinide allowed patients to miss a meal without apparently increasing the risk of hypoglycemia. GLP-1 has insulinotropic action, which may explain the increased insulin response after oral compared to intravenous glucose administration, and exerts several other functions such as reduction of glucagon concentration, reduction of gastric emptying, stimulation of proinsulin biosynthesis and reduction of food intake (upon intracerebroventricular administration in animals). On these grounds, GLP-1 seems to offer an interesting perspective in treatment of diabetic patients. The observations that GLP-1 induces both secretion and production of insulin, and that its activities are mainly glucose-dependent, led to the suggestion that GLP-1 may present a unique advantage over sulfonylurea drugs in the treatment of type 2 diabetes. This peptide is able to lower and perhaps normalize fasting hyperglycemia and to reduce postprandial glycemic increments (especially in type 2 diabetic patients) but its usefulness is not completely established. Due to rapid proteolytic cleavage, the half-life of GLP-1 is too short for therapeutical use with subcutaneous injections. GLP-1 analogues with different pharmacokinetic properties (or some preparations that could be orally administered) are in development. Given the large amount of GLP-1 present in L-cells, it appears worthwhile to look for some agents that could ‘mobilize’ this endogenous pool of the ‘antidiabetogenic’ gut hormone GLP-1. Interference with sucrose digestion using a-glucosidase inhibition moves nutrients into distal parts of the gastrointestinal tract and, thereby, prolongs and augments GLP-1 release. Antiarrhythmic agents with Vaughan Williams class Ia action have been found to induce a sporadic hypoglycemia. Recent investigation has revealed that these drugs induce insulin secretion from pancreatic b-cells by inhibiting ATP-sensitive K+ (K-ATP) channels in a manner similar to sulfonylurea drugs. It is possible that in the future, pharmacological compounds will be found that may act on GK and improve b-cell insulin secretion.
Belfiore/Iannello
36
Suggested Reading Belfiore F, Rabuazzo AM, Iannello S, Campione R, Castorina S, Urzı´ F: Extrapancreatic action of glibenclamide: Reduction in vitro of the inhibitory effect of glucagon and epinephrine on the hepatic key glycolytic enzymes phosphofructokinase and pyruvate kinase. Eur J Clin Invest 1989;19:367–371. Draeger E: Clinical profile of glimepiride. Diabetes Res Clin Pract 1995;28(suppl):139–146. Drucker DJ: Glucagon-like peptides. Diabetes 1998;47:159–169. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG: A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21:1897–1903. Lebovitz HE: Oral hypoglycemic agents; in Rifkin H, Porte D (eds): Diabetes mellitus. Theory and Practice, ed 4. New York, Elsevier, 1990, pp 554–574. Matschinsky FM: Banting Lecture 1995: A lesson in metabolic regulation inspired by glucokinase glucose sensor paradigm. Diabetes 1996;45:223–241. Philipson LH, Steiner DF: Pas de deux or more: The sulfonylurea receptor and K+ channels. Science 1995;268:372–373, 423–429.
F. Belfiore, Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, I–95123 Catania (Italy) Tel. +39 095 330981, Fax +39 095 310899, E-Mail
[email protected]
Insulin Secretion and Its Pharmacological Stimulation
37
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 38–55
Chapter III
............................
Insulin Resistance and Its Relevance to Treatment F. Belfiore, S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Insulin Action Introduction Insulin exerts its metabolic effects on the insulin-sensitive tissues, i.e. on liver, muscle and adipose tissue. In these tissues, insulin action is the result of complex mechanisms. We can distinguish (1) insulin binding to specific receptors and the following sequence of events along the insulin signalling pathway, which ultimately lead to (2) the insulin metabolic effects at postreceptor level.
The Insulin Receptor The insulin receptor is a heterodimer composed of two chains or subunits, the a- and the b-chain, linked by disulfide bridges. The a-subunit is extracellular in location and is the site of insulin binding. The b-subunit is transmembrane in location and originates from the signal transduction. Normally there is a large surplus in the number of receptors (i.e. there is a large amount of spare receptors). Nevertheless, considering that insulin binding to its receptors is a random phenomenon, it follows that the higher the number of insulin molecules or receptor units, the higher the number of insulin molecules which will bind to the receptor units. An increase in the insulin level causes a decrease in the receptor number on the plasma membrane (downregulation of insulin receptors), a phenomenon that may occur in conditions of persistent hyperinsulinemia (insulin-resistant states, including obesity).
38
Fig. 1. Schematic representation of dose-response curves of insulin action in the normal state and in conditions of impaired insulin action. For explanation, see the text.
When the receptor number is decreased, the number of insulin molecules that bind to the receptors at a given insulin level will be reduced, and therefore the insulin effects will be diminished, i.e. there is insulin resistance. However, by increasing the insulin level, the number of insulin molecules that bind to the receptors can be increased toward the normal and therefore the insulin effects can be restored; moreover, by increasing further the insulin level, the maximum effect can be reached. This condition is called decreased insulin sensitivity. By plotting the insulin concentrations (on the abscissa) against the insulin effect (on the ordinate), the insulin dose-response curve is obtained. This curve, in the case of insulin resistance due to reduced receptor number, will be shifted to the right, as the maximum effect is reached at very high insulin levels. On the other hand, when the insulin resistance is due to defects in postreceptor steps of insulin action (see below), the dose-response curve is flattened and the maximum insulin effect is not reached even at very high insulin concentrations. When the two conditions coexist, the insulin doseresponse curve will be shifted to the right and flattened (fig. 1). Concerning the fate of the insulin-receptor complexes, several data suggest that they are internalized and delivered to endosomes, the acidic pH of which induces the dissociation of insulin molecules from insulin receptors and their sorting in different directions: insulin molecules are targeted to late endosomes
Insulin Resistance and Its Relevance to Treatment
39
and lysosomes where they are degraded whereas receptors are recycled back to the cell surface in order to be reused. To understand the function of insulin receptors, it should be recalled that protein kinases that directly phosphorylate proteins are divided into two major classes: those that phosphorylate tyrosine (tyrosine-specific protein kinases) and those that phosphorylate serine and threonine (the serine/threonine-specific protein kinases). The receptor b-subunit can be phosphorylated on serine, threonine and tyrosine residues and possesses intrinsic protein-tyrosine kinase activity. Insulin stimulates this activity (i.e. the insulin receptor is itself an insulin-sensitive enzyme) which is responsible for both autophosphorylation of the receptor itself and phosphorylation of tyrosine residues of various cellular substrates, including the insulin receptor substrates (IRS-1 and IRS-2). The latter, through a mechanism not yet fully understood, trigger a sequence of events which include phosphorylation/dephosphorylation of several cytoplasmatic proteins which, in turn, will induce the spectrum of insulin effects (fig. 2). Two insulin receptor isoforms have been identified, the A and the B form, which, however, revealed no difference in their tyrosine kinase activity in vivo. Protein-tyrosine phosphatases (PTPases) play an essential role in the regulation of reversible tyrosine phosphorylation of cellular proteins that mediate insulin action. In particular, some data suggest a possible role of the transmembrane PTPase in insulin receptor signal transduction. Recent studies suggest that the insulin receptor tyrosine kinase inhibitor, the membrane glycoprotein PC-1, may modulate insulin activity (and may play a role in insulin resistance – see the second part of this chapter).
Metabolic Effects of Insulin (Postreceptor Effects) The mechanisms of postreceptor insulin effects can be distinguished into: (a) translocation (and activation) of glucose transporters (the GLUT-4 isoform) from the intracellular pool to the cell membrane; (b) activation/inhibition of several enzymes of intermediary metabolism through either changes in concentrations of ions or regulatory compounds which bind to the enzyme at sites distinct from the substrate-binding site (allosteric effectors), or covalent modifications of the enzyme molecules often consisting of phosphorylation/ dephosphorylation processes; (c) induction/repression mechanisms leading to changes in enzyme concentration through regulation of the synthesis of the enzyme proteins. Translocation and activation/inhibition processes are shortterm mechanisms (occurring within seconds or minutes), the induction/repression processes are long-term mechanisms (hours).
Belfiore/Iannello
40
Stimulation of glucose transport across the cell membrane is one of the main effects of insulin in muscle and adipose tissue, and is the result of the translocation of glucose transporter (the GLUT-4 isoform)-containing vesicles from an intracellular storage pool to the surface membrane. This event is mediated through IRSs, which in turn activate PI-3-kinase isoforms (fig. 2). Translocation and activation of GLUT-4 is favored by its dephosphorylation. In addition to glucose transport, insulin also stimulates the transport across the cell membrane of amino acids and ions, mainly potassium and phosphate. Insulin regulates several key metabolic steps (fig. 1). In doing so, insulin is opposed by the four counterregulatory hormones (the rapid-acting glucagon and catecholamines, and the slow-acting growth hormone and cortisol). Insulin affects the pathways of glucose utilization as well as the synthesis and degradation of macromolecules (glycogen, triglycerides and proteins) by regulating the activity of ‘key enzymes’. Indeed, along each metabolic pathway, there is one or more key step(s) catalyzed by key enzymes. These are enzymes which, because of their low activity and sensitivity to regulatory factors (including hormones), regulate the overall rate of the pathway to which they belong. In particular, insulin (or, better, its prevalence over the counterregulatory hormones) exerts the following effects (fig. 1): (a) favors glucose utilization by activating the three key glycolytic kinases, namely hexokinase (and GK in the liver), phosphofructokinase and pyruvate kinase; in the liver, this is associated with repression of the opposing key gluconeogenic enzymes: glucose-6-phosphatase, fructose bisphosphatase and phosphoenolpyruvate carboxykinase plus pyruvate carboxylase; (b) stimulates glucose oxidation, by activating the key enzyme pyruvate dehydrogenase in the mitochondria; (c) lowers FFA level by inhibiting lipolysis in the adipose tissue and reduces ketogenesis from FFA in the liver (see chapter VII on ketoacidosis for further explanation); (d) favors glycogen synthesis and depresses glycogenolysis by activating the enzyme glycogen synthase while inhibiting glycogen phosphorylase; (e) enhances triglyceride synthesis and refrains triglyceride hydrolysis (lipolysis) by inhibiting the hormone sensitive lipase; (f ) finally, insulin stimulates protein synthesis and opposes protein degradation (or proteolysis). The main insulin actions are summarized in table 1. Thus, the overall action of insulin is (1) to increase glucose utilization in muscle, liver and adipose tissue while depressing glucose production in the liver, which results in blood glucose lowering; (2) to lower FFA level by refraining lipolysis, and (3) to prevent ketone formation in the liver by opposing ketogenesis.
Insulin Resistance and Its Relevance to Treatment
41
Fig. 2. Simplified representation of the mechanisms of action of insulin, glucagon, catecholamines (sympathetic activation) and acetylcholine (parasympathetic activation). (Continuous lines ending with black arrows indicate transformation or translocation of substrates or ions; dotted lines ending with white arrows indicate stimulation; dotted lines ending with filled circles indicate inhibition.) Insulin: Insulin receptors, with their tyrosine kinase activity, phosphorylate several protein substrates (IRS1, IRS2, Shc, etc.) which in turn phosphorylate (activate) several protein kinases (PI3-K, MAP-K, PKB, PKCz, PKCl, etc.) and these, through a complex cascade of phosphorylation/dephosphorylation, produce the various insulin effects (glucose transport, enzyme activation/inhibition, induction/repression of enzymes and other proteins). Other hormones: Glucagon and catecholamines (b-receptors) activate adenylate cyclase (with the participation of Gs proteins), thus producing cAMP and stimulating PKA. Catecholamines (a2-receptors) inhibit adenylate cyclase (with the participation of Gi proteins) and therefore exert opposite effects. Acetylcholine (parasympathetic stimulation) activate PLC (with the participation of Gp proteins) which split PIP3 thus producing IP3 and DAG. IP3 favors the increase in cytosolic Ca (release of Ca from the endoplasmic reticulum stores or Ca influx from outside the cell) thus activating the CaCalm PK. DAG activates PKC. The activation of these protein kinases will eventually result in enzyme activation-inhibition. Note that protein kinases may activate (through phosphorylation) some protein phosphatases, resulting in dephosphorylation of some key enzymes. Most key enzymes of anabolic pathways are active in the dephosphorylated form (example: glycogen synthase), and are activated by insulin and inhibited by glucagon and catecholamines. Most key enzymes of catabolic pathways are active in the phosphorylated form (example: glycogen phosphorylase, hormonesensitive lipase) and are activated by glucagon or catecholamines and inhibited by insulin. Abbreviations (alphabetic order): a2>a2-adrenergic receptor; AC>adenylate cyclase; b>b-adrenergic receptor; cAMP>cyclic AMP; DAG>1,2-diacylglycerol; G-4>isoform 4
Belfiore/Iannello
42
Table 1. Metabolic effects of insulin Stimulation
Inhibition
Synthesis of macromolecules (and allied processes): Glycogen Glucose transport Glucose phosphorylation Triglycerides Lipoprotein lipase Proteins Amino acid transport Nucleic acids Other: Ion transport Substrate utilization: Glycolysis Glucose oxidation
Degradation of macromolecules (and allied processes): Glycogen Proteins Amino acid oxidation Gluconeogenesis Lipolysis FFA oxidation Ketogenesis
Insulin Resistance Introduction Insulin resistance can occur because of defects in insulin action at prereceptor, receptor or postreceptor level. Besides rare cases of abnormal insulins or presence of receptor antibodies (prereceptor defects), reduction in the insulin receptor number is a relatively common factor contributing to insulin resistance. In addition, insulin binding (and therefore insulin action) may also be affected in rare conditions in which qualitative alterations occur in the receptor (e.g. decrease in the receptor affinity). Postreceptor mechanisms include the signals triggered by insulin binding to the receptor as well as the resulting changes in several key steps of intracellular metabolism. of the glucose transporter; Glg>glucagon receptor; Gq>a further type of G protein; Gs and Gi> stimulatory and inhibitory G proteins; Ins>insulin receptor; IP3>inositol-1,4,5trisphosphate; IRS1>insulin receptor substrate-1; IRS2>insulin receptor substrate-2; M>muscarinic receptor; MAP-K>mitogen-activated protein kinase; PC-1>an ecto-protein kinase probably interfering with insulin receptor tyrosine kinase; PI3-K>phosphatidylinositol-3 kinase; PIP2>phosphatidylinositol-4,5-P; PKA>protein kinase A; PKB>protein kinase B; PKC(f, k)>protein kinase C, forms f and k; PKC>protein kinase C; PLC> phospholipase C; Shc>protein containing a single SH2 domain, substrate of insulin receptor tyrosine kinase; TNFa>tumor necrosis factor-a; Tyr-K>tyrosine kinase activity of the insulin receptor.
Insulin Resistance and Its Relevance to Treatment
43
Insulin Resistance in Type 2 Diabetes and Obesity In type 2 diabetic patients, insulin resistance is due to impaired insulin action either at receptor and postreceptor level, and may result from two etiological components, the genetic background and some acquired factors, of which overweight and obesity are certainly the most important ones. Insulin Receptor Defects A common cause contributing to decreased insulin action consists of reduction in the insulin receptor number which, however, most often is secondary to insulin resistance and the associated hyperinsulinemia, through the ‘downregulation’ mechanism. In type 2 diabetes, an incomplete activation of the insulin receptor tyrosine kinase appears to contribute to the pathogenesis of the signalling defect. Available data suggest that the impaired tyrosine kinase function of the insulin receptor is not due to an inherited defect but rather is caused by a modulation of insulin receptor function. The B isoform is increased in the skeletal muscle in type 2 diabetes, which may not have significant functional significance. In this context, it is worthwhile noting that in obese subjects, increased PTPase activity has been found in the adipose tissue that can dephosphorylate and inactivate the insulin receptor kinase. The membrane glycoprotein PC-1 (PC-1) has been proposed to be an ecto-protein kinase capable of phosphorylating itself as well as exogenous proteins, and would act as an inhibitor of the tyrosine kinase activity of the insulin receptor. PC-1 was found to be increased in tissues (muscle and fibroblasts) of insulin-resistant subjects. Moreover, in transfected cell lines that overexpress PC-1 there is a reduction in the insulin-stimulated insulin receptor tyrosine phosphorylation. These and other data raise the possibility that PC-1 has a role in the insulin resistance of noninsulin-dependent diabetes mellitus as well as of obesity. In obese patients, skeletal muscle shows reduction in the phosphorylation of insulin receptor and IRS-1 and in PI-3-kinase activation. The scarce expression of these proteins would contribute to determine muscular insulin resistance. Hyperglycemia might directly inhibit insulin-receptor tyrosine kinase activity and the receptor function. This appears to be mediated by activation of certain protein kinase C isoforms which form stable complexes with the insulin receptor and modulate the tyrosine kinase activity of the insulin receptor through serine phosphorylation of the receptor b-subunit.
Belfiore/Iannello
44
Postreceptor, Metabolic Mechanisms Key Metabolic Steps Resistant to Insulin. Concerning glucose metabolism, by means of complex procedures including the glucose clamp technique, labelled compound infusion and indirect calorimetry, it has been shown that in patients with type 2 diabetes there is an impairment of insulin-mediated glucose utilization by peripheral tissue (muscle) as well as a reduced insulin suppression of hepatic glucose production. Thus, reduction in insulin sensitivity occurs for both the peripheral glucose utilization and the hepatic glucose production. Reduction in the receptor number may play a role, although it is more probable that this is a secondary phenomenon due to the downregulation of receptors by the hyperinsulinemia which accompanies insulin resistance. A defect in intracellular dissociation of the insulin-receptor complex might contribute by altering the receptor recycling and insulin processing. However, especially in the most severe cases, reduction in insulin responsiveness of peripheral glucose utilization does occur, suggesting postbinding defects in insulin action. Impairment of insulin-mediated glucose utilization by peripheral tissue (muscle) is due mainly to reduction in nonoxidative glucose utilization (glycogen synthesis) and to a minor extent to reduced glucose oxidation. Concerning nonoxidative glucose utilization (glycogen synthesis), the defect has been tentatively located at the level of the key enzyme glycogen synthase, or the glycogen-synthase-activating enzyme, protein phosphatase-1. Other data suggest the implication of earlier steps of glucose utilization, such as glucose transport and/or glucose phosphorylation to glucose-6-P (effected by the enzyme hexokinase), which may secondarily impair glycogen synthase activation. On the other hand, the defect in glucose oxidation has been located at the level of the pyruvate dehydrogenase reaction. Concerning lipid metabolism, resistance of lipolysis to the antilipolytic action of insulin often occurs in type 2 diabetic patients, especially when overweight or obesity is present, which results in elevated FFA plasma levels. However, it should be noted that, when obesity is present, elevation of plasma FFA may also be due to the increased fat mass, even in the presence of normal lipolysis. Insulin suppresses VLDL production in insulin-sensitive humans partly by suppressing plasma FFA levels and partly by a non-FFA-mediated, direct hepatic mechanism (inhibition of ApoB synthesis). Insulin-resistant hyperinsulinemic obese individuals are resistant to this suppressive effect of insulin on VLDL-ApoB production. Resistance to the normal suppressive effect of insulin, in addition to other metabolic abnormalities associated with insulin resistance, may contribute to postprandial and postabsorptive hypertriglyceridemia. When obesity is present, insulin resistance of fat storage may also be present, which may be an adaptation limiting further fat deposition, but is maladaptive in terms of risk factors for atherosclerosis.
Insulin Resistance and Its Relevance to Treatment
45
Genetic Factors (Changes in Predisposed Individuals). The genetic component of the insulin resistance is suggested by the observation that in firstdegree relatives of type 2 patients, the insulin-stimulated glucose metabolism was reduced, which was accounted for by a defect in nonoxidative glucose utilization (glucose storage as glycogen), whereas glucose oxidation rate appeared normal. Consistently, impaired activation of glycogen synthase by insulin has been reported in these individuals. The glycogen-synthase-activating enzyme, protein phosphatase-1, also has an abnormally low level of activity in these subjects. Moreover, in insulin-resistant offspring of parents with noninsulin-dependent diabetes mellitus, after muscle glycogen-depleting exercise, there is a severely diminished rate of muscle glycogen synthesis during the recovery period (2–5 h), which is known to be insulin-dependent. These data, however, do not necessarily mean that the defect is located at the glycogen synthase level, since defects in the earlier step of glucose metabolism, such as transport and/or phosphorylation, may also impair glycogen synthase activation. Acquired Factors: The Reciprocal Negative Influences of FFA and Glucose Metabolism. Among the acquired factors favoring insulin resistance, obesity, which results from absolute or relative hyperphagia and/or hypoactivity, is certainly the most important one. Obesity is associated with elevated FFA levels, as well as with enhanced availability of glucose (hyperphagia) and insulin. In these conditions, there is a competition between FFA and glucose as energetic fuels. Indeed, reciprocal negative influences between FFA and glucose metabolism occurs through the mechanisms outlined below (fig. 3). In fact, the utilization of FFA (tendencially enhanced in obesity, because of the trend to high plasma FFA levels) leads to the formation of long-chain CoA or acyl-CoA (LC-CoA) in the cytosol, followed by the entry of LC-CoA into the mitochondria through the action of the enzyme carnitine palmitoyl transferase-1 (CPT-1) and by the b-oxidation of LC-CoA to acetyl-CoA. Both these compounds inhibit glucose utilization, thus inducing insulin resistance. In fact: (a) acetyl-CoA inhibits the key enzyme of glucose utilization, pyruvate dehydrogenase; the resulting inhibition of oxidative glucose utilization will maintain saturated the glycogen stores, thus refraining further glucose conversion to glycogen, i.e. the nonoxidative glucose utilization; (b) LC-CoA (directly or through the generation of regulatory metabolites) exerts complex metabolic effects, including inhibition of nonoxidative glucose metabolism (fig. 3). On the other hand, the metabolism of glucose (favored in obesity by dietary carbohydrates and hyperinsulinism) leads to the formation of malonyl-CoA (fig. 3), a regulatory compound which inhibits CPT-1, thus reducing the intramitochondrial transport of LC-CoA and therefore its b-oxidation. This favors the accumulation of LC-CoA in the cytosol.
Belfiore/Iannello
46
Fig. 3. Reciprocal inhibitory effects between the metabolism of glucose and that of FFA. Metabolism of FFA (gray background, steps 1–6): The metabolism of FFA leads to inhibition of glucose oxidation (through the effect of acetyl-CoA on pyruvate dehydrogenase – step 4) and of nonoxidative glucose utilization (through the complex effects of LC-CoA – steps 5 and 6). Moreover, glycolysis is also inhibited through the effect of citrate on the key glycolytic enzyme phosphofructokinase (step 9). The inhibition of pyruvate dehydrogenase (step 4) by acetyl-CoA is the basis of the Randle’s glucose-FFA cycle. Metabolism of glucose (white background, steps 4, 7–13): Glucose utilization leads to formation of malonyl-CoA which, by inhibiting carnitine palmitoyl transferase-1 (step 3), reduces FFA b-oxidation and increases LC-CoA concentration. Dotted arrows indicate the regulatory effects. From: Belfiore F, Iannello S, Mol Genet Metab 1998;65:121–128.
In summary, when the metabolism of FFA is stimulated (as it occurs in obesity), the enhanced production of LC-CoA (cytosol) and of acetyl-CoA (mitochondria) leads to inhibition of glucose utilization, thus inducing insulin resistance which is often followed by hyperinsulinemia. The latter stimulates glucose utilization and therefore the production of malonyl-CoA, which inhibits CPT-1, thus decreasing intramitochondrial transport and b-oxidation of FFA (and therefore acetyl-CoA formation). This, however, may further increase the LC-CoA concentration in the cytosol, which may maintain insulin resistance (fig. 3). It is noteworthy that obesity, through the increased formation of acetylCoA and LC-CoA (derived from the enhanced availability and oxidation of FFA), exerts an inhibitory effect on the two metabolic steps (glycogen synthesis
Insulin Resistance and Its Relevance to Treatment
47
Fig. 4. Scheme showing the metabolic effects of enhanced availability and oxidation of FFA, as occurs in obesity. In muscle: reduction of glucose utilization. In liver: reduced glucose utilization (and insulin uptake) and enhanced gluconeogenesis. In the pancreas: stimulation of insulin secretion. From: Belfiore F, Iannello S, Mol Genet Metab 1998;65: 121–128.
and glucose oxidation) which are already defective in the type 2 diabetic patients and in the genetically predisposed subjects. The metabolic picture resulting from increased FFA availability and oxidation in obesity is outlined in figure 4. Hormonal Factors Counterregulatory Hormones. Prevalence of counterregulatory hormones (stress hormones) over insulin may contribute to the insulin resistance phenomenon. Glucagon tends to be elevated because of a decreased b-cell/a-cell ratio in the pancreas. This hormone counteracts the insulin actions, especially in the liver, by favoring glycogenolysis and gluconeogenesis over the opposing processes of glycogeno-synthesis and glycolysis (promoted by insulin). In occasional patients or under particular circumstances (intercurrent infections or other illnesses, stress, trauma, etc.), other counterregulatory hormones, primarily cortisol, might participate in opposing the insulin actions. Tumor Necrosis Factor-a (TNFa). TNFa is one of the proteins formed by adipocytes, whose production increases with increasing adipocyte mass (obesity). Indeed, TNFa (as well as chronic hyperinsulinemia that induces insulin resistance) triggers increased Ser/Thr phosphorylation of the insulin
Belfiore/Iannello
48
receptor (IR) and of its major insulin receptor substrates, IRS-1 and IRS-2, which may be a molecular mechanism for uncoupling insulin signaling, as enhanced Ser/Thr phosphorylation of IRS-1 and IRS-2 impairs their interaction with the juxtamembrane region of IR. Thus, the TNFa produced by adipocytes may function as a local ‘adipostat’ to limit fat accumulation. Increased production of TNFa by fat cells stimulates downregulation of the insulin-sensitive glucose transporter, GLUT-4, in adipocytes. TNFa is overexpressed in the adipose tissue of obese rodents and humans, and is associated with insulin resistance. The exact role of TNFa, however, remains to be established. Leptin. Leptin is the product of OB gene. This 16-kDa protein is produced by mature adipocytes and is secreted in the plasma. Its plasma levels are strongly correlated with adipose mass in rodents as well as in humans. Leptin inhibits food intake, reduces body weight and stimulates energy expenditure. Leptin binds to a long-form of leptin receptor in the hypothalamus, thus stimulating the release of GLP-1 and decreasing the production of neuropeptide Y, a neuromediator (stimulator) of food intake. Recent studies have shown that leptin inhibits insulin secretion and has anti-insulin effects on liver and adipose tissue. If these effects are confirmed, leptin could play a role similar to that of TNFa and could participate in the insulin resistance of obesity and type 2 diabetes. Serum leptin is increased in insulin-resistant offspring of type 2 diabetic patients. Other Factors Contributing to Insulin Resistance Decreased blood flow and capillary density has been proposed as mechanisms contributing to insulin resistance both in type 2 diabetes and in obese insulin-resistant Pima Indians. It has been suggested that insulin action may be modulated by blood flow. Insulin resistance in moderately obese women was associated with an abnormal vascular reactivity to stress, entailing exaggerated blood pressure response; an enhanced vasoconstriction to stress may mediate this response. Insulin-induced attenuation of noradrenaline-mediated vasoconstriction is impaired in the obese rats. This defect in insulin action could reside in the endothelial generation of nitric oxide, as endothelial function is also abnormal. A distinct capillary endothelial dysfunction may be involved in the insulin resistance syndrome. However, the capillary wall crossing is rate-limiting for muscle glucose uptake (and lactate release) in control subjects but not in postabsorptive hyperglycemic insulin-resistant subjects. On the other hand, in a prospective (15 years) study it was found that capillary density was increased rather than decreased in subjects with impaired
Insulin Resistance and Its Relevance to Treatment
49
glucose tolerance who later developed diabetes, a fact that might be regarded as a compensatory mechanism for intracellular defects in glucose metabolism. In healthy young men, there is a negative relationship between directly measured whole-blood viscosity and insulin sensitivity (clamp technique) as a part of the insulin resistance syndrome, which supports the hypothesis that insulin resistance has a hemodynamic component. Insulin-resistant first-degree relatives of type 2 diabetic patients were shown to have an increased number of the glycolytic, fast-twitch (white), type IIb muscle fibers compared to the oxidative, slow-twitch (red), type I and IIa fibers (which are those normally responsive to insulin). Whether this finding reflects a reduced physical activity level and fitness in the relatives or is of primary genetic origin remains to be determined.
Insulin Resistance in Type 1 Diabetes Although type 1 diabetes is due to severe insulin deficiency, it should be considered that chronic lack of insulin action may produce insulin resistance, through several mechanisms. As already pointed out, insulin exerts both short-term and long-term effects, the latter consisting of induction or repression of the synthesis of key enzymes. Therefore, in the tissues of the insulin-deficient subject there will be a decreased content of the enzymes ‘induced’ by insulin (example: hepatic GK) and accumulation of the enzymes repressed by insulin (example: gluconeogenic enzymes). Upon insulin administration, some degree of ‘resistance’ (reduced effect) may occur until the enzyme balance is normalized, i.e. until the amount of those enzymes ‘induced’ by insulin is restored and the accumulation of those enzymes ‘repressed’ by insulin decreases to the normal level, which may takes several hours or even 1–2 days. In addition, severe insulin deficiency is always associated with active lipolysis and enhanced release of FFA, which counteract insulin action through the mechanism of the glucose-FFA cycle, already discussed. When the type 1 diabetic patient becomes severely decompensated and ketoacidosis supervenes, the insulin action may be further disturbed by the interference of the acidosis with insulin binding to its receptor as well as by the reduced response of the intracellular enzymes caused by the hyperosmolality.
Rare Genetic Forms of Insulin Resistance These are described in chapter I on Etiological Classification, Pathophysiology and Diagnosis.
Belfiore/Iannello
50
Drugs Ameliorating Insulin Resistance Introduction The recognized major role played by insulin resistance in the pathogenesis of type 2 diabetes is the rational basis for the use of drugs capable of improving insulin sensitivity and consequently enhancing insulin action. The most used of these drugs today is the biguanide compound metformin (dimethylbiguanide), but other potentially useful agents, today under clinical investigation, will also be considered, such as the thiazolidinediones (pioglitazone, troglitazone and rosiglitazone) and still others.
Metformin The main biguanides (phenformin and metformin) were first synthesized in 1929 and were shown to be potent antihyperglycemic agents. They were rediscovered in 1957 and were widely used in Europe to treat obese type 2 diabetic patients. Phenformin was withdrawn in many countries because of an association with lactic acidosis, but metformin, which does not bear the same risk when appropriately prescribed, resurfaced in the 1980s and was shown to increase insulin sensitivity. This led to its approbation for use in the USA in 1994. Actions. Unlike sulfonylureas (and the biguanide phenformin), metformin does not bind to plasma proteins and is not metabolized by the liver. Metformin has an absolute oral bioavailability of 40–60%, and gastrointestinal absorption is apparently complete within 6 h of ingestion. An inverse relationship was observed between the dose ingested and the relative absorption with therapeutic doses ranging from 0.5 to 1.5 g, suggesting the involvement of an active, saturable absorption process. Metformin is eliminated rapidly by the kidney and has a mean plasma elimination half-life after oral administration of between 4.0 and 8.7 h (approx. 6 h). The elimination is prolonged in patients with impairment of renal function and correlates with creatinine clearance. Therapeutic blood levels may be 0.5–1.0 mg/l in the fasting state and 1–2 mg/l after a meal. However, monitoring of blood levels may be useful only to confirm the diagnosis of lactic acidosis. Metformin has no effect in the absence of insulin, because the drug seems to act primarily by enhancing insulin action at postreceptor level. Metformin ameliorates hyperglycemia by improving peripheral sensitivity to insulin and reducing hepatic glucose production (via gluconeogenesis) as well as by limiting gastrointestinal glu-
Insulin Resistance and Its Relevance to Treatment
51
cose absorption. Metformin also increases glucose utilization by intestine, primarily via nonoxidative metabolism. This results in extra lactate prodution, which is taken up by the liver and used as a gluconeogenic substrate. Unlike sulfonylureas, it does not stimulate insulin secretion, nor does it aggravate hyperinsulinemia or cause hypoglycemia or weight gain (weight stabilizes or decreases mainly because of loss of adipose tissue). Its more prominent effect in type 2 diabetic patients is on postprandial hyperglycemia. In the UKPDS, it was noted that among patients allocated intensive blood-glucose control (aimed to reduce fasting plasma glucose to =6 mmol/l), metformin showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint, all-cause mortality and stroke. Addition of metformin in sufonylurea-treated patients was associated with an increased risk of diabetes-related death compared with continued sulfonylurea alone, but this point was not supported by sufficient evidence. Moreover, epidemiological assessment in 4,416 patients did not show an increased risk in diabetes-related death in patients treated with a combination of sulfonylurea and metformin. Other Effects. Metformin, alone or added to a sulfonylurea (glyburide), besides its lowering effect on fasting plasma glucose and glycated hemoglobin, also reduces plasma total and LDL cholesterol and triglycerides. Metformin may exert other potential beneficial effects, such as weight loss (or minimal weight gain), improved blood flow in patients with peripheral vascular disease, reduction in tissue plasminogen activator inhibitor (tPAI-1) and fibrinogen. Metformin action on fibrinolysis and von Willebrand factor (vWF) was evaluated in the ‘Biguanides and the Prevention of the Risk of Obesity (BIGPRO)1’ trial; weight loss was the main factor associated with the decrease in PAI-1, in accordance with the recent demonstration of production of PAI-1 by adipocytes. Metformin had a significant lowering effect on two factors, tPA antigen and vWF, mainly secreted by the endothelial cells, which suggests an effect of the drug on the production or the metabolism of these two hemostatic proteins. Use in Type 1 Diabetic Patients. For its potentiation of insulin actions, metformin has been evaluated as an adjunct to insulin in type 1 diabetic patients. Although when metformin is added to insulin therapy the insulin requirement is likely to decrease, further studies on large populations and of long duration are required before the insulin+metformin therapy can be routinely recommended for type 1 diabetic patients. Side Effects. The most common side effects of metformin are mild, transient, gastrointestinal symptoms (diarrhea, nausea, anorexia, abdominal pain, metallic taste, in decreasing order) which are usually self-limiting, as well as malabsorption of vitamin B12 and folic acid (although reported
Belfiore/Iannello
52
cases of megaloblastic anemia are rare). Gastrointestinal side effects can be minimized by initiating metformin therapy at a low dose and gradually titrating upward, and by taking metformin with meals. Unlike phenformin, metformin can be used with a very low risk of lactic acidosis. The observed association between metformin and lactic acidosis may be coincidental rather than causal. Intravascular administration of iodinated contrast media to patients who are receiving metformin can result in lactic acidosis. However, this rare complication occurs only if the contrast medium causes renal failure. Therefore, metformin must be withheld after the administration of the contrast agent for 48 h, during which the contrast-induced renal failure becomes clinically apparent. If renal function is normal at 48 h, the metformin can be restarted. Concerning drug interactions, it should be noted that plasma levels of metformin may be reduced by fibers (guar gum) and a-glucosidase inhibitors, and increased by cimetidine (which decreases the elimination of metformin). Dose. In the UKPDS, metformin treatment was started with one 850-mg tablet per day. If normoglycemia was not obtained, the dose was increased to 850 mg twice daily and, if hyperglycemia still persisted, to 1,700 mg in the morning and 850 mg with the evening meal (maximum dose 2,550 mg). Conclusions. Metformin is actually an antihyperglycemic (rather than hypoglycemic) drug, which has shown some lipid-lowering effect and vasoprotective properties. It should be considered a first-line agent, particularly in obese and/or hyperlipidemic type 2 diabetic patients. Metformin will be most useful in managing patients with poorly controlled postprandial hyperglycemia, as its postprandial effect is much greater than that of the sulfonylureas. In contrast, sulfonylureas or insulin are more effective for managing patients with poorly controlled fasting hyperglycemia. In secondary sulfonylurea failure, combined metformin+sulfonylurea treatment significantly improves glycemic control beyond that achieved with either agent alone. Metformin-sulfonylurea also appears to be as effective as insulin or insulin plus sulfonylureas, suggesting that such combination therapy may obviate or substantially delay insulin therapy in type 2 diabetic patients (‘combined’ therapy is discussed in chapter VI on Overview of Diabetes Management: Combined Treatment and Therapeutic Additions).
Thiazolidinediones Thiazolidinediones (pioglitazone, troglitazone, rosiglitazone) reduce fasting hyperglycemia and insulinemia by improving insulin sensitivity in skeletal
Insulin Resistance and Its Relevance to Treatment
53
muscles, adipose tissue and hepatocytes, while normalizing a wide range of metabolic abnormalities associated with insulin resistance. Reported effects include: (a) decrease in plasma triglyceride, FFA and LDL cholesterol levels and increase in plasma HDL cholesterol; (b) increased expression of glucose transporters GLUT-1 and GLUT-4; (c) activation of glycolysis in hepatocytes; (d) antagonism towards some of the effects of TNFa; (e) decrease in blood pressure; (f ) inhibition of vascular smooth muscle cell proliferation and hypertrophy; (g) enhanced endothelium-dependent vasodilation, and (h) antioxidant action. Finally, although thiazolidinediones do not stimulate insulin secretion, they improve the secretory response of b-cells to insulin secretagogues. Rosiglitazone (a PPARc Agonist). Rosiglitazone, like other thiazolidinedione compounds, is a PPARc agonist, inasmuch as it potently and specifically stimulates peroxisome proliferator-activated receptors-c (PPARc) and sensitizes cells to insulin. Indeed, rosiglitazone is an antidiabetic agent which enhances sensitivity to insulin in the liver, adipose tissue and muscle, resulting in increased insulin-mediated glucose disposal. This compound, therefore, improves insulin resistance, which is a key underlying metabolic abnormality in most patients with type 2 diabetes. In contrast with troglitazone, rosiglitazone does not appear to be hepatotoxic, on the basis of clinical and in vitro studies, and does not induce cytochrome P450 3A4 metabolism. However, the drug is contraindicated in patients with history or signs/symptoms of liver diseases and its use requires monitoring of liver function tests. Moreover, rosiglitazone does not interact significantly with nifedipine, oral contraceptives, metformin, digoxin, ranitidine, or acarbose. In clinical trials, rosiglitazone 2–12 mg/day (as single daily dose or two divided daily doses) improved glycemic control in type 2 diabetic patients, as shown by decrease in fasting plasma glucose and glycated hemoglobin (HbA1c). Addition of rosiglitazone 2–8 mg/day to existing sulfonylurea, metformin or insulin therapy achieved reductions in fasting plasma glucose and HbA1c. Consistent with its mechanism of action, rosiglitazone appears to be associated with a low risk of hypoglycemia (=2% of patients receiving monotherapy) and did not increase the risk of alcohol-induced hypoglycemia.
Other Compounds The long-acting, nonsulfhydryl-containing ACE inhibitor, trandolapril, alone and in combination with the Ca2+-channel blocker, verapamil, can significantly improve whole-body glucose metabolism by acting on the insulin-
Belfiore/Iannello
54
sensitive skeletal muscle glucose transport system in obese Zucker rats. Data on the role of TNFa raise the possibility that pharmacological inhibition of this factor may provide a novel therapeutic target to treat patients with type 2 diabetes.
Suggested Reading American Diabetes Association: Consensus Development Conference on Insulin Resistance, Nov 5–6, 1997. Diabetes Care 1998;21:310–314. Bell PM, Hadden DR: Metformin. Endocrinol Metab Clin North Am 1997;26:523–537. Scheen AJ: Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359–371. Daniel JR, Hagmeyer KO: Metformin and insulin: Is there a role for combination therapy? Ann Pharmacother 1997;31:474–480. Davidson MB, Peters AL: An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102:99–110. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: A balanced overview. Diabetes Care 1992;15:318–368. Melchior WR, Jaber LA: Metformin: An antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother 1996;30:158–164. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.
F. Belfiore, Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, I–95123 Catania (Italy) Tel. +39 095 330981, Fax +39 095 310899, E-Mail
[email protected]
Insulin Resistance and Its Relevance to Treatment
55
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 56–71
Chapter IV
............................
Diet and Modification of Nutrient Absorption S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Diet Introduction In the treatment of diabetes mellitus, changes in lifestyle play a major role, in addition to treatment with insulin or oral glucose-lowering drugs. For most patients with type 2 diabetes, the changes in lifestyle (concerning diet and exercise) are the cornerstone of treatment whereas the pharmacologic intervention represents a supplementary treatment for those patients who do not respond adequately to lifestyle changes. Dietary caloric restriction ameliorates hyperinsulinemia and hyperglycemia in obese type 2 diabetics (and improves other metabolic parameters; see table 1) and reduces the incidence of type 2 diabetes in subjects at risk or with impaired glucose tolerance (IGT). Glucose tolerance and insulin sensitivity improve when normal body weight is achieved or approached. Indeed, even a 7–10% of weight loss is enough to improve insulin resistance in all obese type 2 diabetics. Nutritional needs are different in type 1 (lean) or type 2 (overweight or obese) diabetic patients. Diet education is crucial and requires the participation of the patient and its family in the planning-diet process and in the implementation of the adequate strategies to promote adherence to dietary intervention. Goals of dietary therapy in diabetes are to reach and maintain ideal body weight (IBW), to maintain fasting and postprandial glycemic levels as close as possible to normal and to achieve optimal blood lipid values, while providing adequate caloric intake as required for the various metabolic needs.
56
Table 1. Effects of weight loss on altered parameters in obese type 2 diabetics
Insulin resistance B Hyperglycemia B Hypertriglyceridemia B Total hypercholesterolemia B LDL cholesterol B HDL cholesterol C Hypertension B
Modern recommended diet for diabetes is relatively high in complex carbohydrates (55–60% of total calories) and fibers, low in fats (25–30%) especially saturated (=10%, to reduce dyslipidemia and atherosclerosis associated to diabetes) and limited, but adequate, in proteins (15%).
Body Weight and Fat Distribution Increase in body weight (related to height) or frank obesity are highly relevant to the pathogenesis of type 2 diabetes. The ‘ideal’ body weight (actually the weight associated with the lowest mortality) for each inch of height can be derived from the 1983 Metropolitan Life Insurance Weights for Heights tables, referring to 4.2 million subjects aged 20–59. For people over 55, the tables of median weights derived from the data of the National Health and Nutrition Examination Surveys (NHANES) may also be used. A commonly used parameter relating weight to height is the body mass index (BMI), which is calculated as follows: BMI>weight (kg)/height (m)2. In the clinical setting, a BMI from 20 to 25 can be regarded as ‘normal’ while a BMI ?27 can be regarded as indicative of overweight. In some studies, the following values have been suggested for the BMI: =23.9>normal value for women; =25> normal value for men; 23.9–28.6 (female) and 25–30 (male)>overweight; ?28.6 (female) or ?30 (male)>obesity. In 1995, the WHO established the following BMI values: normal>18.5–24.9; overweight, 1st degree>25.0–29.9; overweight, 2nd degree (or obesity)>30.0–39.9; overweight, 3rd degree (or severe obesity) q40. It should be noted that the BMI associated with the lowest mortality increases with age, ranging from =20 at age 20 to about 28 at age 70. It should be noted that from the above values of BMI it is possible to calculate the corresponding weight values through the formula: weight (kg)>BMI¶height (m)2. Assessment of adipose tissue distribution is of paramount importance to distinguish between visceral (or central or abdominal
Diet and Modification of Nutrient Absorption
57
or android) obesity and subcutaneous (or gynoid) obesity. A largely used parameter is the the waist-to-hip ratio (WHR), i.e. the ratio between the circumference at the waist and that at hip level. The cut-off value distinguishing normal from abnormal WHR has not yet been definitely established. In some studies, values of WHR ?0.81 for female and ?0.92 for male subjects were considered indicative of visceral/android obesity whereas lower WHR values were regarded as indicative of subcutaneous/gynoid obesity. The American Heart Association has reported that a WHR ?0.80 should be used to indicate increased risk of cardiovascular disease in women. Other recent data suggest an upward shift in the critical threshold for WHR to q0.90, at which point there is an elevation in cardiovascular disease risk factors. It has also been shown that the simple waist circumference is a good index of central (visceral) obesity, as is also the sagittal diameter. The values of waist circumference indicating increased visceral fat and cardiovascular risk were found to be ?94 cm in men and ?80 cm in women. Recently, it has been reported that, while a waist circumference q96.5 cm is associated with high cardiovascular risk, even a waist circumference q76.2 cm entails significant risk. Interestingly, threshold values of waist girth corresponding to critical amounts of visceral adipose tissue do not appear to be influenced by sex or by the degree of obesity. It has also been estimated that a waist girth of approximately 95 cm in both sexes, WHR values of 0.94 in men and of 0.88 in women, and sagittal diameters of 22.8 cm in men and 25.2 cm in women correspond to a critical amount of visceral adipose tissue, equal to a fat area of 130 cm2. The amount of intra-abdominal (visceral) fat may be precisely measured with computed tomography (CT), which however is an expensive procedure. Echography is also being used to quantify the fat tissue and its distribution.
Total Caloric Requirement The caloric requirement of diabetic patients is similar to that of normal subjects and changes with age, sex and occupational daily work or physical activity (i.e. patients engaged in a heavy activity require a larger caloric intake). Other factors may influence dietary regimen, as the type of diabetes and the associated diseases. In lean adult diabetic patients, caloric intake should maintain a normal weight, while in obese diabetic patients (especially with upper body fat distribution) a caloric restriction is required to achieve a desirable weight. Noticeably, dietary restriction may improve metabolic control even before weight loss is attained.
Iannello
58
Sedentary normal patients need approximately 30 cal/kg IBW/day while active normal patients need approximately 35–40 cal/kg/day. Overweight sedentary patients need 20–25 cal/kg/day and active obese patients need 30–35 cal/kg/day, while underweight patients need 35 cal/kg/day if sedentary and 40–50 cal/kg/day if active. In elderly sedentary diabetic patients, 20 cal/kg/day are usually required (after 50 years of age approximately 10% less calories for each decade is required). A more accurate assessment of the caloric needs may be achieved by using appropriate formulas to calculate the rest metabolic rate (RMR), such as those of Harris & Benedict which are based on weight, height, age and sex. Since subjects of the same weight but of different height have similar RMR, formulas may be simplified by considering only weight, age and sex. RMR should be increased by 30, 50 or 70% for low, medium or high levels of physical activity. Table 2 shows the caloric requirement according sex and age for selected weights and activity levels, based on similar formulas. In diabetic children the caloric needs depend on the rate of growth and activity pattern. Children 4–6 years old require 90 cal/kg/day and children 7–10 years old require 80 cal/kg/day. It is important to allow an adequate caloric intake in juvenile diabetes. Caloric requirement in children may also be calculated by adding to the baseline value of 1,000 cal/day the amount of 100–125 cal for every year of age up to 12 years. Youngsters should consume 3 meals daily with 2 or 3 snacks (eaten at the same time each day) to minimize glycemic fluctuations and the risk of hypoglycemic episodes. After the caloric content and the composition of the diet are established, the prescription of a diet was in the past made by utilizing the data in the Exchange Lists for Meal Planning published by the American Diabetes Association. A more useful approach might be to use the precalculated diets (of various caloric content) prepared by several diabetes associations or other authoritative sources. However, it is now recognized that the diet should be individualized and prepared by taking into account the eating habits and other lifestyle factors. It is clinically relevant that 7–35% of adolescent females with type 1 diabetes may have an eating disorder, such as anorexia or bulima nervosa.
Dietary Components Dietary Carbohydrate Carbohydrates are the most important source of energy and provide about 4 cal/g. The carbohydrate intake of diabetic patients should be equal to that of nondiabetic subjects. A dietary carbohydrate content of about 50–60% of total energy intake seems adequate in diabetic patients.
Diet and Modification of Nutrient Absorption
59
Table 2. Caloric needs according to age, sex, weight1 and physical activity Sex and age group
Weight kg
Men 18–30 years old
Average 31–60 years old
Average Women 18–30 years old
Average 31–60 years old
Average
Physical activity rest rest low low medium kcal/kg kcal/day kcal/kg kcal/day kcal/kg
medium high high kcal/day kcal/kg kcal/day
68 72 76 80 74
25 25 24 24 24.5
1,723 1,784 1,844 1,905 1,814
33 32 32 31 31.9
2,240 2,319 2,397 2,476 2,358
38 37 36 36 36.8
2,585 2,675 2,766 2,857 2,721
43 42 41 40 41.7
2,929 3,032 3,135 3,238 3,084
68 72 76 80 74
25 24 23 23 23.5
1,667 1,713 1,760 1,806 1,736
32 31 30 29 30.6
2,167 2,227 2,288 2,348 2,257
37 36 35 34 35.3
2,500 2,570 2,639 2,709 2,605
42 40 39 38 40.0
2,833 2,912 2,991 3,070 2,952
56 60 64 68 62
24 23 23 22 22.8
1,323 1,383 1,442 1,502 1,413
31 30 29 29 29.7
1,720 1,798 1,875 1,953 1,836
35 35 34 33 34.2
1,985 2,074 2,164 2,253 2,119
40 39 38 38 38.8
2,249 2,351 2,452 2,553 2,401
56 60 64 68 62
23 22 21 21 22.0
1,309 1,342 1,374 1,407 1,358
30 29 28 27 28.6
1,701 1,744 1,787 1,829 1,765
35 34 32 31 33.0
1,963 2,012 2,062 2,111 2,037
40 38 37 35 37.4
2,225 2,281 2,336 2,392 2,309
1
Caloric needs at rest (RMR) per day were calculated according to the following formulas (as reported by G. Bray): for 18- to 30-year-old men: (0.0630¶kg weight+2.8957)¶240; for 31- to 60-year-old men: (0.0484¶kg weight+3.6534)¶240; for 18- to 30-year-old women: (0.0621¶kg weight+2.0357)¶240; for 31- to 60-year-old women: (0.0342¶kg weight+3.5377)¶240. RMR was then multiplied by 1.3, 1.5 or 1.7 for low, medium or high physical activity, respectively.
Carbohydrates are available as complex or simple sugars. In diabetic patients, complex carbohydrates or polysaccharides should be preferred. Complex carbohydrates include: starches (present in large amounts in rice, cereals, potatoes, pulses and vegetable roots), dextrins (derived from hydrolyzed starch), glycogen (contained in liver and muscle), cellulose or pectins (indigest-
Iannello
60
Table 3. Glycemic index of some foods Bread Rice Potatoes Bananas Spaghetti Oranges
100% 83% 81% 79% 66% 66%
Beans Grapes Apples Milk Pears Lentils
65% 62% 53% 49% 47% 43%
ible complex carbohydrates contained in plant foods). In diabetics, simple carbohydrates should be restricted. They include monosaccharides (glucose present in oranges and carrots, fructose present in honey and ripe fruits, and galactose derived from hydrolyzed lactose) and disaccharides (sucrose present in beetroot and sugar cane, lactose present in milk, and maltose derived from hydrolyzed starch). The formerly claimed diabetogenic effect of sucrose overconsumption has not been confirmed by epidemiological or experimental studies. However, in diabetic patients, sucrose-rich foods cause a rapid rise in glycemic values, which can be prevented by consuming these foods as part of a mixed meal. The recommended disaccharide (sucrose plus other glucosecontaining disaccharides) consumption by diabetic people should not exceed 5–10% of the total caloric intake. Sucrose addition as sweetener should not exceed 20 g/day. Fructose is a natural monosaccharide, used as a sweetener. It is converted to glucose (and stored as glycogen) or triglyceride in liver. In diabetics with insulin deficiency and impaired hepatic glycogen synthesis, fructose-derived glucose contributes to the hyperglycemia. Thus, the safety of fructose use in diabetes is a debated topic. Starches are hydrolyzed to dextrins, then to maltose and finally to glucose (through the effect of gastric acid and intestinal enzymes). They are useful in the diabetic diet because they are slowly digested and absorbed, inducing lower increments of the glycemic and insulinemic values than equivalent amounts of glucose or simple sugars. It is well established that equimolar amounts of carbohydrate in different foods induce different glycemic postprandial excursions. Jenkins et al. [1981] have elaborated a ‘glycemic index’, representing the incremental area under 2 h glycemic curve of food divided by the corresponding area under 2 h glycemic curve after ingestion of a portion of white bread containing equivalent amounts of carbohydrates, multiplied by 100 (table 3). Reference can also be made to the glycemic response after glucose ingestion, in which instance the glycemic index for glucose is 100. Foods containing simple sugars have a high glycemic index, raising glycemia and insulinemia faster and to a greater extent, and therefore are contraindicated in diabetic patients. However, several factors can influence the food glycemic response, including: (a) type of diabetes, age,
Diet and Modification of Nutrient Absorption
61
sex, body weight, physical activity and race; (b) physical form of starches, size of food particles, food processing and preparation, fiber or fat or protein content of food, different digestion or absorption or transit of different starchor sugar-containing foods, etc. Dietary Fat Fats are an important source of energy, providing about 9 cal/g, and difference in the amount and type of dietary fat can have relevant metabolic effects. In patients with IGT or type 2 diabetes or decompensated type 1 diabetes, elevated plasma levels of triglycerides and cholesterol frequently occur. Both hypertriglyceridemia and hypercholesterolemia respond in part to diet alterations. The recommended fat intake is p30% of total calories (=10% of saturated fats, 6–8% of polyunsaturated fats and 14–12% of monounsaturated fats given as olive oil). Low-fat diets are often high in carbohydrate (being the proportion of proteins relatively constant), which may favor hypertriglyceridemia. This effect may be attenuated by supplementation with fibers. Saturated fats (which are solid at room temperature) are most often from animal source (milk, butter, cheese, bacon fat, fatty meat, etc.), but they are also contained in high concentrations in coconut and palm oils. Diets high in saturated fat are atherogenic (increasing total and LDL cholesterol levels) and favor insulin resistance; thus, a diet restricted in saturated fats is recommended. Unsaturated fats (which are liquid at room temperature) derive from vegetable source and include monounsaturated and polyunsaturated fats. A diet high in monounsaturated fatty acids or MUFA (most often assumed as olive oil, as it occurs with the Mediterranean diet) does not increase LDL levels, may improve insulin sensitivity, glycemic control and HDL cholesterol levels, and decreases plasma triglycerides. For this reason, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) set free the intake of monounsaturated fat in diabetic patients. On the contrary, a diet high in polyunsaturated fatty acids or PUFA (such as corn, sunflower and safflower oils) reduces total and LDL cholesterol but decreases HDL cholesterol as well; moreover, some data from the literature would suggest that they may promote carcinogenesis in experimental animals. The intake of cholesterol should be restricted to =300 mg daily, avoiding cholesterol-rich foods (table 4), which can produce a 15–20% reduction of plasma cholesterol level. Excessive cholesterol intake causes increase in total plasma cholesterol and LDL cholesterol, which can be reduced by increasing the polyunsaturated/saturated fat ratio (which should be kept at ?0.8). The polyunsaturated fatty acids of the omega-3 class (eicosapentaenoic and docosahexaenoic acids), which can be formed from a-linolenic acid
Iannello
62
Table 4. Cholesterol content of some foods (mg/100 g) Brain Egg yolk Lamb kidney Chicken liver Caviar Butter
2,000 1,480 804 746 350 250
Oysters Lobster Cream Cheese, cheddar Whole milk Egg white
200 150 133 100 34 0
(through elongation and desaturation), are contained in fish oils and are useful to reduce the coronary risk of diabetic patients (decreasing VLDL production, lowering arterial blood pressure, reducing platelet aggregation and prolonging bleeding time). This explains the low prevalence of coronary heart disease in the Greenland Eskimos (consuming 5–10 g of fish oil fatty acids daily for a lifetime) and in the Japanese fish eaters of coastal villages. A dietary supplementation with fish or fish oil should, therefore, be recommended. It would be advisable to replace in 2–3 meals a week the red meat with fish. However, three considerations speak against an excessive intake of fish or fish oil: (a) fishes of coastal waters and lakes accumulate a large quantity of mercury and chlorinated hydrocarbons; (b) in some type 2 diabetic patients, 3-omega fatty acids may deteriorate glycemia (both increasing hepatic glucose production and impairing insulin secretion), and (c) in patients with hypercholesterolemia but without hypertriglyceridemia the metabolic effects of fish oil are uncertain. Recently, new fat substitutes were proposed for use in the diet of diabetic patients. One of these products is named Olestra and is made from sucrose and long-chain fatty acids, is heat-stable, tastes like vegetable oil, promotes cholesterol excretion and is calorie-free being not metabolized or absorbed. Another fat substitute is named Simpless and is made from egg white or whey protein of milk (using a process of microparticulation which confers a taste of fat), has a low-calorie content, and is useful to make ice-cream, yogurt, margarine, cheeses, etc. Dietary Protein Proteins are formed by amino acids and provide about 4 cal/g of energy. Some amino acids cannot be synthesized by humans and must be introduced with diet (essential amino acids). The animal proteins (contained in meat, chicken, fish, egg, milk, etc.) are of high biological value, containing adequate amount of essential amino acids, while vegetable proteins (peas, beans, dry fruits, cereals, etc.) are of low biological value, laking some essential amino acids. Leucine and arginine have important biologic effects, stimulating insulin
Diet and Modification of Nutrient Absorption
63
secretion, while other amino acids are gluconeogenic and ketogenic. The amount of proteins that should be recommended to diabetic patients depends upon several factors, such as the patient age, the nutritional status (undernutrition or malnutrition) and particular situations (growing, pregnancy, lactation, debilitating diseases, nephropathy, uremia, hepatic diseases, etc.). The role of dietary protein in the development and progression of diabetic nephropathy is debated while it is clearly defined that a moderately low protein diet is the best approach for treating renal disease of diabetic patients (see chapter on Diabetic Nephropathy). The recommended amount of proteins in diabetic diet is of 12–20% of total calories. In diabetic subjects a high-protein diet can increase renal blood flow, glomerular filtration rate and intraglomerular pressure, accelerating glomerulosclerosis to end-stage renal failure (Brenner’s hypothesis). It is useful to substitute, at least in part, vegetable proteins for animal proteins, even if proteins from animal source do not seem to significantly increase kidney workload. In subclinical or incipient stages of diabetic nephropathy, glycemic control and low protein intake (0.8 g/kg IBW/ day) may reduce renal blood flow, restore normal glomerular hemodynamics, decrease proteinuria and delay the progression of nephropathy. In overt diabetic nephropathy with albumin excretion, the recommended protein restriction should be from 0.6 to 0.8 g/kg/day. In cases of protein restriction, essential amino acids should be supplemented. To maintain energy balance, a low protein diet must be high in carbohydrates and fats and may exacerbate hyperglycemia, hypertriglyceridemia or hyperinsulinemia, increasing total and LDL cholesterol and decreasing HDL cholesterol. Moreover, in diabetic patients a low protein dietary content may favor a negative nitrogen balance and muscle wasting. Dietary Fibers In normal subjects and type 2 diabetic patients, several studies demonstrated an improvement of glucose tolerance and a reduction of insulin secretion when a diet high in fiber was consumed. In type 1 diabetics, high-fiber diet was found to decrease glycosuria, as well as basal and postprandial glycemic levels. Moreover, high-fıber intake may improve other metabolic parameters, and may also exert a preventive effect on cancer of bowel and diverticular disease (diseases favored by the modern tendency to consume lowfiber, refined foods). Dietary fibers are heterogeneous and consist of several complex polysaccharides resistant to gastrointestinal digestive enzymes (even if certain fibers are metabolized in the colon). Fibers can be water soluble or insoluble and their effects are variable according to the different biochemicalphysiological characteristics. Celluloses, hemicelluloses and lignins bind water and cations and are insoluble (wheat products and bran) whereas pectins,
Iannello
64
Table 5. Foods naturally rich in fibers Legumes
Beans, peas, chickpeas, lentils
Vegetables
Broccoli, artichokes, zucchini, carrots, eggplants, string beans, squash, potatoes, tomatoes, celery, cabbage, onions, beets, fennels, turnips, radishes, asparagus, cucumbers, cauliflower, mushrooms
Fruits
Apples, blackberries, pears, strawberries, oranges, plums, bananas, grapefruit, pineapples, peaches, cherries, apricots, kiwis, mandarins
Cereals
Bran (100%), bread (rye), bread (whole-grain wheat), rice, wheat flour (whole grain)
gums and mucilages form gels and are soluble (oats, fruits and legumes). The foods naturally rich in fibers are legumes, roots, tubers, whole-grain cereals, fruits and green leafy vegetables (table 5). Usually, the soluble fibers (especially those with high viscosity) exert useful metabolic effects, whereas insoluble fibers contribute to increase fecal bulk, promote movements of intestinal content, being useful in constipation (which may also result from autonomic diabetic neuropathy). The physiological effects of fibers are influenced by osmolality or pH, mixture of fibers and foods, water retention, fermentation by bacteria, etc. Soluble fibers would exert their beneficial effects on carbohydrate and lipid metabolism through several mechanisms, which include: (a) satiating effect; (b) delayed gastric emptying time; (c) decreased release of gut hormones, including intestinal insulin secretagogues (as GIP); (d) delayed small intestine transit time and altered colonic emptying time; (e) binding of bile acids, with impaired intestinal absorption of cholesterol; (f ) formation of gels that sequester or hide nutrients (carbohydrates, fats, cholesterol, etc.), providing a physical barrier that separates complex carbohydrates from digestive enzymes, with reduced digestion and absorption in small intestine; (g) increase of fecal bulk with accelerated intestinal transit, which may reduce absorption of nutrients; (h) fermentation by the bacteria in the colon to gases and short-chain fatty acids, which would suppress neoglucogenesis, and (i) improved peripheral insulin sensitivity and increased insulin receptor binding. It is interesting that fibers have the best effects when naturally contained in aliments while they have poorer effects when added as pharmaceutical products to dietary foods. Diets useful to improve both fasting and postprandial hyperglycemia in diabetic patients have been suggested, which are rich in fibers naturally contained in foods. These diets are very rich in carbohydrates (up to 70%) and fibers (up to 35 g/day/1,000 kcal, both in soluble
Diet and Modification of Nutrient Absorption
65
and insoluble forms). In these fiber-rich diets, fibers would mitigate the deleterious effect of the high carbohydrate content on glucose metabolism, and would reduce total or LDL cholesterol and triglycerides (only in diabetics), while lowering blood pressure and favoring weight loss in obese patients. In hypocaloric diets, the usually recommended fiber supplementation is in the amount of 25 g/1,000 kcal (associated with high water assumption to induce fiber swelling). High-fiber diets can cause (especially in the first 7–10 days) cramping, abdominal discomfort, flatulence and diarrhea. These diets may also impair absorption of minerals and vitamins if used for a long time (in which instance, supplementation of calcium, trace elements and vitamins may be required). They may also increase the risk of bezoar formation, especially when a diet high in fibers is contraindicated (patients with gastrointestinal dysfunction, gastroparesis or altered absorption from pancreatic enzyme deficiency). Large amounts of dietary fibers may not be well tolerated by children, pregnant diabetic women and elderly subjects. Alcohol and Other Nutrients Alcohol provides about 7 cal/g, is not a food but is another source of energy that should be considered in a dietary plan. Interestingly, in women a decreased risk (50%) of developing diabetes with increasing alcohol intake was found and this effect was probably related to lower BMI linked with alcohol consumption. Allowed intake should not exceed 10 g/day. Excessive alcohol intake should be avoided in diabetic patients, because it inhibits gluconeogenesis and can favor hypoglycemic episodes in subjects treated with insulin or drugs. In hypertriglyceridemic patients, alcohol may exacerbate dyslipidemia and liver steatosis. Diabetic patients may also suffer from associated diseases which require special modified diets. In the presence of congestive heart failure, hypertension and kidney disease, dietary sodium should be restricted. The sodium restriction may range from 500 to 1,000 mg/day (maximum intake =3 g/day), although the use of diuretics may reduce the need for a severe sodium restriction, which makes foods less palatable and may provocate hypotension and fluid or electrolyte disorders. Sweeteners Sweeteners can be distinguished into caloric (or natural) sweeteners and noncaloric (or artificial) sweeteners (table 6). In both type 1 and 2 diabetic patients, the classical sweetener, sucrose, can be allowed in the maximum amount of 20 g/day, especially if associated to a mixed meal, because it does not deteriorate metabolic control. An excessive sucrose intake should be avoided,
Iannello
66
Table 6. Sweeteners for diabetic patients Caloric or natural sweeteners Sucrose Fructose Sugar alcohols (sorbitol, mannitol, xylitol) Noncaloric or artificial sweeteners Saccharin Cyclamates Aspartame
especially in hypertriglyceridemic or obese or severely decompensated diabetic subjects. Sucrose is the most cariogenic of the nutritive sweeteners, and caries is a problem in people with diabetes. Alternative sweeteners have been proposed (sometimes as combinations of caloric and noncaloric sweeteners). An ideal sucrose substitute for diabetic patients should taste good and not induce hyperglycemia or elevation of plasma lipids; it should also contain few calories, have an adequate stability and consistency and be of low cost. Fructose is naturally found in honey and fruits and is 1–1.8 times as sweet as sucrose. Its caloric content is about 4 cal/g (equal to that of sucrose) but fewer calories are required to provide the same sweetness. The ingested fructose is phosphorylated to fructose-1-P in the liver, independently by insulin, and after splitting by aldolase it enters the glycolytic pathway and may be converted into glucose or triglyceride. The fructose intake does not cause side effects unless it exceeds 75 g (0.5 g/kg/day in children). Large oral amounts (?50 g) may cause diarrhea. In doses up to 30–35 g it does not impair glycemic control in well-compensated diabetics while in decompensated patients it may aggravate hyperglycemia and hypertriglyceridemia. Xylitol is a sugar alcohol derived from xylose, which is naturally present in fruits and vegetables. It has a sweetness equivalent to that of fructose, produces about 4 cal/g, is slowly absorbed and does not exacerbate glycemia or triglyceridemia (although it may induce a transient increase of uric acid synthesis). In excessive doses it may cause osmotic diarrhea. Sorbitol (as well as mannitol) is a sugar alcohol, obtained by reduction of glucose or fructose, which contains about 4 cal/g. It is slowly absorbed, yet it may increase glycemia in poorly compensated diabetic patients. Large amounts (30–50 g/day) may induce osmotic diarrhea. Saccharin is the most used artificial sweetener with no caloric content. It is not metabolized and is excreted unchanged in urine. In high doses, saccharin was reported to induce malignancy of the urinary bladder in experimental animals, but studies in diabetic subjects indicate no relationship between sac-
Diet and Modification of Nutrient Absorption
67
charin and bladder cancer. The FAO/WHO suggests a dose of 0–2.5 lg/kg in adults. Cyclamates are 30 times as sweet as sucrose and have no caloric value; in very high doses (2,500 mg/kg/day) they are reported to induce tumors of the urinary bladder in rats. Although no evidence of malignancy exists in humans, cyclamates were banned from the US market; however, they are still available outside the USA. Aspartame is a nutritive sweetener consisting of a synthetic dipeptide. Compared to sucrose, it has the same caloric content (about 4 cal/g) but is 180–200 times more sweet, so that negligible calories are required to provide the same sweetness. It has a good taste, but it is instable in liquid solution and during heating, and is 4–5 times as expensive as saccharin. Some side effects were reported such as phenylketonuria in predisposed subjects, neuroendocrine disorders and brain tumors. These data were not confirmed by FDA, that has set 50 lg/kg/day as a safe daily aspartame intake. The alternative sweeteners with no or low caloric value are certainly useful in the management of diabetic and obese patients that find pleasantness in sweet foods.
Hypocaloric Diet in Overweight Type 2 Diabetes In type 2 diabetes, caloric restriction should be correlated with the degree of overweight or obesity, and the calculation of appropriate calories depends upon the body weight and the physical activity of the patient. In slightly overweight patients, a 1,600–1,800 kcal/day diet may be appropriate. In the cases with more marked overweight, a hypocaloric diet of about 1,000–1,500 kcal/day should be prescribed. In these diets, the protein content should not be =0.8 g/kg IBW. With weight loss, in most obese diabetic patients the carbohydrate metabolism will improve, so that insulin or hypoglycemic drugs may be reduced or withdrawn. Even a modest weight loss may be associated with significant metabolic improvement, although marked individual variations occur. This improvement primarily involves fasting glycemia and is correlated with decreased hepatic glucose output. These favorable effects may have a positive impact on the overweight diabetic patient with regard to the compliance to the hypocaloric diet. The very low calorie diet (VLCD: 800–500 kcal/day, mostly derived from high-quality proteins, with vitamin and mineral supplementation) should be avoided in diabetic patients for the risk of severe arrhythmias or coronary symptoms. Moreover, a long-term evaluation of VLCD (compared to conventional diets) has demonstrated no significant difference on weight loss. A VLCD should be limited to type 2 diabetic patients who are 50% or more
Iannello
68
over IBW and who do not respond to conventional balanced diets, excluding those with recent myocardial infarction, hepatic disease, renal failure or cerebrovascular disease. Monitoring of electrocardiographic changes, urea or creatinine level and electrolyte disorder is required.
Diet and Exercise Exercise is a relevant component in a program of weight loss in diabetic patients. It improves glucose tolerance, lowers glycemia, increases peripheral insulin sensitivity and reduces risk factors for coronary heart disease (ameliorating hypertension and blood lipid profile). The combination of diet plus exercise is more effective than diet alone or exercise alone in producing longterm weight loss, in maintaining the weight loss over time and in reducing the dose of hypoglycemic drugs. The recommended exercise (walking or stationary bicycle riding) should be of low or moderate intensity but of long duration, and is especially useful in adult or older obese type 2 diabetic subjects. The exercise should be performed at least every 2–3 days for optimum effect (examples: stationary bicycle riding or brisk walking for 30 min/day, or active swimming for 1 h 3 times/week). Because exercise may increase the risk of acute or delayed hypoglycemia, a prospective reduction in insulin dose for regular exercise should be used as well as a supplementary snack of about 40 g of carbohydrates. In decompensated diabetic patients with insulin deficiency, exercise is contraindicated (especially if prolonged, severe or unusual) raising glycemia and ketone levels. Alcohol may exacerbate the risk of hypoglycemia after exercise. Diabetic patients should be encouraged to increase their physical activity gradually, with increments of the activities within their daily lives (walking to work, using stairs rather than elevators, etc.). However, the effects of exercise on the caloric balance (and therefore on weight loss) may be less than expected for several reasons. In fact, from the energy lost during exercise, those calories should be subtracted that the patient would have lost with his usual activity. Moreover, often the exercise stimulates the appetite, leading to enhanced caloric assumption. Finally, in some tense individuals, exercise may induce muscular relaxation, which means decreased isometric muscular work.
Conclusion In conclusion, the reduction of the caloric intake in obese people may have a relevant effect on the frequency of type 2 diabetes. On the other hand, a proper nutritional management of obese diabetic patients is the most
Diet and Modification of Nutrient Absorption
69
important factor of treatment (even if often patients are unable to lose weight or to maintain the reduced weight). A professional consultation with the physician or the dietician is recommended (especially for new patients) at the beginning of diet and then at regular intervals to promote the adherence to dieting and to verify metabolic control of diabetes and weight loss. Dietary adherence is a serious problem in both type 1 and, especially, type 2 diabetic patients. To improve compliance to diet, some strategies were recommended: (a) a meal plan (adequate to the patient’s lifestyle and to the stage of the disease) that involves long-term changes of eating and nutritional habits; periodical reviews of meal plan are needed; (b) the education, which can improve motivation and dietary adherence providing the patient with useful information in an acceptable form to manage effectively nutrition and exercise; (c) a strong feeling between physician and patient (and his relatives for young people), and (d) an interaction afforded by group sessions, in which diabetic patients can exchange experiences and information, providing solutions and behavioral changes through peer example.
Modification of Nutrient Absorption Agents capable of modifying the absorption of complex carbohydrates or lipids, such as a-glucosidase inhibitors and Orlistat, will be discussed in Chapter VI (Overview of Diabetes Management).
Suggested Reading American Diabetes Association: Nutritional principles for the improvement of diabetes and related complications. Diabetes Care 1994;17:490–518. American Diabetes Association: Clinical practice recommendations 1997. Diabetes Care 1997;20(suppl 1): 1–70. Diabetes and Nutrition Study Group of the EASD: Nutritional recommendations for individuals with diabetes mellitus. Diabetes Nutr Metab 1995;8:1–5. Han TS, van Leer EM, Seidell JC, Lean ME: Waist circumference as a screening tool for cardiovascular risk factors: Evaluation of receiver operating characteristics (ROC). Obes Res 1996;4:533–547. International Diabetes Federation (IDF), 1998–1999 European Diabetes Police Group: A Desktop Guide to Type 2 (Non-Insulin-Dependent) Diabetes mellitus. Brussels, IDF, 1999. Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM, et al: Glycemic index of foods: A physiological basis for carbohydrate exchange. Am J Clin Nutr 1981;34:362–366. Lemieux S, Prud’homme D, Bouchard C, Tremblay A, Despres JP: A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996;64:685–693. Perry AC, Miller PC, Allison MD, Jackson ML, Applegate EB: Clinical predictability of the waist-tohip ratio in assessment of cardiovascular disease risk factors in overweight, premenopausal women. Am J Clin Nutr 1998;68:1022–1027.
Iannello
70
Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE: Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843–1848. Vinik A, Wing RR: Nutritional management of the person with diabetes; in Rifkin H, Porte D (eds): Diabetes mellitus. Theory and Practice, ed 4. Amsterdam, Elsevier, 1990, pp 464–496. WHO Expert Committee: Physical Status: The use and interpretation of anthropometry. WHO Tech Rep Ser No 854. Geneva, WHO, 1995.
S. Iannello, Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, I–95123 Catania (Italy) Tel. +39 095 330981, Fax +39 095 310899, E-Mail
[email protected]
Diet and Modification of Nutrient Absorption
71
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 72–89
Chapter V
............................
Insulin Treatment in Type 1 and Type 2 Diabetes: Practical Goals and Algorithms F. Belfiore, S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Introduction In type 1 diabetes, insulin therapy is focused on the replacement of insulin secretion, even if lifestyle changes are required to optimize insulin treatment. In type 2 diabetes, insulin treatment may be required when diet and oral therapy do not suffice. A variety of highly purified preparations of human insulin (the only form of insulin today sold in industrialized countries) are commercially available, differing in time of onset and duration of action. These pure human insulins result in very few problems linked to insulin antigenicity, because human insulins are less antigenic than porcine and much less antigenic than bovine insulins. The production of human insulins by recombinant DNA technology has made possible a limitless use of different insulin preparations, thus solving the previous problem of a limited supply of animal pancreases for the large demand of insulins. The most important indications for insulin treatment are listed in table 1.
Types of Insulins Insulin is formed by two peptide chains, the A and B chains (consisting of 21 and 30 amino acids, respectively), joined by disulfide bridges. Different kinds of insulin are available for clinical use, which differ according to the species of origin, the degree of purity and the duration of action.
72
Table 1. Indications for insulin treatment Type 1 diabetes Ketoacidosis or ketoacidotic coma Hyperosmolar coma Diabetic pregnancy Acute diabetes decompensation for: Severe illness or fever Infections or sepsis Stress or steroid treatment Injury or surgery
Diabetic vascular complications Liver diseases in diabetic patients Renal failure in diabetic patients Secondary failure with oral hypoglycemic drugs in type 2 diabetes
Species: Bovine insulin differs from human insulin because it contains alanine, valine and alanine at the sites A-8, A-10 and B-30, respectively, whereas human insulin contains threonine, isoleucine and threonine at the same sites. Porcine insulin is more similar to human insulin inasmuch as it has the same amino acids as bovine insulin at positions A-8 and B-30 but the same amino acid as human insulin at position A-10. Human insulin can be obtained by modification of animal (pork) insulin (human semisynthetic insulin) or can be synthesized by the recombinant DNA technique. Human insulin is today the type of insulin most used in many countries. Human insulin (especially the long-acting preparations – see below) is more rapidly absorbed and has a quicker and shorter action than the porcine insulins, perhaps because it is more soluble in subcutaneous tissues. Some patients may have less awareness of hypoglycemia with human insulins than with animal insulins. Purity: In the past years, conventional insulin preparations contained a significant amount (10,000 parts per million (ppm)) of impurities (proinsulin and proinsulin-like compounds, insulin dimers, glucagon, somatostatin, VIP, PP, etc). Impurity content was much less in ‘single peak’ (monocomponent) insulins (=50 ppm) and even lower in purified insulins (1–10 ppm). Today, in most countries, only very pure human insulin prepared by the recombinant DNA technique is used. Duration of Action: Three types of insulin are available which differ in the duration of action: (a) the rapid-acting, (b) the intermediate-acting and (c) the long-acting insulin. (a) The rapid-acting insulin preparations include the regular insulin as well as the semilente insulin which is a suspension of insulin and zinc in acetate buffer (with formation of zinc-insulin crystals). (b) The intermediate-acting insulins comprise the lente insulin, which is a 30:70% mixture of semilente and ultralente (see later) insulin as well as the
Insulin Treatment in Type 1 and Type 2 Diabetes
73
Neutral Protamine Hagedorn (NPH) insulin, obtained by adding the protein protamine to insulin and adjusting the pH. (c) The long-acting insulin preparations include the ultralente insulin, obtained by modifying, during the preparation, the pH of a mixture of zinc and insulin to produce larger zinc-insulin crystals (the larger the crystals, the slower the release of the injected insulin) as well as the protamine-zinc insulin obtained by adding also protamine and adjusting the pH. After subcutaneous injection, regular insulin presents a rapid onset of action (0.5–1 h), an early peak of activity (2–4 h) and a duration of action of 4–6 h. Thus, rapid-acting insulin, beginning to act in about 30 min, should be given 20–30 min (perhaps 45 min) before a meal to optimize synchronization of postprandial glycemia and circulating insulin levels. It is effective in blunting elevations in glucose following meals and for rapid adjustments in insulin dosage, but the pharmacokinetics of rapid-acting insulins entails that a definite time interval is observed between insulin injection and eating. A better synchrony between insulin peaks and meal absorption after injection of rapid-acting insulin is observed with human insulin, which acts more rapidly after injection and exerts shorter effects compared to previously used animal insulins. Intermediate-acting NPH insulin presents a delayed onset of action (3–4 h), a delayed peak of activity (8–12 h) and a duration of action of 20–24 h; similar activity is possessed by the lente insulin. The NPH and lente intermediate-acting insulins have the same, long time-course of action, which is useful to provide the basal level of insulin through the 24 h when given twice per day. Intermediate-acting human insulin produces earlier peaks, that may cause hypoglycemic events during sleep and fails to maintain an adequate effect for a full 24-hour period. Ultralente (long-acting) insulins present a slow onset of action (6–8 h), a much more delayed peak of activity (14–24 h) and a duration of action of about 32 h. The ultralente human insulin has a shorter duration of action, compared to the animal preparations, and requires also twice-daily injections. Table 2 summarizes the most common insulin preparations and their onset, peak and duration of action. Insulin Analogues Recently, to improve the outcome of insulin therapy and to use human insulin products with more physiological effect, a short-acting monomeric insulin analogue, insulin lispro (Lys[B28], Pro[B29]), was developed which was approved for clinical use and is already commercially available. It has been used extensively in clinical practice. Reversal of the amino acids proline and lysine at position B28 and B29 of human insulin produces an analogue
Belfiore/Iannello
74
Table 2. Types of insulin Type
Preparation
Onset of action h
Peak action h
Duration of action h
Rapid-acting Intermediate-acting Long-acting
Regular NPH or lente Ultralente Bovine Human
0.5–1 3–4
2–4 8–12
4–6 16–24
4–6 4–6
14–24 10–20
28–36 24–28
There is great variability in the onset, peak and duration of insulin action from patient to patient, as indicated by the time intervals given. Human insulin tends to show somewhat earlier onset and peak and shorter duration of action, compared to nonhuman insulins. This is especially true for long-acting preparations. For this reason, different figures for the time intervals are reported in the table for this insulin preparation.
with less tendency to self-association. Conventional insulin preparations are prevailingly in hexameric form, which delays the absorption from subcutaneous injection sites, requiring the dissociation of hexamers into monomers. The monomeric insulin lispro is rapidly absorbed from subcutaneous tissues (so reducing the postprandial hyperglycemia) and shows a shorter duration of action that should decrease the risk of hypoglycemia between meals and at nighttime. Indeed, it shows early peak (1 h) (which allows a much shorter interval between injection and eating) and a shorter duration of action (3–4 h). The insulin lispro in appropriate dosage may result in a profile of insulin close to the physiological one and is suitable for treating both type 1 and type 2 diabetic patients under intensive insulin therapy. Another rapidacting insulin analogue is currently under evaluation (B28 Asp). Longeracting ‘basal’ analogues are also under development such as HOE 901 that is an insulin analogue with a lower peak of activity than NPH and a duration of action very long (about 24 h), especially appropriate for type 1 diabetics. Insulin Concentration The insulin preparation available on the market today is a concentration of 100 U/ml (U-100). In the past (and still today in some countries) a concentration of 40 U/ml (U-40) was in use. However, preparations with more concentrated insulin also exist (500 U/ml or U-500).
Insulin Treatment in Type 1 and Type 2 Diabetes
75
Factors Influencing Insulin Concentration or Bioavailability Pharmacokinetics of Injected Insulin An optimal therapeutic use of insulin requires the knowledge of the factors affecting its absorption, disposal and action. Within 5–7 min, insulin given intravenously is concentrated in the heart, liver and kidneys and after 15 min mainly in the latter two organs. It has been shown that, in the range of physiological concentrations, liver extracts as much as 70% of insulin on a single passage, and that the kidney also removes a significant percentage of the insulin from the blood. The importance of liver and kidney in the insulin disposal is apparent as well as the need to adjust the insulin dosage in patients with hepatic or renal diseases. Insulin Concentration and Dose Insulin bioavailability is unaffected by insulin concentrations between 40 and 100 U/ml, while more diluted insulin is more rapidly absorbed. A more concentrated regular insulin (which has a more prolonged action) can be used for insulin-resistant patients. Increasing the dose of regular insulin delays the time of peak serum level and prolongs the duration of action, while increasing the dose of NPH insulin can reduce insulin absorption. It is noteworthy that, when the dose of insulin lispro is increased, the duration of action is not prolonged. Insulin Mixtures Manufactured insulin mixtures exist on the market. Biphasic premixed insulins have been developed in various ratios of rapid-acting to NPH (30/70, 40/60, 50/50, etc.). The effect of 30/70 mixtures of regular and NPH insulins is the same as if the components were injected separately and simultaneously, because regular insulin retains its pharmacokinetic characteristics. When a mixture of lente and regular insulins is used, the excess of zinc tends to bind to regular insulin and may cause precipitation of regular insulin out of solution, delaying its absorption and blunting its quick-acting effect. Thus, there are some advantages in using NPH for insulin mixtures. When two types of insulin are mixed, it is important to consider (to assure accuracy of the dose) the variable amount of ‘dead space’ between the hypodermic syringe and the needle. For this reason, it can be useful to always use syringes from the same manufacturer. Type of Administration and Site of Insulin Injection Subcutaneous administration (with all its disadvantages) remains the only practical method for the delivery of insulin. The peak concentration of insulin
Belfiore/Iannello
76
can be influenced by the site of injection, being achieved more quickly with abdominal injection than with injection in the anterior thigh. Absorption is faster in an upper than in a lower limb. When insulin is injected into an extremity, absorption increases if the extremity is subsequently involved in exercise. Absorption also increases if the injection site is massaged or warmed. Patients should inject insulin in the different locations at the same time each day, i.e. in the abdomen in the morning to optimize insulin delivery and in the leg or buttock at night to slow absorption. Rotation of sites within these areas is very important. It is noteworthy that the absorption rate of insulin lispro is consistent from each of the injection sites. Interestingly, it has been shown that the patient can safely reuse the plastic insulin syringes and the needles. Pen injectors have been introduced for clinical use, loaded with insulin cartridges of 1.5 ml (containing 150 U) or 3 ml (300 U). They are more practical than syringes, especially for the traveler patients, and give more accurate dosage. Only short-acting insulin and NPH insulins can be used with pens (lente insulins are in crystal form and crystals would be broken by the glass marble present in the pen cartridges to help insulin stirring). Intravenous administration (continuous or pulse) is not practical but permits much more physiological insulin profiles. Other routes of insulin delivery have been proposed, including the intraperitoneal route (which allows insulin to enter, at least in part, the portal vein, similarly to the endogenously secreted insulin), as well as the subcutaneous insulin pellets, skin iontophoresis, oral administration (insulin is degraded by gastrointestinal enzymes and therefore the absorption is extremely variable), nasal or pulmonary spray of insulin (mixed with 1% deoxycholate capable to increase the mucosal insulin absorption) and rectal suppositories (unable to induce a physiological profile of insulinemia). It should be underlined that the physiologically secreted insulin enters the portal vein and is taken up in substantial amount by the liver, so that only the remaining amount reaches the general circulation and is distributed to the peripheral tissues. In contrast, insulin given for therapeutic purposes through the commonly used routes (subcutaneous or intravenous) enters the general circulation and is distributed to all tissues (liver and peripheral tissues) in approximately similar amount. Therefore, during insulin treatment, liver is relatively hypoinsulinized and the peripheral tissues relatively hyperinsulinized. Depth of Injection and Massage The depth of insulin injection is an important variable. In fact, the deeper insulin is injected, the quicker the onset of action and the higher the peak.
Insulin Treatment in Type 1 and Type 2 Diabetes
77
Usually, it is recommended to place insulin consistently into deep subcutaneous tissue by means of a lifted flap with the injection device at a 45º angle. Absorption is much faster when insulin is injected intramuscularly rather than subcutaneously, and erratic intramuscular injections in thin individuals may occur. Massage of the injection site increases insulin absorption. Exercise and Stress Exercise of a leg may increase absorption of the insulin injected in that extremity; moreover, stress (by increasing epinephrine) may affect local blood flow and absorption of insulin. Insulin Antibodies Insulin antibodies bind insulin and can delay the onset of action and the duration of its effect. Among patients, the time course of a given insulin preparation is highly variable, probably for differences in circulating insulin antibodies. Human insulin generates lower titers of insulin antibodies and therefore is most useful in patients who are initiating insulin therapy (and who have not yet produced antibodies) and in patients requiring insulin intermittently (intermittent use of insulin increases its antigenic effects). Destruction of Insulin Insulin is destroyed variably at the site of injection by some insulindegrading enzymes. An unusual cause of altered insulin pharmacokinetics may be the local degradation of insulin by proteases, at the site of injection. This mechanism, however, has not been established in patients with poorly controlled diabetes either at the injection site or by in vitro studies with patient’s fat incubated with insulin. Storage of Insulin Insulin can be kept at room temperature (=25 ºC) for 1–2 months without losing activity, whereas for longer conservation it should be stored in the refrigerator (between 4 and 8 ºC). Insulin does not withstand temperatures =2 ºC and freezing must therefore be avoided.
Insulin Requirement Insulin dose depends on the patterns of food intake and physical activity, on diurnal variations in insulin requirement, on experience of hypoglycemia, on the state of injection sites and on the type of diabetes. Insulin requirement of young, adolescent diabetic patients is sometimes high and changing. As a
Belfiore/Iannello
78
basic concept, it may be useful to bear in mind that the average insulin production in a normal subject is about 25 U/day. In diabetics, however, insulin requirement may be higher due to the presence of insulin resistance. Average starting doses of 0.7 U/kg body weight per day have been suggested. However, it may be more advisable to start with lower doses. In nonobese diabetics the starting daily insulin dose might be 15–20 U, whereas in obese diabetics it might be somewhat higher, in the range of 20–25 U. It is advisable to start therapy with caution, to avoid hypoglycemia, and to increase the insulin dose with prudence, after the previous dose has been experienced for a few days, with increases of 4–8 U per step.
Insulin Regimens Insulin treatment can range from the simple regimens based on one or two daily insulin injections (conventional insulin therapy) to the more complicated multiple daily insulin injection regimens (intensive insulin therapy) or the continuous subcutaneous insulin infusion (CSII). Single Daily Insulin Injection It is the simpler and easier regimen to administer insulin. Some newly diagnosed type 1 diabetic patients (with some degree of residual b-cell function) can achieve glycemic control with less intensive effort by means of a single injection of lente or NPH insulin alone or combined with regular insulin. Type 2 diabetic patients, poorly controlled with diet and oral hypoglycemic drugs, can be treated with a single daily insulin injection (often a night injection of lente or NPH insulin will suffice), as well as older patients with impaired vision or physically disabled who may experience difficulties with injections. This regimen is also useful for individuals with limited motivation and poor compliance to the diabetic therapy. The initial insulin requirement can depend on several factors: (a) the current degree of hyperglycemia; (b) the dietary habit; (c) the amount of remaining endogenous insulin secretion; (d) the physical activity or exercise, and (e) the body weight or degree of obesity. A total dose of intermediate-acting insulin of 0.5–0.7 units/kg has been suggested (usually from 20–30 to 40–50 units/day), with subsequent adjustments according to the glycemic values obtained 2–4 times daily (as well as according to the hypoglycemic episodes, the presence of urinary ketones and the HbA1c values). With large doses of intermediate-acting insulin, availability of insulin may be inappropriate at certain times and there is the risk of nocturnal hypoglycemia. For some patients, an insulin preparation consisting
Insulin Treatment in Type 1 and Type 2 Diabetes
79
of a 30/70 mixture of regular and intermediate insulin can be used. In patients with persistent hyperglycemia there is the indication for changing insulin regimen (twice-daily insulin injections – see below). When a hospitalized patient is discharged, the diet may be slightly increased or the insulin dose reduced because the physical activity of the patient will increase; for this reason, during the first days after discharge a contact between the patient and the physician is important to adjust the insulin dose. Twice-Daily Insulin Injection When a single dose is inadequate or produces hypoglycemia, twice-daily injections of NPH insulin are frequently used in insulin-dependent diabetics. Most patients should use two daily injections of a mixture of intermediateacting (2/3) and rapid-acting (1/3) human insulins before breakfast and dinner. It is a relatively simple regimen that provides a good insulin availability over a 24-hour period, even if it may induce late afternoon and nocturnal hypoglycemia with pre-breakfast hyperglycemia. Twice-daily insulin regimen is little flexible, inasmuch as insulin must be given at the same time every day and meal times must also be kept constant. Multiple Daily Insulin Injections (MDI ) The intensive treatment regimens (as opposed to the simpler conventional regimens, described above) are not suitable for everyone and should be adopted in the appropriate patients. Intensive insulin therapy should be encouraged in type 1 diabetes without residual insulin secretion and when twice-daily insulin injections are no longer adequate. Recently, this regimen was also proposed for type 2 diabetics (particularly the younger patients with a life expectancy of 10–15 years or more). The scope is to obtain a good glycemic control which may reduce the development of diabetic microangiopathy, as shown by the DCCT (Diabetes Control and Complications Trial) study. However, this insulin intensive regimen may favor weight gain. Moreover, it has been postulated in the past that enhanced insulinization may be associated with increased risk of mortality from cardiovascular disease and it was suggested that chronic hyperinsulinemia may cancel the beneficial effects of the better glycemic control. However, more recent data (from the DCCT for type 1 diabetes and from UKPDS for type 2 patients – see chapter VI) allow us to exclude that intensive insulin therapy entails risk for macrovascular disease. An absolute indication for intensive therapy is pregnancy (see chapter XVIII on Managing Diabetes and Pregnancy). An optimal glycemic control requires that insulin delivery simulates the normal pattern of insulin secretion, which consists of continuous ‘basal’ insulin
Belfiore/Iannello
80
secretion (throughout the day and night) and acute increases of insulin levels connected to ingestion of meals. This regimen improves diabetic control, reduces excursions in glycemic levels and provides a good flexibility. Four different regimens may be used: (a) The simplest intensive regimen entails the use of three injections, regular and intermediate-acting insulin before breakfast, regular insulin before supper and intermediate-acting insulin at bedtime. This 3 times daily insulin dose regimen is useful in diabetic patients with frequent nocturnal hypoglycemia and pre-breakfast hyperglycemia. The primary disadvantage of this approach is that meal schedules must be fixed rather rigidly. (b) Regular insulin before each meal and intermediate-acting insulin at bedtime (4 daily insulin doses). This regimen provides the greatest flexibility because regular insulin can be adjusted to cover each meal, avoiding postprandial hyperglycemia. (c) Regular and intermediate-acting insulin before breakfast, regular insulin before lunch and supper, and intermediate-acting insulin at bedtime (4 daily insulin doses). (d) Regular insulin before each meal and ultralente insulin in the morning (to replace basal insulin secretion) or subdivided before breakfast and before supper (4 daily insulin doses). It is less preferable to the (b) regimen because ultralente presents unexpected small peaks 15–24 h after injection. Human insulin lispro is very appropriate for multiple injection therapy, especially in patients with marked postprandial hyperglycemia and nocturnal hypoglycemia or with a variable lifestyle. Patients on insulin lispro had significantly lower glucose levels following meals (however with the potentially unwanted result of a rise in preprandial glucose) and showed a reduction in the incidence of severe hypoglycemia by 30% (compared to regular human insulin). In patients treated with insulin lispro (compared to those treated with human regular insulin) there should be less need for snacks. The majority of patients on insulin lispro reported an improved quality of life. However, there are some ‘failures’ with this type of insulin, as a number of patients may appear unable to control their diabetes with insulin lispro. At present, insulin lispro should be used with caution in children under the age of 12 as well as in gestational diabetes or pregnancy, because of lack of experience. Other, far too complex, multiple-injection regimens have also been suggested. Certainly, the adherence to therapy is less likely to occur when the program of treatment is far too complicated. Some patients object to such frequent needle injections and ask for changing from this insulin regimen to a simpler program. Pen devices or jet injectors filled with insulin (that are easy to carry) make the multiple daily insulin regimens better accepted.
Insulin Treatment in Type 1 and Type 2 Diabetes
81
It is advisable to use no more than two types of insulin. It is noteworthy that in some patients a morning fasting hyperglycemia (the dawn phenomenon) occurs, that depends on the hepatic glucose overproduction activated in the morning due to inadequate overnight delivery of insulin and a sleepassociated GH release. This phenomenon is most pronounced in type 1 diabetic patients for their inability to compensate by raising endogenous insulin secretion. The magnitude of the dawn phenomenon can be attenuated by designing insulin regimens which ensure that the effects of exogenous insulin do not peak in the middle of the night and then become dissipated by morning. Some patients (about 1/3 of type 1 diabetic patients) may experience early in the course of disease a brief honeymoon period, during which there is a partial recovery of b-cell function and a transient or a prolonged fall in the exogenous insulin requirement (=0.5 U/kg/day). The honeymoon phenomenon may be due to the termination of a ‘stress’ episode (infections, etc.) that has anticipated the manifestation of diabetes in a subject with ongoing b-cell destruction process. Spontaneous remission is less frequent in children and adolescent or pubertal patients, and more frequent in adult postpubertal patients. A low residual insulin secretion (probably linked to a more aggressive destruction of b-cells) can be implicated in children while a low insulin sensitivity (probably linked to the increased secretion of GH hormone) may be important in pubertal patients. The honeymoon should not be regarded as a signal to reduce efforts aimed at glycemic control, because optimized insulin therapy may help to preserve b-cell function. It is recommended to continue insulin treatment even at low doses (even 1–4 U/day), since this can preserve b-cell function and may favor the remission. Continuous Subcutaneous Insulin Infusion (CSII ) In sufficiently motivated diabetic patients, an alternative that provides a greater flexibility of insulin treatment (minimizing variations in its absorption) is CSII, with which insulin delivery may somewhat mimic that occurring in nondiabetic individuals. Insulin delivery pumps may be implantable or portable (with ‘closed loop’ or ‘open loop’ insulin infusion systems). The CSII method administers rapid-acting insulin around the clock using a battery-powered (externally worn) infusion pump, that delivers basal rates continuously (usually 0.5–2.0 U/h) and can be programmed to vary the flow rate automatically, reducing the flow rate at 1.0–4.0 a.m. and increasing it to compensate for increased insulin requirements early in the morning. Before meals, insulin boluses are given by manually activating the pump, in amounts based on frequent blood glucose self-monitoring determinations. Usually, a 3- to 5-day hospital stay is required for learning to use the insulin pump,
Belfiore/Iannello
82
Table 3. Problems limiting the use of CSII Interruption of insulin delivery (commonly due to insulin precipitation within the catheter) that leads to rapid severe hyperglycemia and ketoacidosis (because there is no depot insulin and all insulin being used is short-acting) Pump malfunction (a pump malfunction with insulin overdose can produce severe and even fatal hypoglycemia) Loss of battery charge Leakage from the catheter Empty insulin reservoir Needle displacement Local infections (such as abscesses at the catheter site, only occasionally reported)
and successively a health-care professional should be available 24 h/day to assist the patient. Most pumps contain a syringe or a reservoir filled with insulin attached to an infusion set consisting of a catheter and a 27-gauge needle which is inserted into subcutaneous tissue (preferably in the abdomen). Unfortunately, the CSII presents several problems that limit its use (table 3), and the patients with brittle diabetes (see below) may not be the best candidates for a successful use of CSII. Most modern pumps present alarm systems for the different pump problems. Some diabetic patients are absolutely incapable to safely employ the insulin pump and to use the appropriate infusion rates. The high cost is another relevant disadvantage of CSII.
Self-Monitoring Self-monitoring is an important component of diabetes management, which helps to achieve a good glycemic control and therefore to prevent complications (especially microangiopathy). Several factors may influence the method and frequency of self-monitoring, such as the type of insulin regimen prescribed, glycemic goals of therapy, capabilities of diabetic patient, etc. Selfmonitoring includes the following tests: (a) Urine testing for glucose (2 or 4 times/day) is the less reliable option for self-monitoring, inasmuch as it allows only a coarse estimation of glycemia. It might be used for insulin or dietary adjustments in patients with stable diabetes. (b) Urine testing for ketones is a component of self-monitoring routines of type 1 diabetic patients, especially in presence of unexplained hyperglycemia or to manage acute events of metabolic decompensation.
Insulin Treatment in Type 1 and Type 2 Diabetes
83
(c) Blood glucose self-monitoring is the most important advance in diabetes care. It requires the use of devices or meters that read blood glucose testing strips. All the modern meters can store and recall obtained blood glucose readings. These glucose determinations provide an estimation of glycemic control at any given moment, from day to day, and may be especially useful for specific problems (hypoglycemia, acute illness, ketonuria, periods of unstable diabetes, etc.). Several factors may limit the use of this method, such as a low level of motivation, a poor accuracy of determination, technical errors, intellectual inability to use the glycemic results, low visual or physical abilities, lack of education, high costs, etc. For some diabetic patients, blood glucose self-monitoring is perceived as too difficult or intrusive into individual’s routine, while other patients who desire to improve their glycemic control may accept to perform blood glucose tests several times a day on a regular basis. In these motivated patients, it is very important to monitor their technical competence, to define the desired glycemic range to be achieved, and to provide all the appropriate technical instructions, including the comparison of meterobtained results with laboratory values.
Glycated Hemoglobin (HbA1c) The patient with diabetes should have a periodic determination of HbA1c because this measurement is the most objective method of glucose control measurement over a long period. HbA is glycated in an irreversible and nonenzymatic fashion, and the levels of HBA1c reflect the mean glycemia over the 2–3 months prior to the test.
Serum Fructosamine Test This test has been suggested as a less difficult to perform and less costly alternative to HBA1c determination, with which shows a good correlation. This test measures the level of glycosylated proteins in the blood (mainly albumin), and reflects the mean glycemic control during a 2- to 3-week period. Its validity is uncertain when interfering substances (bilirubin, hemolysis, etc.) are present or serum albumin concentration is abnormal. The test accuracy can be improved by correcting the fructosamine result for variations in serum albumin. HBA1c, compared to fructosamine test, should be considered as the preferable test for monitoring diabetic control.
Belfiore/Iannello
84
Complications of Insulin Treatment The most important complication of insulin therapy is hypoglycemia, which is discussed in chapter VIII (Clinical Emergencies in Diabetes. 2: Hypoglycemia). The other complications are listed below. Insulin Edema In poorly controlled diabetic patients, insulin therapy can result in a marked accumulation of fluid, with localized (periorbital, pretibial or presacral) or generalized edema. The causes are probably multiple (table 4). A dietary restriction of salt and a temporary use of diuretics can be recommended. Edema will most often subside within 3–5 days. Table 4. Causes of insulin edema ADH increase (ascribed to hypovolemia resulting from osmotic diuresis) Cessation of natriuretic effect of hyperglucagonemia Increased plasma volume and transcapillary escape of albumin (with reduced colloid osmotic pressure) Excessive infusion of isotonic saline Na retention (induced by excess of insulin infused or injected)
Insulin Lipoatrophy It was a common complication prior to the introduction of monocomponent insulins, consisting of a loss of fat at the site of insulin injection or, occasionally, at distant sites. In 25% of lipoatrophic patients, local allergy coexists. Lipoatrophy is frequently observed in young children (50%) or in young women (20%), compared to male adults (5%). Lipoatrophy, moreover, may occur after repeated injections of other substances such as narcotics or GH preparations. Thus, atrophy might be the result of a repeated mechanical trauma, even if insulin impurities can stimulate immune factors or immune complex formation which lead to local release of lipolytic substances. These reactions occur without overt inflammation and were considered also secondary to insulin degradation or aggregation products. Indeed, in biopsy specimens of lipoatrophic areas, antigen-antibody reactions were not seen. Local reactions to protamine (a constituent of insulin preparations) and to silicone oil (the lubrificant in disposable syringes) may play a role in some patients. Switching to purified or human insulins and rotating the site of injections result in improvement of skin alterations in 97% of lipoatrophic patients. Very few cases were reported with recombinant human insulins, and the reason why it
Insulin Treatment in Type 1 and Type 2 Diabetes
85
still occasionally occurs is unknown. Injecting the purified insulin at the edges and center of the affected atrophic area improves lipoatrophy (due to the lipogenic effect of insulin). Addition of dexamethasone to the insulin in the syringe (4 lg/U, total daily dose not exceeding 0.75 mg) has also been suggested. In a recent case of severe well-circumscribed lipoatrophy, good results were obtained by treating the area with a fatty acid mixture while the patient was instructed to avoid this area for insulin injection. Insulin Lipohypertrophy It consists of visible or palpable increase of localized subcutaneous fat (most prevailingly in the anterior or lateral part of thighs) at the site of insulin injection, sometimes coexisting with lipoatrophy. Repeated and prolonged use of the same site for insulin injection is a main determinant in the development of lipohypertrophy. Often the affected patients report that injection into lipohypertrophic areas is less painful, perhaps because the subcutaneous tissue tends to be fibrous. Lipohypertrophy is due to a possible growth factor effect of insulin on cellular elements of subcutaneous tissue, and may alter the absorption rate of insulin, thus possibly affecting metabolic control. Prevalence rates of lipohypertrophy vary between 20–45% in type 1 and 3–6% in type 2 diabetic patients. Independent risk factors which contribute to the presence of lipohypertrophy are female sex, type 1 diabetes, higher BMI and missing rotation of insulin injections. The most severe cases of insulin lipohypertrophy can be treated with liposuction, but prevention is important, primarily by systematized rotation of injection sites within the recommended areas. An important role is played by educational interventions to establish an organized rotation system for insulin injection sites, to self-recognize lipohypertrophy and to normalize the high BMI. Syndrome of Immunologic Insulin Resistance All patients who receive insulin develop circulating antibodies, whose production can be influenced by several factors (table 5). Patients never treated with exogenous insulin may have circulating insulin antibodies, probably involved in the autoimmune reactions of type 1 diabetes. The high level of insulin antibodies may function as a reservoir from which insulin may be released unpredictably (thus inducing delayed hypoglycemia), or may bind insulin (thus causing hyperglycemia), or may form immune complexes (thus sequestering insulin in the reticuloendothelial system or stimulating procoagulant activity and favoring diabetic complications). In diabetic patients, this syndrome may result in an excessive insulin requirement (100–200 U/day in adults and up to 2.5 U/kg in children). In the most severe cases, steroids even at high doses for 3–4 weeks should be used. It is noteworthy that the immunogenicity of insulin
Belfiore/Iannello
86
Table 5. Factors influencing the formation of insulin antibodies Insulin species (human insulin is less immunogenic than animal insulins) Insulin purity (monocomponent insulins are less immunogenic) Insulin pharmaceutical form (regular insulin is less immunogenic than modified insulins) Pattern of insulin treatment (episodic therapy and CSII may increase insulin immunogenicity) Genetic factors (HLA-A2-B44 and HLA-B44-DR7 predispose to immune complications of insulin therapy) Residual insulin secretion (when present, it reduces immune response to insulin)
lispro has been found to be similar to that of human insulin in both type 1 and type 2 diabetic patients. Insulin Allergy It includes different forms: (a) Local allergy comprises immediate or biphasic or delayed reactions and consists of erythematous and pruritic indurated lesions or more severe reactions in subcutaneous areas injected with insulin preparations. Protamine or zinc have been implicated. These reactions are IgE-dependent and may occur with conventional insulin treatment or CSII in subjects with intermittent insulin treatment or with allergy to other drugs (such as penicillin) or with obesity. The affected patients will improve within 30–60 days continuing the use of insulin (probably because of a spontaneous desensitization), whereas in the most severe cases local steroids in low doses or oral antihistaminics may be considered. (b) Generalized allergy ranges from a simple urticaria to more severe reactions such as anaphylaxis with angioedema, bronchospasm, pharyngeal edema and collapse. These generalized reactions are due to the interaction of insulin (acting as an antigen) with specific IgE bound to mast cells or blood basophils and are very uncommon (=0.05%). No deaths for insulin allergy are reported. Human insulins are efficacious in the majority of allergic patients for the treatment of this systemic allergy, while in the remainder desensitization is successful (about half of patients who cannot be desensitized are overweight). Immunologic insulin resistance may coexist with or following insulin allergy. Insulin allergy is different from stress-induced urticaria, in which the central nervous system is important in the generation of immune response.
Conditions of Altered Insulin Responses Conditions of altered insulin responses include: (a) insulin resistance linked to occult infections; (b) iatrogenic hypoglycemia or factitious inten-
Insulin Treatment in Type 1 and Type 2 Diabetes
87
tional insulin overdosing (see chapter VIII on Clinical Emergencies in Diabetes. 2: Hypoglycemia); (c) labile or ‘brittle’ diabetes, which can be idiopathic or secondary and includes a group of insulin-dependent diabetic patients (about 2–10%) characterized by unexplainable and extreme glycemic shortterm and long-term fluctuations with frequent ketosis proneness or hypoglycemic crises, or both. Brittle diabetes can depend on altered insulin absorption, or poor residual insulin secretion, or excess of counter-hormone regulation, or emotional stress. Some of these patients are adolescent women who distort their insulin treatment to prolong the stay in the hospital for psychosocial problems. In these instances, the treatment of brittle diabetes requires a strong effort by the patient’s family and the medical and psychological team.
Role of Education A successful insulin management requires actively applied systems of patient education. The aim of education and training is to provide adequate information in a simple form suitable to the ability of the subject, in order to allow the diabetic patients to develop the required knowledge to self-manage their disease and to ensure an optimal and appropriate use of insulin therapy (and other therapeutical measures). Behavioral changes and insulin treatment adjustments may be made in a graduated manner (step-by-step), and a systematic reinforcement is critical after the goals are achieved. Nutritional management is also an integral part of initial and following programs of education. The provision of a diabetes professional team (doctors, educators or diabetes nurse specialists, nutritionists or dieticians, and podiatrists or chiropodists) is also necessary as well as a continuing education for the professional staff. Several factors should be considered for a good therapy, including patient’s lifestyle, physical activity, dietary habits, glucose self-monitoring, correct time to injection (some patients may take regular insulin 5–15 min before the meal, instead of 30 min before), insulin dosage adjustments, usual injection sites and, finally, possible interactions with other drugs. How to avoid hypoglycemia, what to do during an episode of hypoglycemia or the correct behavior during acute illness or stress must be included in the education program. Each visit should be an opportunity to assess the current level of self-management, the behavioral change and goal achievement. Overall glycemic control is optimized when education and motivation are emphasized. In this approach, every diabetic patient should be considered unique.
Belfiore/Iannello
88
Suggested Reading Anderson JH, Brunelle R, Koivisto VA: Reduction of post-prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment. Diabetes 1997;46:265–270. Campbell PJ, May ME: A practical guide to intensive insulin therapy. Am J Med Sci 1995;310:24–30. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986. Dimitriadis G, Gerich J: Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983;6:374–377. Galloway JA, deShazo RD: Insulin chemistry and pharmacology; insulin allergy, resistance, and lipodystrophy; in Rifkin H, Porte D (eds): Diabetes mellitus. Theory and Practice, ed 4. Amsterdam, Elsevier, 1990, pp 497–512. Sane T, Helve E, Yki-Jarvinen H: One year’s response to evening insulin therapy in non-insulin-dependent diabetes. J Intern Med 1992;231:253–260. Strowing S, Raskin P: Insulin treatment and patient management; in Rifkin H, Porte D (eds): Diabetes mellitus. Theory and Practice, ed 4. Amsterdam, Elsevier, 1990, pp 514–525.
F. Belfiore, Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, I–95123 Catania (Italy) Tel. +39 095 330981, Fax +39 095 310899, E-Mail
[email protected]
Insulin Treatment in Type 1 and Type 2 Diabetes
89
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 90–102
Chapter VI
............................
Overview of Diabetes Management: ‘Combined’ Treatment and Therapeutic Additions F. Belfiore, S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Lessons from Recent Large Trials on Diabetes Treatment The Diabetes Control and Complication Trial (DCCT), a large multicenter study conducted on more than 1,400 type 1 diabetics (aged 12–39 years) for a period of 7–10 years, has established that close blood glucose control (even if complete normalization of glycemic level was not obtained) reduces the frequency of late diabetic complications. Patients were assigned randomly to either intensive insulin therapy (3 or more daily injections or insulin pump, glucose self-monitoring 4 or more times per day, and frequent contact with a diabetes health-care team) or conventional therapy (1 or 2 injections of insulin mixtures per day, less frequent monitoring and medical contacts). The target goals of therapy were markedly different. Compared to the conventional care group, the intensive care group showed lower glycated hemoglobin (by 1.5–2.0%) and mean glucose level (by 60–80 mg/dl), yet most of the intensive care patients group failed to achieve normal glycemic levels. However, intensive care reduced the development of retinopathy by 76% (and its progression by 54%), the risk of microalbuminuria by 39%, frank proteinuria by 54%, and clinical neuropathy by 60%. Major cardiovascular events were also reduced, although statistical significance was not reached, in any case excluding that intensive insulin therapy may entail risk for macrovascular complications. The correlation of mean blood glucose with the frequency of retinopathy progression was linear, suggesting that there is no threshold glycemic level at which complications occur, so that any degree of improvement in glycemic control exerts beneficial effects on the progression of complications. These
90
beneficial effects, however, were obtained at the expense of a more common weight gain and, especially, of an increased (3-fold) risk of severe hypoglycemic episodes, often not accompanied by the classical symptoms (intensive treatment reduces the adrenergic response to hypoglycemia), which makes intensive treatment less appropriate for some people (hypoglycemia unawareness, special occupations, children, old people, etc.). Finally, it should be noted that the DCCT results were obtained through a close cooperation between the patients themselves and an expert team, primarily nurse educators and dieticians. Therefore, it may not be easy to follow the DCCT criteria in everyday clinical practice. The data from DCCT conclusively demonstrate that in type 1 diabetes the control of blood glucose really matters to prevent late complications. A recently concluded multicenter investigation on a very large study population (?5,000 patients), the United Kingdom Prospective Diabetes Study (UKPDS), whose results were presented at the European Association for the Study of Diabetes in Barcelona, September 1998, has obtained similar results in type 2 diabetic patients. As summarized by Laakso [1999], this study has shown that, compared to ‘diet alone’, the intensive control of blood glucose (regardless of the treatment used – sulfonylureas, metformin or insulin) reduced retinopathy or nephropathy by 25%, myocardial infarction by 16% and any diabetesrelated endpoint by 12%. For every one percentage point reduction in HbA1c, there is a 35% reduction in retinopathy, nephropathy or neuropathy, and a 25% reduction in diabetes-related deaths (stroke frequency was not affected). As observed in the DCCT, there was no evidence of any glycemic threshold for micro- or macrovascular complications. With strict metabolic control, the risk of hypoglycemic episodes increased. Obese type 2 diabetic patients treated with metformin, compared with diet treatment, had even more pronounced benefits, showing reduction of 32 and 42% of diabetes-related endpoints and diabetes-related deaths, respectively, as well as a 36% reduction of all-cause mortality. In addition, they gained less weight and had fewer hypoglycemic episodes compared to the insulin- or sulfonylurea-treated patients. The UKPDS also pointed out that type 2 diabetic patients with tight control of blood pressure (mean 144/82 mm Hg), obtained either by ACE inhibitors or b-blockers, compared to the untreated group (154/87 mm Hg), showed reduction of any diabetes-related endpoint (by 24%), diabetes-related deaths (by 32%), stroke (by 44%) and microvascular complications (by 37%). Reduction of myocardial infarction of 21% occurred but did not reach statistical significance. It should be noted that in the UKPDS the treatment goal of maintaining fasting glycemia below 6 mmol/l (108 mg/dl) was not achieved. Strict metabolic control would consist of keeping glycemia below 10 mmol/l or 180 mg/dl at
Overview of Diabetes Management
91
all times during the day. The UKPDS conclusively demonstrated that strict control of blood glucose and of blood pressure are greatly beneficial in type 2 diabetes for preventing micro- and macrovascular complications. UKPDS also has evidenced that about 50% of newly diagnosed type 2 diabetic patients already show early signs of complications. This study has also showed that treatment with insulin or sulfonylureas is not harmful. However, this study did not demonstrate that this is also the case for elderly diabetic patients. Moreover, metformin was compared with other intensive treatments combined, not separately, with insulin and sulfonylureas. Concerning the possible negative effects of the association sulfonylurea-metformin, UKPDS did not provide sufficient evidence to suggest that this combination should not be used. Not all possible therapeutical combinations were tested, as, for instance, the combination insulin-metformin, which might bear the advantage that weight gain is prevented. Finally, it should be noted that the glucose levels fixed as therapeutical goal in the UKPDS may not be achievable in all patients; individual patient targets should be defined in relation to age and other risk factors. On the basis of the UKPDS data, the British Diabetic Association recommends that the treatment should be aimed at the following goals: blood pressure levels of 140/80 mm Hg or below; HbA1c levels of 7.0% (or within 1% of the upper end of the laboratory’s normal range); fasting blood glucose levels of 4–7 mmol/l (72–126 mg/dl), and self-monitored blood glucose levels before meals of 4–7 mmol/l (72–126 mg/dl). According to the IDF guidelines [1999] for type 2 diabetes, the risk for vascular complications as related to metabolic compensation (blood glucose and HbA1c) is as follows: ‘Low risk’: HbA1c (DCCT standardized) p6.5%; fasting/preprandial venous plasma glucose (VPG) =100 mg/dl (6.0 mmol/l); fasting/preprandial selfmonitored blood glucose (SMBG) =100 mg/dl (p5.5 mmol/l); postprandial SMBG =135 mg/dl (=7.5 mmol/l). ‘Arterial risk’: HbA1c>6.6–7.5%; fasting/preprandial VPG>110–125 mg/dl (6.1–6.9 mmol/l); fasting/preprandial SMBG>100–109 mg/dl (5.6–6.0 mmol/l); postprandial SMBG>135–160 mg/dl (7.5–9.0 mmol/l). ‘Microvascular risk’: HbA1c ?7.5%; fasting/preprandial VPG?125 mg/dl (?7 mmol/l); fasting/preprandial SMBG q110 mg/dl (q6.0 mmol/l); postprandial SMBG ?160 mg/dl (?9.0 mmol/l).
Type 2 Diabetes In those patients with type 2 diabetes in whom good metabolic control cannot be achieved with diet and physical exercise, pharmacological treat-
Belfiore/Iannello
92
ment should be introduced, based on sulfonylureas (to stimulate insulin secretion) or metformin (to ameliorate insulin action), as discussed in chapter II on Insulin Secretion and Its Pharmacological Stimulation and chapter III on Insulin Resistance and Its Relevance to Treatment. Further aspects of treatment will be considered in this chapter. According to the IDF guidelines [1999] to type 2 diabetes, oral therapy should be started when, despite an adequate trial of lifestyle intervention/education, HbA1c is ?6.5% and fasting VPG is ?110 mg/dl (?6.0 mmol/l), or (in thin subjects without arterial risk factors) HbA1c is ?7.5% and fasting VPG is ?125 mg/dl (q7.0 mmol/l). Sulfonylurea Failure In type 2 patients treated with sulfonylureas, the phenomenon of sulfonylurea failure, either primary or secondary, may occur. Primary Sulfonylurea Failure. It is the failure to show any significant response to therapy and it occurs in about 5% of the patients treated with sulfonylureas. It has been suggested that probably some of these patients are unrecognized type 1 diabetics. The cause of this failure is uncertain. Primary failure occurs with greater frequency in underweight diabetic patients, in those with diabetes duration longer than 5 years, or in diabetic patients previously treated with insulin. Secondary Sulfonylurea Failure. It is defined as a persistent hyperglycemia in spite of maximal doses of drug after an initial successful response for at least 6 months, and may occur in about 5–10% of type 2 diabetic patients, although this percentage varies with the populations studied. The majority of secondary failures occurs during the first 3 years of oral therapy. Most likely, secondary failure is caused by increased insulin resistance consequent to increased dietary intake and body weight, or to intercurrent illness and, usually, the correction of these causes restores sulfonylurea responsiveness. In other instances, a further deterioration of b-cell function may be the responsible factor (as revealed by decreased C-peptide response to intravenous glucagon). It is noteworthy that about 33% of the diabetic patients with sulfonylurea failure show islet cell antibodies (ICA or GAD antibodies), or multiple autoantibodies (islet cell, thyroid antimicrosomal, gastric parietal cell, etc.), or possess the HLA phenotype DR3/DR4, characteristics which suggest that these diabetic patients may actually be affected by late-onset type 1 diabetes. Among the firstgeneration sulfonylureas, failure was less often observed with chlorpropamide. With the indroduction of second-generation drugs the incidence of failure has become very low (about 0.3%). In the event that a complicating illness is causing a secondary failure, the patient can usually be treated with sulfonylureas again after the intercurrent problem has cleared.
Overview of Diabetes Management
93
For the patients who show secondary failure of sulfonylureas or respond only partially to maximum doses of oral sulfonylureas, various combined therapies can be employed. In the IDF guidelines [1999] to type 2 diabetes, the following combination therapy is suggested: (a) metformin with sulfonylureas; (b) sulfonylureas with a-glucosidase inhibitors, and (c) sulfonylureas with PPARc agonists. Combined Sulfonylurea-Metformin Therapy The oral hypoglycemic drugs, sulfonylureas and metformin, are largely used in combination in the treatment of type 2 diabetic patients, inasmuch as they exert different and complementary effects. Sulfonylureas stimulate insulin secretion whereas metformin ameliorates insulin action by enhancing peripheral glucose utilization and repressing hepatic glucose production. Recent in vitro studies reported that metformin may potentiate glucosestimulated insulin release from human pancreatic islets. Not enough evidence exists to support the suggestion that the association sulfonylureas-metformin entails a risk for diabetes-related deaths. In some countries, tablets containing a mixture of metformin and sulfonylureas (examples: 400 or 500 mg of metformin and 2.5 mg of glibenclamide) are available on the market. Combined Sulfonylurea-Insulin Therapy This combined therapy may be successful in type 2 insulin-resistant diabetic patients who are no longer responsive to oral drugs. Sulfonylureas decrease the exogenous insulin doses required to achieve a good glycemic control. Many studies have tested this therapeutic combination and have shown that about 30–40% of patients require significantly less insulin or sulfonylureas when treated this way. These patients, usually, show higher basal and stimulated serum C-peptide levels and increased insulin-mediated glucose disposal. The beneficial effects of the combination sulfonylurea-insulin can depend on an increase of endogenous insulin secretion or on a reduction of liver and peripheral insulin resistance, and may be transient or prolonged. The recommended regimen is a dose of intermediate-acting insulin at night (to control overnight glucose production) and oral sulfonylureas during the day at meals (to reduce postprandial hyperglycemia). Therapy with Other Drugs Repaglinide. This is a nonsulfonylurea insulinotropic hypoglycemic agent of the meglitinide family (meglitinide is a compound with a poorly efficient insulinotropic activity), and shows a common conformation with the hypoglycemic sulfonylureas glibenclamide and glimepiride (see chapter II on Insulin Secretion and Its Pharmacological Stimulation).
Belfiore/Iannello
94
Orlistat. In obese-diabetic patients who need to lose weight, a new nonsystemically acting antiobesity drug, orlistat, may be a useful add-on. It possesses an inhibitory activity against gastrointestinal lipase A, thus selectively reducing the absorption of dietary fat in the gastrointestinal tract. After drug withdrawal, the lipase activity is rapidly restored, due to the continuous enzyme secretion. Orlistat has little or no effect on gastrointestinal enzymes other than lipase A such as amylase, trypsin, chymotrypsin and phospholipases. About 30% of dietary triglycerides remain undigested and is not absorbed, producing an additional caloric deficit compared to diet alone. Orlistat treatment also decreases the solubility and subsequent absorption of cholesterol, so improving lipid levels (both total and LDL cholesterol levels are reduced). More than 4,800 patients have received orlistat in clinical trials (the recommended dosage is 120 mg t.i.d. taken during meals), and the results demonstrate the efficacy (weight loss was 70% greater than with placebo plus diet), safety and tolerability of the drug for long-term use. Orlistat-treated obese-diabetic patients present a best compliance with dietary restriction (because a severe dietary fat restriction is unnecessary) and a metabolic improvement (lowering of fasting blood glucose or HbA1c and reduction of sulfonylurea dosage requirement). This drug is free of systemic side effects, and gastrointestinal symptoms (related to the increased fecal fat excretion) are mild and self-limited. Orlistat treatment does not seem to increase the risk of gallstone formation (which can be favored by weight loss). Other Drugs. The possible use of some thiazolidinedione derivatives, such as pioglitazone, troglitazone, and rosiglitazone, has been discussed in chapter III (Insulin Resistance and Its Relevance to Treatment). Since fasting hyperglycemia in diabetes is correlated with high hepatic glucose production, which is determined by an elevated gluconeogenesis favored by FFA, inhibition of both FFA release (from adipose tissue) and oxidation (in the liver) may be an efficient modality to treat fasting hyperglycemia. Several drugs have been developed which inhibit FFA release from adipose tissue (acipimox, a nicotinic acid derivative) or hepatic FFA oxidation (etomoxir, a mitochondrial inhibitor of the carnitine palmitoyl transferase-1, the rate-limiting step in FFA oxidation). Severe fasting hypoglycemia and other side effects may occur with these drugs and limit their clinical use. Somatostatin or somatostatin analogues improve glucose metabolism in diabetic patients, especially under stress, selectively inhibiting the secretion of glucagon and GH without influencing insulin secretion. A role of somatostatin was also suggested in late diabetic vascular complications, but it remains to be elucidated. Amylin is a recently discovered 37-amino-acid peptide, that is cosecreted with insulin by pancreatic b-cells (it is regarded as the second b-cell hormone)
Overview of Diabetes Management
95
Table 1. Physiological actions of amylin or pramlintide Inhibition of food intake (through a central mechanism) Slowing of gastric motility and inhibition of gastric emptying Inhibition of postprandial glucagon secretion Suppression of postprandial hepatic glucose production Suppression of arginine-stimulated glucagon secretion Preservation of the glucagon increase in response to hypoglycemia Inhibition of insulin secretion in response to a variety of secretagogues Renal effects (stimulation of the renin-angiotensin-aldosterone system in rats and humans with possible induction of hypertension) Inhibition of gastric acid secretion, and gastroprotection
in response to nutrient stimuli. It has been isolated and characterized as the major component of pancreatic amyloid deposits present in type 2 diabetic patients. In normal humans, plasma amylin concentrations vary in response to blood glucose levels, whereas in type 1 diabetic subjects and in late-stage type 2 diabetics it is reduced (being often almost undetectable) and do not increase in response to glucose load. Amylin secretion appears to be delayed and diminished in these populations. Human amylin tends to aggregate or forms insoluble particles and is not suitable for therapeutical use. A synthetic analog of human amylin, pramlintide, was developed, which is readily soluble in water and which possesses the same biological activities as amylin. The physiologic actions of human amylin or pramlintide are shown in table 1. Amylin appears to complement the glucose disposal actions of insulin and improves glucose regulation in type 1 or type 2 diabetic patients, who are absolutely or relatively deficient in amylin. This peptide, administered subcutaneously at 10–100 lg 4 times/day, was able in a multicenter trial to effectively reduce the 24-hour plasma glucose profile in type 1 diabetic patients, without important side effects (only transient, dose-related, upper gastrointestinal symptoms such as nausea were observed). In type 2 diabetics treated with exogenous insulin, pramlintide improved metabolic control and produced statistically significant reduction of serum fructosamine, HbA1c and total cholesterol as well as a trend towards decreased body weight.
Type 1 Diabetes The treatment of type 1 diabetes with diet and insulin has been discussed in chapter IV on Diet and Modification of Nutrient Absorption and chapter
Belfiore/Iannello
96
Table 2. Immunoregulation therapies in animal models
IL-2, IL-4, IL-10 and TNF-a Anticytokine and anti-IFN-c antibodies Anti T-cell antibodies, anti-CD3, -CD4, -CD8 Anti T-cell-receptor antibodies Anti-MHC class I and class II antibodies Immunosuppressive drugs (cyclosporine) Immunomodulating agents Adjuvants (BCG vaccine and CFA) Nicotinamide Treatment with autoantigen: Insulin GAD Heat-shock protein
Table 3. Immunoregulation treatments in diabetic humans Cyclosporine treatment (low benefit, several toxic side effects and recurrence of disease limit its clinical use) Preventive treatment with intravenous or subcutaneous insulin (with a moderate protective effect in 60% of high-risk individuals, compared to 0% in controls) Daily oral insulin (7.5 mg/day) Low doses (nonhypoglycemic) of subcutaneous insulin (capable to prevent or delay type 1 diabetes in prediabetic subjects) Daily oral nicotinamide (3 g/day) (useful to prevent type 1 diabetes)
V on Insulin Treatment in Type 1 and Type 2 Diabetes. Here, additional aspects will be considered. Immunologic Treatment Immunoregulatory Therapy. This intervention is suggested in the prediabetic state (before the autoimmune b-cell destruction) and is directed to the following goals: to prevent the induction of diabetogenic T lymphocytes (or to delete these cells), to induce regulatory cells which inhibit these diabetogenic lymphocytes, and to induce immunological tolerance to autoantigens. Two animal models of autoimmune juvenile diabetes provide a very useful system to evaluate efficacy of the various proposed therapies, i.e. NOD (nonobesediabetic) mice and BB mice. In these animals, several immunoregulation strategies appeared capable to prevent type 1 diabetes (table 2). Only few of these therapies can be applicable to human diabetes. In high-risk prediabetic subjects, clinical trials are in progress with different treatments (table 3).
Overview of Diabetes Management
97
Immunosuppression Therapy. This form of therapy is directed to prevent the action of diabetogenic T cells (in the early stage of insulitis) in order to preserve insulin secretion, at least in the short term. In a study, BCG antituberculosis vaccination was reported to be effective, with a 66% remission in the newly diagnosed treated patients as compared to 7% in the controls. Two other clinical trials with BCG vaccine in newly diagnosed type 1 diabetics have found no beneficial effects. Autoantigen Therapy. It is a new promising approach to prevent type 1 diabetes, explored in animal models but whose applicability in humans has not yet been established. It includes: nasal immunization or oral feeding with insulin (which is a b-autoantigen in susceptible subjects), and nasal immunization or oral feeding with GAD, IA-2, ICAp69 and heat-shock protein. Gene Therapy It is the frontier of immunological therapy in diabetes mellitus and is directed to express regulatory cytokines (such as IL-4, IL-10 and TGF-b) or autoantigens in the thymus (selection of T cells in the thymus results in deletion of cells that cause autoimmunity), thus preventing or delaying type 1 diabetes. In overt clinical diabetes, both immunoregulatory and immunosuppressive therapy are unsuccessful. However, it is useful to identify the appearance of antibodies already in the preclinical period in order to preventively treat susceptible people (who will develop type 1 diabetes). Pancreas or Islet Transplantation Pancreas Transplantation. Pancreas transplantation (total or segmental) is most often performed together with kidney transplantation, when the latter is needed. This requires immunosuppression treatment. Transplant of the pancreas alone is perhaps not advisable, because the advantage of good metabolic control should be evaluated against the risks of the immunosuppression therapy. However, successful pancreas transplantation, until rejection occurs, is able to normalize blood glucose. Pancreas transplantation is the only treatment of type 1 diabetes that consistently establishes an insulin-independent, normoglycemic state. Currently, long-term (?1 year) insulin independence is achieved in ?80% of recipients of pancreas grafts placed simultaneously with the kidney and ?70% in recipients of a pancreas after a kidney, and ?60% of nonuremic recipients of a pancreas alone. The penalty is immunosuppression, already obligatory for a kidney recipient, but the benefits are improvement in quality of life and the effect that perfect control of glycemia can have on secondary complications. Pancreas grafts may function for a long time and b-cell ‘exhaustion’ does not occur in patients with high preoperative C-peptide (?1.37 ng/ml) levels. Pancreas transplantation can reverse the lesions of dia-
Belfiore/Iannello
98
betic nephropathy, but reversal requires more than 5 years of normoglycemia. Moreover, with the improvement of metabolic control, reduction of hypertension is often observed. However, pancreas-kidney transplantation provokes proportional hyperproinsulinemia, which is closely associated with reduced clearance in the kidneys. Long-term follow-up after transplantation indicates that GAD antibodies persist and ICA reappear despite immunosuppressive therapy in patients with functioning pancreas transplants, which may entail a risk for diabetes recurrence. Islet Transplantation. Transplantation of isolated islets has not yet yielded fully satisfactory results. The same is true for the implantation of nonislet cells engineered to produce human insulin. Yet, islet transplantation could become an attractive alternative to whole organ transplantation, since it is a simpler and safer procedure. However, the requirement for long-term immunosuppression has limited the indication of islet transplantation to patients receiving a simultaneous kidney transplant or already bearing one. Although the majority of recipients of islet allografts did not become insulin independent, the long-term results in patients with even partial graft function are comparable or better than those achievable with intensive insulin therapy. Indeed, successful islet transplantation is a difficult challenge, but current achievements with human islet allografts may greatly improve glycemic control. In some studies, serum C-peptide levels diminished after a few months, and after 6–10 months were undetectable. Islet function loss is probably to be explained by rejection or cytomegalovirus infection. Moreover, trials of donor bone marrow infusions combined with solid organ transplants are in progress to determine whether donor-specific tolerance can be achieved with the potential to expand the future indications of islet transplantation in diabetes.
Drugs Suggested for Both Type 1 and 2 Diabetes a-Glucosidase Inhibitors. These include acarbose (an insoluble a-glucosidase inhibitor) and miglitol (a soluble short-term a-glucosidase inhibitor). Both are alternative drugs, orally active, that act at the brush border of the small intestine by inhibiting a-glucosidase, thus interfering with the conversion of disaccharides to monosaccharides. Therefore, they delay the digestion of complex carbohydrates and disaccharides by reducing absorption of glucose and flattening the postprandial glucose level. Acarbose is an antihyperglycemic agent which has been proposed as add-on therapy in type 2 diabetic patients not well controlled with diet alone, sulfonylureas, metformin or insulin, and in type 1 diabetic patients with large meal-related plasma glucose excursions. Treatment with acarbose has several effects (table 4). The efficacy and side
Overview of Diabetes Management
99
Table 4. Effects of acarbose treatment Delay in digestion of complex carbohydrates Reduction in glucose absorption Decrease in postprandial glycemia Decrease in postprandial insulinemia Decrease in postprandial C-peptide level Decrease in fasting glycemia (only in some diabetic patients)
Increase in breath hydrogen Decrease in nutrient-stimulated insulin secretion Decrease in nutrient-stimulated GIP secretion Decrease in fasting serum triglycerides Decrease in fasting serum cholesterol
effects of this drug seem to depend on national nutrition habits. Numerous controlled studies in type 2 diabetes have demonstrated the usefulness of acarbose, at a dose of 150–600 mg/day, in decreasing fasting and postprandial glucose levels as well as HbA1c concentrations (mean decrease of 0.7%), whether acarbose was given as first-line therapy in diet-treated diabetic patients or in combination in individuals already receiving a sulfonylurea, metformin or insulin. Only a few controlled studies have compared the effects of acarbose with those of either sulfonylurea or metformin, yielding controversial results. In type 1 diabetic patients, a small reduction of HbA1c levels was also reported after addition of acarbose to insulin therapy, which in some cases allowed a slight reduction of daily insulin needs. All these favorable biological effects occurred without exposing the patient to hypoglycemia or weight gain. A few studies have also reported favorable effects on postprandial lipid profile and some other vascular risk factors. In a recent study, acarbose was suggested as a first-line drug in the treatment of either type 2 diabetic patients with mild elevation of glycemia, alone or as an adjunct to sulfonylureas, or in type 1 patients associated with insulin therapy. Acarbose was reported to reduce HbA1c by 0.4–1.5% with a maximum effect at 3 months, which was further well maintained. In the UKPDS, glibenclamide as well as insulin therapy induced a weight gain of 4.8 kg, whereas the intake of acarbose (probably through reduction of hyperinsulinemia) was associated with a mild weight loss (0.7 kg after 1 year follow-up). Acarbose also has the advantage that it does not cause hypoglycemia, being an antidiabetic rather than a hypoglycemic agent. It is well tolerated in the dose range of 25–250 mg t.i.d., but small doses (from 25 to 50 mg t.i.d.) can also be effective and cause only fewer gastrointestinal side effects. The latter include meteorism, flatulence, nausea, borborygmus, diarrhea and abdominal cramps or distension. The frequency of gastrointestinal complaints is not related to the acarbose dose and decreases over time. Adaptation of intestinal enzyme activity may account for the diminution of intestinal side
Belfiore/Iannello
100
effects. The drug was shown to be safe and well tolerated. It may also improve hyperlipoproteinemia. However, it is not clear whether the extra cost of acarbose, when compared to that of older oral antidiabetic agents, is justified since no study has yet demonstrated its potential benefit on the complications and long-term prognosis of diabetic patients. Insulin-Like Growth Factor I (IGF-I ). IGF-I (or somatomedin C) is one of the major components of nonsuppressible insulin-like activity. IGF-I and insulin share common steps in signal transduction, and the action of IGF-I on carbohydrate metabolism is preserved in certain insulin-resistant states. GH hypersecretion and reduced circulating IGF-I levels are prevalent in poorcontrolled insulin-dependent diabetes. Recently, both bacteria and fungi have been engineered to produce sufficient quantities of recombinant human IGF-I (rhIGF-I), so that rhIGF-I has been proposed as a potential therapeutic agent in the treatment of both type 1 and type 2 diabetic patients. rhIGF-I not only improves glucose tolerance and increases insulin sensitivity, but also improves insulin secretion in response to intravenous glucose. It is uncertain whether this is a direct effect of rhIGF-I on the pancreatic b-cell or an effect secondary to improved glycemic control (reduced glucose toxicity). The most appropriate dose to achieve efficacy and safety remains to be defined. Nicotinamide. This soluble vitamin of the B group, alone or with sulfonylureas, increases serum C-peptide release in type 1 patients as well as in type 2 diabetic patients with sulfonylurea failure, improving glycemic control.
Suggested Reading Alejandro R, Ricordi C: Current indications and limits of pancreatic islet transplantation in diabetic nephropathy. J Nephrol 1997;10:245–252. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996;334:574–579. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova Kurktschiev T: European study on doseresponse relationships of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: Efficacy and safety of low and high doses. Acta Diabetol 1998;35:34–40. Genuth S: Management of adult onset diabetes with sulfonylurea drug failure: Diabetes mellitus, perspective on therapy. Endocrinol Metab Clin North Am 1992;21:351–369. International Diabetes Federation (IDF), 1998–1999 European Diabetes Police Group: A Desktop Guide to Type 2 (Non-Insulin-Dependent) Diabetes mellitus. Brussels, IDF, 1999. Laakso M: Benefits of strict glucose and blood pressure control in type 2 diabetes. Lessons from the UK Prospective Diabetes Study. Circulation 1999;99:461–462. Lebovitz HE: Oral hypoglycemic agents; in Rifkin H, Porte D (eds): Diabetes mellitus. Theory and Practice, ed 4. New York, Elsevier, 1990, pp 554–574. Linse L, Brasseur R, Malaisse WJ: Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family. Biochem Pharmacol 1995;50:1879–1884. Masetti M, Inverardi L, Ranuncoli A, Iaria G, Lupo F, Vizzardelli C, Kenyon NS, Sutherland DE: Pancreas transplantation as a treatment for diabetes: Indications and outcome. Curr Ther Endocrinol Metab 1997;6:496–499.
Overview of Diabetes Management
101
Moses AC, Morrow LA, O’Brien M, Moller DE, Flier JS: Insulin-like growth factor I as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995;28(suppl): 185–194. Singh B: Possible immunological treatment for type 1 diabetes in the 21st century. Pract Diabetes 1997; 14:197–200. Thomson RG, Pearson L, Schoenfeld SL, Kolterman OG, and the Pramlintide in Type 2 Diabetes Group: Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care 1998;21:987– 993.
F. Belfiore, Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, I–95123 Catania (Italy) Tel. +39 095 330981, Fax +39 095 310899, E-Mail
[email protected]
Belfiore/Iannello
102
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 103–110
Chapter VII
............................
Clinical Emergencies in Diabetes. 1: Diabetic Ketoacidosis and Hyperosmolar Nonketotic Syndrome F. Belfiore, S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Diabetic Ketoacidosis Diabetic ketoacidosis (DKA) is the classical acute metabolic complication of type 1 diabetes, although it may also occur much less commonly in type 2 diabetes, being primarily due to severe insulin deficiency. The hormonal pattern favoring DKA is represented by severe insulin deficiency and/or excess of counterregulatory hormones (or stress hormones) which include glucagon, catecholamines, cortisol and GH. Among counterregulatory hormones, however, glucagon plays the major role, so that the key hormonal condition favoring DKA is depression of the insulin/glucagon ratio. Insulin deficiency may occur because of interruption or inadequacy of insulin administration or in the setting of the first manifestation of type 1 diabetes. Counterregulatory hormones may increase following physical (infections, surgery, trauma) or emotional stresses, and oppose insulin action. In addition, epinephrine may also stimulate glucagon release, which is also favored by lack of insulin. The deficiency of insulin reduces peripheral glucose utilization, while the low insulin/glucagon ratio stimulates hepatic gluconeogenesis (and therefore hepatic glucose production) by inducing a decrease of the key regulatory compound fructose-2,6-P (which stimulates glycolysis and depresses gluconeogenesis). Gluconeogenesis utilizes the gluconeogenic precursors which come from muscle (pyruvate and lactate derived from glucose, alanine derived from proteolysis as well as from amination of pyruvate, and other amino acids derived from proteolysis) and to a minor extent from adipose tissue (glycerol, released together with FFA during lipolysis). These changes result in marked
103
hyperglycemia. The lack of insulin will also produce a high rate of lipolysis (insulin exerts an antilipolytic action by inhibiting the hormone-sensitive lipase), so that the adipose tissue releases large amounts of FFA with consequent hyperafflux of FFA to the liver. As outlined in figure 2 and its legend in chapter I, in the liver the FFA may be reesterified to triglycerides (in the cytosol) or b-oxidized to acetyl-CoA. Triglycerides so formed may be deposited in the hepatocytes (causing steatosis) or may be incorporated into VLDL which are secreted into the circulation. The b-oxidation of FFA to acetylCoA occurs after the transport of FFA into the mitochondria, effected by the enzyme CPT-1. Glucagon activates the latter mechanism (ketogenesis) both by enhancing the availability of carnitine (a metabolite required for the CPT-1 reaction) and, especially, by lowering the concentration of malonyl-CoA, a key regulatory compound which inhibits CPT–1. Glucagon lowers the malonylCoA level by two mechanisms: (a) by inhibiting glycolysis (through the diminution of the regulatory compound fructose-2,6-P – see above) and therefore the concentration of pyruvate, through the sequence pyruvate (cytoplasm) K acetyl-CoA (mitochondria) K citrate (mitochondria) K citrate (cytoplasm) K acetyl-CoA (cytoplasm) K malonyl-CoA (cytoplasm), and (b) by inhibiting the enzyme acetyl-CoA carboxylase that catalyzes the latter step (conversion of acetyl-CoA to malonyl-CoA). The resulting activation of b-oxidation of FFA leads to formation of excessive amounts of acetyl-CoA which is then condensed to form b-hydroxybutyrate (two molecules of acetyl-CoA are converted into acetoacetate, which can then be converted to b-hydroxybutyrate). Thus, in DKA the liver exerts two main functions: (a) as concerns carbohydrate metabolism, it takes up gluconeogenic precursors and releases glucose (producing hyperglycemia, osmotic diuresis and dehydratation, with osmolality in the 310–330 mosm/l range) and (b) concerning lipid metabolism, it takes up FFA and releases VLDL and ketone bodies (which results in hypertriglyceridemia and acidosis). Clinical Picture Preceded by polyuria (due to osmotic diuresis), the clinical picture begins with anorexia, nausea, vomiting (which precludes oral fluid intake) and, often, abdominal pain (periumbilical and constant) which can mimic a surgical emergency. If treatment is not started, alterations in consciousness ensue, which may evolve to frank coma. Physical signs are due to dehydration and acidosis and include: sweet, sickly smell of the patient’s breath, deep and rapid respiration (Kussmaul respiration), low jugular venous pressure and tachycardia. In most severe cases, vascular collapse and acute renal failure may develop. White blood cell count may be markedly elevated, even in the absence of infection. Body temperature is normal or tendencially low, unless infections develop.
Belfiore/Iannello
104
Laboratory Data Laboratory data show increase of the anion gap, and abnormalities in potassium, sodium, triglycerides, azotemia and amylase. The anion gap is the difference between the routinely measured cations and anions. Normally, to maintain a pH close to neutrality (7.35–7.45), the sum of cations, including sodium, potassium, calcium and magnesium, should be approximately equal to the sum of anions, such as chloride, bicarbonate, and other routinely not measured anions comprising some organic acids (lactic acid, pyruvic acid, FFA, etc.) and inorganic acids (phosphates, sulfates) as well as anionic proteins (albumin and others). When, in pathologic conditions, an acidic compound enters or increases in the blood (ketone bodies in the case of DKA), it is neutralized with the sodium (and potassium) subtracted from bicarbonates. The latter in this way become carbonic acid which rapidly dissociates into CO2 (which will be lost with the breath) and H2O (which will be eliminated by the kidneys). As result of this process, the concentration of blood bicarbonates falls to an extent proportional to the amount of the acidic compounds which originate from the perturbation. In the clinical setting, the cations and anions measured as routine are Na+, K+, ClÖ and HCOÖ 3 whereas other cations and anions remain unmeasured. Therefore, considering only the routinely measured cations and anions there is, already in the normal state, an anion gap which can be calculated as follows: Serum anion gap> ([Na+]+[K+])Ö([ClÖ]+[HCOÖ 3 ]), with normal values of about 14–16 mmol/ l or, in a simpler way: Serum anion gap>[Na+]Ö([ClÖ]+[HCOÖ 3 ]), with normal values of about 10–12 mmol/l. About half of the normal anion gap is accounted for by albumin and the other by anionic proteins. With the technical procedures in use in recent years, which yield higher values for ClÖ, the normal anion gap may be remarkably lower. It is therefore useful to refer to the normal values of the local laboratory. In DKA, the increased anion gap is due to the fall in bicarbonate (6–10 mmol/l) caused by the accumulation in the blood of the ketone bodies (acetoacetate and b-hydroxybutyrate), with minimal contribution of lactate and FFA. Potassium content of total body decreases markely, although serum K+ levels may be initially normal due to the cell buffering mechanism (exchange of intracellular K+ for extracellular H+), before diminishing as a consequence of the osmotic diuresis (together with other electrolytes such as magnesium and phosphates). Sodium concentration tends to be moderately lowered (in the 130–132 range) due to the osmotic shift of water into the plasma space, and may become severe if prolonged vomiting plus water drinking occur. Triglycerides are elevated, sometimes to very high values, due to both enhanced hepatic prodution of VLDL (stimulated by the hyperafflux of FFA to the liver) and diminished VLDL disposal due to reduced activity of lipoprotein
Clinical Emergencies in Diabetes
105
lipase (which is normally stimulated by insulin). It should be pointed out that, when VLDL are very high, artifactually low values of electrolytes may be obtained when measurement is done with the autoanalyzer, because of the high concentration of fats which occupy a substantial percentage of the total serum volume. Azotemia may develop as result of dehydration and volume depletion (prerenal azotemia). Elevation of serum amylase (of nonpancreatic origin) often occurs which, when associated to severe abdominal pain, may simulate pancreatitis. Complications and Mortality While the frequency and mortality rate have markedly diminished with the improvement of diabetes knowledge and patient care, in some settings mortality may still be as high as 10%, and it is due mainly to superimposed complications. The latter include: gastric dilation (vomiting of bloody or dark material), infections (especially pneumonia), mucormycosis (epistaxis, unilateral headache, alteration in mental status, eye symptoms), respiratory distress syndrome, myocardial infarction and vascular thrombosis (signs and symptoms of ischemia in the cerebral or other vascular regions). In addition, cerebral edema is a serious complication, more often seen in children than in adults. It may be due to the low osmolality of plasma compared to brain after therapeutically induced glucose fall and rehydration. Once diagnosed (on the basis of CT findings), it should be treated with mannitol (1 g/kg as 20% solution) and dexamethasone (whose efficacy is not certain); if improvement is not observed, hyperventilation (to lower PaCO2 to about 28 mm Hg) may be helpful. Diagnosis Diagnosis should be made by excluding lactic acidosis, alcoholic ketoacidosis, pancreatitis, uremia, and poisonings. The exact diagnosis is suggested by elevated plasma glucose and ketone bodies. Concerning the latter, measurement in plasma should be performed, since positivity in the urine may also occur with starvation ketosis. A semiquantitative assay can be performed using ketone reagent strips (Ketostix) or tablets (Acetest) on diluted plasma: a positivity with dilution higher than 1:1 suggests DKA (it may also be seen in patients with alcoholic ketoacidosis in whom, however, blood glucose rarely exceeds 160 mg/dl or 8.4 mmol/l). It should be pointed out that ketogenesis produces acetoacetate, which (in addition to undergoing spontaneous decarboxylation to acetone) may be converted into b-hydroxybutyrate through an oxido-reductive reaction, with simultaneous conversion of NADH to NAD. Normally, the ratio b-hydroxybutyrate/acetoacetate is around 3:1, but in severely ill patients with dehydration and vascular collapse, there is some degree
Belfiore/Iannello
106
of hypoxia and acidosis, which favors the conversion of acetoacetate to b-hydroxybutyrate with increased concentration of the latter compounds. When the patient improves with therapy, the total amount of ketone bodies will diminish, yet the accumulated b-hydroxybutyrate is reconverted into acetoacetate, whose concentration may not decrease or may even increase. Since ketone reagent strips measure acetoacetate (and to some extent acetone), this may give the false impression that the treatment is ineffective. Therefore, the correction of the pH and the diminution of the anion gap may be more reliable parameters for evaluating the effectiveness of treatment. Treatment Therapy of DKA relies upon rehydration and insulin administration. It is useful to prepare a local care protocol and to distribute it to relevant professionals. Saline solution should be given intravenously at the rate of 2 liters in 2 h, followed by infusion of 0.4 liter/h of saline or half-normal saline (0.45%) for about 6 h, based on the clinical response. The total fluid deficit is of about 3–5 liters. Hypotonic saline should be given with caution (if plasma Na+?155 mmol/l: 1 liter over 8 h). Colloid solutions should be used in presence of hypotension (systolic blood pressure=100 mm Hg after 2 h). When glucose level decreases to =250–300 mg/dl, infusion of 5% glucose should be added, to prevent excessively rapid glucose fall that may contribute to the severe complication of cerebral edema as well as to allow continuing insulin infusion until ketosis disappears (often plasma glucose falls more rapidly than plasma ketone bodies). Insulin (rapid-acting or regular) should be administered in low doses, by infusing a bolus of about 10 U followed by 8–10 U/h (in contrast to the higher doses previously used), until disappearance of ketone bodies and normalization of glycemia is obtained. This regimen often ensures a progressive decrease in blood glucose, avoiding a precipitous fall which may favor cerebral edema. These doses, however, should not be regarded as ‘low’ when compared to the amount of insulin produced in 24 h in the normal man (25–28 U). However, it should be considered that in DKA, a variable degree of insulin resistance is present, as result of several factors (see chapter III, paragraph on Insulin Resistance in Type I Diabetes). For this reason, in some patients, higher doses of insulin may be required, i.e. a bolus of 20 U or higher followed by infusion of 15 U/h or more. These excessive amounts of insulin are justified in view of the possibility that, after saturation of insulin receptors, the surplus of available insulin may act through activation of the IGF-1 receptors. It is noteworthy that up to 20% of insulin binds to the flask and tubing (much higher percentage with lower doses) and that, when we use the same set for a second infusion, the binding sites are saturated and therefore the amount of free insulin actually infused will be higher.
Clinical Emergencies in Diabetes
107
Potassium administration is often required. This cation may be normal in serum even if the total body content is decreased. When the plasma level is low, 30–40 mmol/h of potassium should be infused, and a lower dose (20 mmol/h) should also be given when serum potassium is normal, because with the beginning of therapy a further fall in serum potassium occurs as a result of the effect of insulin (which causes a shift of potassium into the cells) and fluid replacement (that dilutes serum potassium). ECG represents a useful tool to assess intracellular potassium concentration, showing flat or inverted T waves when intracellular potassium is low and peaked T waves when intracellular potassium is high. Bicarbonate administration is only required in patients with severe acidosis (pH=7). Bicarbonate should be given at a slow rate (about 44 mEq during 1 or 2 h) and discontinued when the pH rises to 7.1. In DKA, 2,3-diphosphoglycerate (2,3-DPG) is low in red cells, which decreases oxygen delivery. This is counterbalanced by acidosis, which favors oxygen delivery. A rapid correction of acidosis with bicarbonate may leave the effect of the 2,3-DPG unopposed, causing impaired oxygen release which, in presence of volume depletion and reduced tissue perfusion may favor the development of tissue hypoxia and lactic acidosis. In presence of infections, antibiotic therapy should be employed. When the patient is comatose, insert a nasogastric tube, use a urinary catheter (if no urine passes within 3 h) and heparinize in case of hyperosmolar coma development or in presence of thrombosis risk factors. After the recovery from a diabetic ketoacidotic episode, it is useful to accurately review the causes to reduce the risk of recurrence.
Hyperosmolar Nonketotic Syndrome Hyperosmolar nonketotic syndrome (HNKS) is an acute complication observed most often in type 2 diabetic patients and is characterized by symptoms and signs due to volume depletion (caused by excessive hyperglycemia and consequent hyperosmolality and osmotic diuresis), with varying degree of clouding of sensorium, ranging from absence of mental impairment (about 10%) to frank coma (about 10%). HNKS is a serious complication, which entails a mortality rate as high as ?40%. Pneumonia (favored by sensory clouding which facilitates aspiration of oropharyngeal secretions) may develop in HNKS patients, as well as other infections. The dehydration elevates plasma viscosity and may favor thrombosis. Disseminated intravascular coagulation (DIC) may also occur, with bleeding manifestations.
Belfiore/Iannello
108
Laboratory findings include a marked hyperglycemia (usually higher than that occurring in DKA, reaching a level of ?800 mg/dl or 44 mmol/l) which causes increase in serum osmolality (which may be as high as ?350 mosm/l), whereas sodium is normal or slightly changed. Urea nitrogen and creatinine are elevated, together with inorganic acids (phosphates and sulfates) because of prerenal azotemia consequent to volume depletion. In contrast to DKA, in HNKS the metabolic acidosis is absent or mild, and bicarbonates are slightly changed. When present, acidosis is due to retention of inorganic acids (see above), i.e. a small amount of ketone bodies as well as a certain amount of lactate (due to tissue hypoperfusion consequent to volume depletion). The extreme hyperglycemia with the ensuing hyperosmolality may be favored by the abundant hyperglycemic diuresis in patients who are unable to compensate the large fluid loss with urine by adequate water drinking, as it often occurs in old patients, who have an attenuated sensation of thirst and who often live alone or in nursing homes. However, it should be kept in mind that HNKS may be precipitated by several factors, including infections, cerebrovascular events, hypertonic peritoneal dialysis, parenteral nutrition or administration of the osmotic agent mannitol or diuretics as well as corticosteroids and phenytoin. The lack of acidosis in HNKS may be the result of several factors. (1) HNKS develops in type 2 diabetic patients, who possess a varying degree of residual endogenous insulin secretion. Since lipolysis is more sensitive to insulin than the glucose homeostatic mechanisms, it is possible that the residual insulin secretion, while unable to stimulate glucose utilizaton and to repress hepatic glucose production, is able to refrain lipolysis, thus limiting the FFA afflux to liver and therefore the ketogenic process. (2) The endogenously secreted insulin reaches, through the portal vein, the liver, which is insulinized to a sufficient degree to prevent activation of ketogenesis (i.e. to allow glucose to be utilized in sufficient amount to produce enough malonyl-CoA, which inhibits the ketogenic process at the level of CPT-1. (3) There may be glucagon resistance, which prevents glucagon to exert its ketogenic effects (see under DKA). (4) There may be an enhanced activity of the Cori cycle, with increased afflux of lactate to the liver, where it may be in part metabolized to malonylCoA, thus refraining ketogenesis. HNKS treatment is primarily directed to restore blood volume and correct hyperosmolality. This may require the supply of intravenous fluid in the total amount up to 8–10 liters. Therapy may be started by intravenous infusion of saline at the rate of 1.5 liters/h for the first 2 h, followed by infusion of 0.5 liter/h of half-normal saline (0.45%) adjusted according to the clinical and laboratory response. Insulin should also be given. This may be done according to the small dose regimen described under DKA, although some patients may
Clinical Emergencies in Diabetes
109
require larger doses. Potassium should be supplied (see under DKA) with special attention because, in the absence of acidosis, the intracellular K+ transfer induced by insulin administration is more pronounced. Attention should also be paid to the possible development of infections or thrombosis or DIC to start timely the appropriate therapy.
Suggested Reading Foster DW, McGarry JD: The metabolic derangements and treatment of diabetic ketoacidosis. N Engl J Med 1983;309:159–169. Genuth SM: Diabetic ketoacidosis and hyperglycemic hyperosmolar coma. Curr Ther Endocrinol Metab 1997;6:438–447. Gonzalez-Campoy JM, Robertson RP: Diabetic ketoacidosis and hyperosmolar nonketotic state: Gaining control over extreme hyperglycemic complications. Postgrad Med 1996;99:143–152. Silink M: Practical management of diabetic ketoacidosis in childhood and adolescence. Acta Paediatr 1998;425(suppl):63–66. Siperstein MD: Diabetic ketoacidosis and hyperosmolar coma. Endocrinol Metab Clin North Am 1992; 21:415–432. Umpierrez GE, Khajavi M, Kitabchi AE: Review: Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Am J Med Sci 1996;311:225–233. Whiteman VE, Homko CJ, Reece EA: Management of hypoglycemia and diabetic ketoacidosis in pregnancy. Obstet Gynecol Clin North Am 1996;23:87–107.
F. Belfiore, Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, I–95123 Catania (Italy) Tel. +39 095 330981, Fax +39 095 310899, E-Mail
[email protected]
Belfiore/Iannello
110
Belfiore F, Mogensen CE (eds): New Concepts in Diabetes and Its Treatment. Basel, Karger, 2000, pp 111–124
Chapter VIII
............................
Clinical Emergencies in Diabetes. 2: Hypoglycemia F. Belfiore, S. Iannello Institute of Internal Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy
Definition The term hypoglycemia refers to a biochemical condition resulting from an abnormally low plasma glucose level, less than the lower value of the normal range (50–45 mg% or 2.8–2.5 mmol/l). Thus, the term hypoglycemia seems inappropriate to define a variety of clinical manifestations associated with abnormally low blood glucose and consisting of signs and symptoms of adrenergic activation and neuroglycopenia, responsive to glucose administration. In infants, during the first 48 h of life, hypoglycemia may occur, with glycemic values =30 mg% or 1.7 mmol/l, with a frequency of about 10% of live births. A brief hypoglycemic episode can cause moderate alterations of the brain whereas prolonged hypoglycemia can cause profound dysfunctions, tissue damage and also death of the brain. This depends on the fact that the deposit of glycogen in brain is negligible (the reserve of energy lasts 2–3 min) and that glucose is not synthesized by the central nervous system (CNS). Thus, glucose (together with oxygen) is an obligate primary energy substrate for the brain tissue and is entirely derived from the circulation. The brain tissue utilizes 120 g/day of glucose and about 90% of total energy needed for cerebral functions derives from glucose oxidation. The brain cannot utilize alternative substrates (as circulating FFA) as energy fuel thus being very sensitive to hypoglycemia. In some particular situations, at least some parts of the brain might utilize ketoacids. Hypoglycemia is a very uncommon event, apart from persons with diabetes treated with insulin or hypoglycemic drugs. The diagnosis of hypoglycemia is based upon Whipple’s triad, i.e. hypoglycemia, symptoms of hypoglycemia, and correction of the symptoms with the normalization of blood glucose.
111
Glucose Counterregulation Insulin regulates glycemia through modulation of hepatic glucose production in the postabsorptive state and glucose utilization in the postprandial state, and it is the only hormone able to physiologically reduce glycemic level. In catabolic states (fasting), insulin concentration falls and the levels of counterregulatory hormones rise; in fact, hypoglycemia is capable of inducing the release of counterregulatory hormones, including glucagon, catecholamines (epinephrine and norepinephrine – released both from adrenal medulla and the sympathetic neurons), cortisol and GH. The glucagon secretory response to hypoglycemia is largely CNS-independent whereas catecholamine, cortisol and GH responses are prevailingly CNS-dependent. Glucagon acts within minutes and is the primary hormone of glucose maintenance (by stimulating hepatic glucose production through increase in glycogenolysis and gluconeogenesis). Catecholamines also act swiftly, stimulating glucose production and limiting glucose utilization in humans through both b2- and a2-